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Abstract 
This thesis comprises a systematic review and an intervention study. The systematic 
review included a meta-analysis and investigated treatment methods for fatigue. Fourteen 
studies (n=1890) were included in the systematic review and results from the meta-
analyses (mean difference -0.25; CI -0.67:0.16; z-score 1.20 and mean difference -0.36; CI 
-0.78:0.06; z-score 1.67) concluded that currently there are no effective methods for the 
treatment of fatigue in people with Parkinson’s disease. 
The intervention study (n=105; intervention group: n=54; control group: n=51) comprised 
three parts. In the first part different measures of fatigue were explored in relation to 
activity levels and exercise tolerance. The second part investigated the adherence to the 
community based six-month exercise programme. The final part of the main study 
explored the effects of the exercise programme in a single blinded randomised controlled 
trial.  
In the first part of the main study significant negative correlations were found between 
self-reported fatigue and respiratory exchange rate (r=-0.309; p=0.002); Rate of Perceived 
Exertion breath (r=-0.282; p=0.024); Rate of Perceived Exertion of the legs (r=-0.261; 
p=0.033) and GENEActiv light activity (r=-0.209; p=0.049). The correlation between self-
reported fatigue and the respiratory exchange rate implies that self-reported fatigue may 
decrease if exercise tolerance is improved by for example an exercise programme. 
The second part of the main study demonstrated an adherence of 24 out of 54 in 
participants that were randomly assigned to the exercise programme, with no intervention-
related adverse events, showing that the proposed programme was feasible for people with 
Parkinson’s disease. 
The final part of the study, exploring the effects of the exercise programme in all patients, 
showed a small reduction in disease severity (Unified Parkinson’s disease Rating Scale 
part III, Cohen’s d: 0.25; 95% confidence interval: 0.02-0.49) in the treatment group 
compared to the control group. Scores on the self-reported fatigue decreased slightly in 
both groups subsequent to the exercise programme, but did not reach significance. 
This is the first study to explore the effects of a combined (aerobic and anaerobic) exercise 
community based longer term (six months) exercise programme on fatigue in people with 
Parkinson’s disease. Results show that both arms of the interventions were adhered to 
reasonably well and small effects were found showing exercise improved disease severity 
in people with Parkinson’s disease; no effects were found in relation to fatigue. 
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Chapter 1 Parkinson’s disease 
Summary 
This chapter provides a general introduction to Parkinson’s disease. The pathology of 
Parkinson’s disease is explained, focusing on pathways in the brain, and the differences in 
these pathways between healthy people and people with Parkinson’s disease. Aetiology, 
prevalence and incidence are discussed, followed by clinical features of Parkinson’s 
disease, including motor and non-motor symptoms with particular emphasis on fatigue. 
Treatment methods for Parkinson’s disease are outlined focusing with emphasis on 
exercise as a treatment, leading to the three main aims for the thesis. 
1.1 Introduction 
Parkinson’s disease is a progressive neurological movement disorder, mostly affecting 
older people (Parkinson's UK 2015). Symptoms suggestive of Parkinson’s disease have 
been described for many centuries, dating back to Egyptian papyrus and Sanskrit texts 
(Playfer and Hindle 2008). Parkinsons was first distinctively described by James Parkinson 
in 1817; he described individuals having ‘involuntary tremulous motion, with lessened 
muscular power, in parts not in action and, even when supported; with a propensity to 
bend the trunk forwards, and to pass from a walking to a running pace; the senses and 
intellect being injured’ (Foltynie, Lewis et al. 2003). There are different forms of 
Parkinsonism including Idiopathic Parkinson’s disease; atypical parkinsonian syndromes 
and other neurodegenerative disorders; secondary or symptomatic causes like drug induced 
parkinsonism (Playfer and Hindle 2008). Throughout this thesis, the focus will be on 
Idiopathic Parkinson’s disease, shortened to Parkinson’s disease. 
1.2 Pathology 
1.2.1 Normal brain pathways 
Most normal movement, voluntary as well as involuntary, is controlled in the basal ganglia 
in the brain (Kandell 2000). The basal ganglia receive their primary input from the cerebral 
cortex and send their output to the brain stem and, via the thalamus, back to the prefrontal, 
premotor, and motor cortices (Kandell 2000). The basal ganglia consist of the striatum, 
comprising of the caudate nucleus, putamen and the ventral striatum; the globus pallidus, 
which consist of the and external Globus Pallidus; the subthalamic nucleus; and the 
substantia nigra, which consists of the pars compacta and the pars reticulate (see Figure 1) 
(Hall 2016). The striatum receives most of the input into the basal ganglia coming from the 
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cerebral cortex, thalamus and brain stem (Hall 2016). The neurons from the striatum 
project to the globus pallidus and substantia nigra, these give most of the output from the 
basal ganglia. The cells of the internal Globus Pallidus and pars reticulate use γ-
aminobutyric acid gamma aminobutyric acid (GABA) as neurotransmitter. GABA is the 
most common of the inhibitory amino acid central nervous system neurotransmitters. This 
transmitter produces hyperpolarization by opening either chloride or potassium channels 
(Martin 2006).  The cells of the pars compacta are dopaminergic. In neurons that utilize 
dopamine as neurotransmitter, the biogenic amine synthetic pathway stops with dopa 
decarboxylase, the enzyme that synthesizes dopamine. Dopamine is involved in many 
forebrain circuits associated with emotion, motivation, and reward (Krebs, Weinberg et al. 
2012) and it acts on two types of receptors, both of which are linked to adenylate cyclase, 
cyclic adenosine mono phosphate second messenger systems. Stimulation of D1 receptors 
causes an increase in cyclic adenosine monophosphate levels, whereas stimulation of D2 
receptors cause a decrease in cyclic adenosine monophosphate, in the postsynaptic neuron 
(Shepherd 1994).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Basal Ganglia 
Abbreviatons: STR: striatum; GPe: globus pallidus pars externa; GPi: globus pallidus pars interna; 
Th: thalamus; subthalamic nucleus; STN: subthalamic nucleus; SNr, substantia nigra pars 
reticulata; SNc, substantia nigra pars compacta (Pereira and Aziz 2006) (reprinted with 
permission).  
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Dopamine is an important neurotransmitter in the sympathetic nervous system. Firstly, 
tyrosine is transported into the sympathetic nerve axon and it is converted to DOPA by 
tyrosine hydroxylase. Then DOPA is converted into dopamine by DOPA decarboxylase, 
which is then converted into norepinephrine by dopamine-β-hydroxylase. Norepinephrine 
is the primary neurotransmitter for postganglionic sympathetic adrenergic nerves (Unglaub 
Silverthorn 2007). 
Opposite to norepinephrine, there is the neurotransmitter acetylcholine that plays an 
important role in the parasympathetic nervous system. Acetylcholine is a neurotransmitter 
that is synthesized by binding choline to acetyl coenzyme A (Martin 2006). The binding is 
produced by choline acetyltransferase. Neurons that contain acetylcholine or choline 
acetyltransferase are called cholinergic neurons, which are found mostly in the motor 
system. The chemical binds to acetylcholine receptors which produces an action potential 
that results in muscle contraction (Martin 2006). Muscle contraction consists of myosin 
binding to actin, contracting, releasing the actin, and then binding to the next actin in a new 
cycle (Krans 2010). Finally, the subthalamic nucleus has glutaminergic cells, which are the 
only excitatory projections of the basal ganglia (Kandell 2000, Hall 2016). 
Release of the neurotransmitters described above (dopamine and GABA) are modulated by 
serotonin receptors (Kandell 2000, Hall 2016). 
Movement is controlled via a direct and an indirect pathway (Kandell 2000). The direct 
pathway in the motor loop starts with an excitatory connection from the cortex cells in the 
putamen. The putamen cells make inhibitory synapses on neurons in the external globus 
pallidus, from there to the subthalamic nucleus in a GABA-ergic pathway, and finally from 
there to the output nuclei in an excitatory glutaminergic projection. From there is an 
excitatory connection via the thalamus to the motor cortex where the discharge of 
movement-related cells is facilitated. This circuit is a positive feedback loop; dopamine 
normally facilitates the direct motor loop by activating cells in the putamen (see Figure 2) 
(Kandell 2000).  
The indirect pathway goes from the cortex to the striatum, then to the external pallidum, 
then to the subthalamic nucleus (which then projects to the pallidum and to the substantia 
nigra), and then, through the thalamus, back to the cortex (see Figure 2). So the indirect 
pathway goes through the subthalamic nucleus, which is bypassed by the direct pathway 
(Latash 1998). The indirect pathway increases inhibition of the thalamus (Kandell 2000).  
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Both pathways are affected differently by the dopaminergic projection from the substantia 
nigra pars compacta to the stratium. Stratial neurons that project in the direct pathway have 
D1 dopamine receptor that facilitates transmission, while those that project in the indirect 
pathway have D2 dopamine receptors that reduce transmission. Both have the same net 
effect and reduce inhibition of the thalamocortical neurons facilitating movements initiated 
in the cortex (Kandell 2000). 
 
Figure 2: Overview of pathways in the brain for normal and parkinsonism  
Red arrows indicate inhibitory connections; blue arrows indicate excitatory connections. The 
thickness of the arrows corresponds to their presumed activity. Abbreviations: CM, centromedian 
nucleus of thalamus; CMA, cingulate motor area; D1,D2, dopamine receptor subtypes; M1, 
primary motor cortex; PMC, premotor cortex, PPN, pendunculopotine nucleus; SMA, 
supplementary motor area; STN, subthalamic nucleus (Galvan and Wichmann 2008) (reprinted 
with permission). 
1.2.3 Pathways in Parkinson’s disease 
Parkinson’s disease affects both the direct and the indirect pathways. Parkinson’s disease 
occurs when dopaminergic cells in the caudate nucleus, putamen, substantia nigra and 
globus pallidus degenerate and die, with greater loss in the putamen than in the caudate 
nucleus (Martin 2006). This results in an increase in activity in the indirect pathway and 
decreased effect in the direct pathway. Both these changes lead to an increased activity in 
the interpallidal segment, which results in increased inhibition of thalamocortical and 
midbrain tegmental neurons which gives hypokinetic features (Kandell 2000). The 
nigrostratial neurons have a high degree of plasticity, with the residual stratial neurons 
compensating for the loss of dopamine by increasing their activity (Martin 2006), and 
symptoms of Parkinson’s disease do not start occurring until 60-80% of the dopaminergic 
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neurons in the brain have degenerated (Grosset 2009). The rate of clinical progression is 
directly related to the loss of dopamine-producing cells (Boelen 2009).  
Besides degeneration of dopaminergic cells, in people with Parkinson’s disease, there is 
degeneration of norepinephrine neurons of the locus coeruleus (Sulzer and Zecca 2000). 
Norepinephrine is a key neurotransmitter involved in wakefulness and attention (Krebs, 
Weinberg et al. 2012). 
1.3 Aetiology 
The exact cause of degeneration of dopaminergic neurons in the brain is still unknown. It is 
however believed that environmental and genetic factors contribute to the onset of 
Parkinson’s disease (de Lau and Breteler 2006). There is growing evidence that 
Parkinson’s disease may arise from a variety of problems causing damage or death of the 
dopaminergic neurons (Schapira and Tolosa 2010). 
Age is the single most important risk factor for developing Parkinson’s disease (Schapira 
and Jenner 2011). Age may cause an increased vulnerability of dopaminergic neurons to 
toxic insult because of increasing failure of normal cellular physiological and biochemical 
processes (Mattson and Magnus 2006). Prevalence rates for Parkinson’s disease in 
epidemiological studies show an exponential increase from one per 1000 in the general 
population to one in 50 in people 80 and older (Playfer and Hindle 2008). The next 
important risk is a family history of Parkinson’s disease impacting about ten per cent of the 
cases of Parkinson’s disease (de Lau and Breteler 2006). Evidence for a genetic role has 
come from a number of sources including twin, family, case control and epidemiological 
studies (Playfer and Hindle 2008). Furthermore, a number of environmental factors, such 
as pesticides, seem to be associated with an increased risk of developing Parkinson’s 
disease (Swinn 2005). A meta-analysis by Priyadarshi et al. (2000) concluded that the 
majority of the studies reported consistent elevation in the risk of Parkinson’s disease with 
exposure to pesticides. The combined odd ratio of the studies was 1.94 [95% confidence 
interval (95% CI) 1.49-2.53] for all the studies indicating that that exposure to pesticides 
may be a significant risk factor for developing Parkinson’s disease (Priyadarshi, Khuder et 
al. 2000).  Post-mortem studies have implicated oxidative damage (Greenamyre and 
Hastings 2004); antioxidants including vitamin C and E have been examined for a 
potentially protective role, but there is no consensus yet (Playfer and Hindle 2008, Van 
Maele-Fabry, Hoet et al. 2012). Morens et al (1995) conducted a systematic review and 
found consistently an association between cigarettes and lower chance of developing 
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Parkinson’s disease (Morens, Grandinetti et al. 1995). One thing that has repeatedly shown 
to be protective factor is smoking cigarettes. The first suggested mechanism for this 
phenomenon is that nicotine causes dopamine release and up-regulation of dopamine 
receptors, which may mask the early signs of the disease. Furthermore, cigarette smoke 
contains monoamine oxidase inhibitor B (MAO-B) (one of the drug treatment methods that 
will be discussed later) (de Lau and Breteler 2006). Coffee drinking has also shown to be 
associated with a reduced risk of developing Parkinson’s disease, the mechanism of this is 
unknown (Playfer and Hindle 2008, Derkinderen, Shannon et al. 2014). 
1.5 Prevalence and Incidence 
In industrialised countries Parkinson’s disease is present in about 0.3% of the entire 
population and in about one per cent in the people above 60 years (de Lau and Breteler 
2006). Studies in the United Kingdom have shown that Parkinson’s disease is more likely 
to occur in men than in women (PDS 2008). Currently, one in 500 people in the United 
Kingdom, or 127 000 nationwide, have Parkinson’s disease (Parkinson's UK 2015). 
Furthermore, there is an annual incidence of thirteen per 100 000 (DoH 2005). The number 
is expected to rise to 162 000 by 2020. Parkinson’s Disease cost the National Health 
Service in 2012/2013 212 million pounds (Parkinson's UK 2013). 
In spite of increasing understanding of the pathophysiology and genetics the prognosis of 
Parkinson’s disease remains unclear (Macleod, Taylor et al. 2014). A recent systematic 
review concluded that Parkinson’s disease is associated with increased mortality and a 
decrease in survival of approximately 5% per year of follow up (Macleod, Taylor et al. 
2014). At present there is no known cure (Parkinson's UK).  
1.6 Clinical features 
Parkinson’s disease presents with both motor and non-motor symptoms. The most common 
features will be discussed below. 
1.6.1 Motor symptoms 
The main motor symptoms of Parkinson’s disease include paucity of movement, rigidity, 
and tremor (Grosset 2009) affecting gait, mobility (Zampieri, Salarian et al. 2011) and arm 
function, including difficulties with handwriting (Tresilian, Stelmach et al. 1997, Van 
Gemmert, Adler et al. 2003). The symptoms will be discussed in more detail below. 
Paucity of movement: Paucity of movement consists of slowness of initiation of movement 
with progressive reduction in speeds and amplitude of repeated movement. It consists of 
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bradykinesia (slowness of movement), hypokinesia (reduced movement) and akinesia 
(inability to initiate movement) (Swinn 2005).  
Rigidity: Rigidity is the increase in resistance to passive movements around a joint. 
Rigidity tends to be more evident in flexors, which contributes to a flexed posture (Playfer 
and Hindle 2008). 
Tremor: Tremor is an involuntary rhythmic oscillatory movement of a body part (Playfer 
and Hindle 2008). There are different types of tremor including postural tremor, which is 
seen with a sustained posture against gravity; action tremor, which is tremor that is present 
during voluntary contraction; and kinetic tremor, which occurs during a movement (Playfer 
and Hindle 2008). 
Gait and balance: As described previously the dopaminergic deficit in Parkinson’s disease 
causes reduction in the excitatory drive of the motor cortex which can affect motor unit 
recruitment and results in muscle weakness. Studies have demonstrated that muscle 
strength is related to gait (Lima, Scianni et al. 2013). People with Parkinson’s disease often 
walk with a reduced gait speed, shorter stride length, stooped posture and reduced arm 
swing (Schaafsma, Giladi et al. 2003). Parkinson’s disease patients typically walk at 40-60 
meters per minute compared to normal 75-90 metres per minute with a reduced stride 
length of one meter or less compared to 1.2 to 1.5 meters in healthy older people (Playfer 
and Hindle 2008). Additional issues with gait in people with Parkinson’s disease are 
freezing, which occurs in about half of the people with Parkinson’s disease, and possibly 
associated with that gait hypokenisia and gait festination (Morris, Iansek et al. 2008). 
Furthermore, people with Parkinson’s disease have a reduced balance which increases their 
risk for falls (Allen, Sherrington et al. 2011). 
1.6.2 Non-motor features  
Lately, there has been more attention for non-motor symptoms like fatigue, and depression 
(Leonardi, Raggi et al. 2012). Non-motor symptoms have been suggested to contribute to 
disability, quality of life, and shortened life expectancy (Chaudhuri, Healy et al. 2006). 
Below, several non-motor symptoms in people with Parkinson’s disease are discussed. 
Cognitive and neuropsychiatric symptoms: these symptoms include cognitive impairment, 
anxiety, apathy, delirium, hallucinations, panic attacks and depression (Chaudhuri, Tolosa 
et al. 2014). Core symptoms of depression are a depressed mood, loss of pleasure, and 
feelings of worthlessness or guilt (NHS 2014). Depression is one of the most common non-
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motor symptoms and affects up to 50% of people with Parkinson’s disease (Dooneief, 
Mirabello et al. 1992). One large study exploring depression in 1449 people with 
Parkinson’s disease, showed that depression was more common in females than males; in 
individuals with more advanced stages of Parkinson’s disease; and in people with dementia 
(Riedel, Heuser et al. 2010). Although it is unlikely that depression is a direct result of 
dopamine depletion in the brain, other changes in neurotransmitter systems that could 
occur as a consequence of dopamine depletion may be involved in the pathophysiology of 
depressive symptoms in Parkinson’s disease (Playfer and Hindle 2008). 
Sleep disorders and dysfunctions: including excessive daytime somnolence, sudden onset 
of sleep, insomnia, non-rapid eye movement parasomnias, rapid eye movement sleep 
behaviour disorder, restless leg syndrome, periodic leg movements, and sleep-disordered 
breathing (Chaudhuri, Tolosa et al. 2014). 
Autonomic dysfunction: including bladder urgency, frequency, nocturia, orthostatic 
hypotension, post-prandial hypotension, sexual dysfunction, erectile dysfunction, and 
thermoregulatory abnormalities (Chaudhuri, Tolosa et al. 2014). 
Gastrointestinal symptoms: including dribbling of saliva, dysphagia, ageusia, constipation, 
faecal incontinence, nausea, reflux, and vomiting (Chaudhuri, Tolosa et al. 2014). 
Other non-motor symptoms: including functional anosmia, visual disturbances, weight 
gain, weight loss, and fatigue (Chaudhuri, Tolosa et al. 2014). Fatigue is defined as ‘a 
sense of tiredness, lack of energy or total body give out’ by the Fatigue Assessment 
Inventory (Friedman, 2007). Fatigue affects 40% to 56% of patients with Parkinson’s 
disease (Herlofson and Larsen 2003, Friedman, Brown et al. 2007, Okuma, Kamei et al. 
2009) which is significantly higher than in age matched controls and age matched geriatric 
patients (Goulart, Godke et al. 2009). More than half of the people with Parkinson’s 
disease rank fatigue as one of their three most severe symptoms (Friedman and Friedman 
1993, Brown, Dittner et al. 2005). Furthermore, a recent review places ‘What interventions 
are effective for reducing or managing unexplained fatigue in people with Parkinson’s?’ in 
the top 26 priorities for the management of Parkinson’s disease, showing that fatigue is an 
important issue for people with Parkinson’s Disease and needs to be addressed (Deane, 
Flaherty et al. 2014). Finally, qualitative research shows that woman with Parkinson’s 
disease experience living with fatigue living with a body that serves as a barrier to daily 
living (Olsson, Stafstrom et al. 2013). 
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A theory on the origin of fatigue in Parkinson’s disease involves the basal ganglia. There 
are three different ways the basal ganglia may be involved in fatigue. First of all, the 
dorsolateral prefrontal circuit in the caudate is involved in the dopamine loss seen in 
Parkinson’s disease; secondly, dopamine antagonists induce fatigue and loss of motivation 
(Chaudhuri and Behan 2000). Some studies observed that levodopa is more effective than 
placebo in reducing physical fatigue, which suggest that dopamine deficiency may be 
involved in causing fatigue in Parkinson’s disease (Fabbrini, Latorre et al. 2013). However, 
clinical studies do not find a correlation between fatigue and doses of dopaminergic 
medications (Fabbrini, Latorre et al. 2013). Finally, disruption of normal basal ganglia 
derived algorithm of a sequential task processing mechanism would delay the initiation of 
a task and prevents smooth execution of a task which is a feature that is typical in patients 
with central fatigue (Chaudhuri and Behan 2000). Previously, several neurotransmitters 
have been described, including serotonin, dopamine, norepinephrine and GABA. Below, 
the influence of these neurotransmitters on fatigue will be described. Firstly, it is shown 
that an increase in serotonin can result in sleep, and it is hypothesized that that an increase 
in serotonin could also cause fatigue (Foley and Fleshner 2008). Furthermore, it is 
observed that altered concentrations of dopamine, norepinephrine, and GABA can also 
influence fatigue (Foley and Fleshner 2008).  
Quality of life: the motor symptoms and non-motor symptoms that people with Parkinson’s 
disease experience all contribute to a lower quality of life. The World Health Organization 
defines quality of life as an individual’s perception of their position in life in the context of 
the culture and value systems in which they live and in relation to their goals, expectations, 
standards and concern (World Health Organization 1997). Quality of life in Parkinson’s 
disease includes perception of symptoms, level of fitness, self-image, satisfaction with 
family life, work, the economic situation, the interaction with other people, social support, 
disease severity, social status, social and living condition (Opara, Brola et al. 2012); 
quality of life in people with Parkinson’s disease is measured by means of questionnaires 
that address these issues (Opara, Brola et al. 2012). People with Parkinson’s disease have a 
lower quality of life than age related controls (Hariz and Forsgren 2011). 
1.7 Diagnosis 
There are no biological markers for a definite diagnosis of Parkinson’s disease, it is 
diagnosed on clinical grounds, which results in misdiagnosis. Only 75% of patients with 
Parkinson’s disease at death meet the neuropathological criteria for idiopathic Parkinson’s 
disease (Foltynie, Lewis et al. 2003). Criteria set to improve the accuracy of clinical 
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diagnosis and accepted as the best clinical practice are the United Kingdom Parkinson’s 
disease Society Brain Bank diagnostic criteria (see appendix 1). Parkinson’s disease is 
diagnosed when bradykinesia is present and either tremor, rigidity or postural instability 
(National Institute for Health and Clinical Excellence 2006). Furthermore, asymmetric 
symptom onset and a good response of the symptoms to levodopa are supportive for a 
diagnosis of Parkinson’s disease (de Lau and Breteler 2006). Since levodopa therapy is 
normally used to treat early symptoms, Parkinson’s disease may not be ruled in or out until 
later in the disease progression (Boelen 2009). Diagnosis of Parkinson’s disease could be 
could be confused with other conditions, such as essential tremor, multiple system atrophy, 
progressive supranuclear palsy, drug-induced parkinsonism and vascular Parkinson’s 
(Parkinson's UK 2014). A definite diagnosis of Parkinson’s disease requires post-mortem 
confirmation (de Lau and Breteler 2006, National Institute for Health and Clinical 
Excellence 2006). 
1.8 Treatment methods for Parkinson’s disease 
Different forms of treatment have been suggested for people with Parkinson’s disease 
including drugs, surgery and exercise. Below these different treatments will be discussed. 
The main treatment for Parkinson’s disease is drug therapy (Parkinson's UK). Drugs are 
used to treat the symptoms of Parkinson’s disease but not the underlying cause. Since 
symptoms occur as a result of low levels of dopamine, treatment is aimed at restoring 
dopamine levels to normal (Parkinson's UK).  A recent study by the Parkinson’s disease 
MED collaboration group concluded that the overall balance of risks and benefits favours 
levodopa over levodopa-sparing therapy with better patient related quality of life in the 
short as well as the long term (Gray, Ives et al. 2014).  
There are four main groups of drug therapies: i) drugs that replace dopamine (levodopa); 
ii) drugs that prevent the breakdown of dopamine (levodopa-sparing therapy): cathechol-
O-methyltransferase (COMT) and MOA-B inhibitors; iii) drugs that mimic the action of 
levodopa (dopamine agonists); iv) drugs that block the action of acetylcholine 
(anticholinergics). 
1.8.1 Levodopa 
The most effective treatment to date is dopamine replacement drug, levodopa (Gray, Ives 
et al. 2014). Gray et al. (2014) conducted a large study where they included 1620 patients 
into a Randomised controlled trial and people were assigned to Levodopa, dopamine 
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agonists or MOA-B. Results showed that levodopa treatment achieved better scores than 
the dopamine agonists or MAO-B on the primary Parkinson’s disease Questionnaire 39 
mobility outcome, and Euroqol-5D generic quality-of-life measures. Furthermore, 
clinician-rated disease status by Hoehn and Yahr staging was significantly improved 
(Gray, Ives et al. 2014). Levodopa is the precursor to dopamine, and once it enters the 
brain it is converted to dopamine by the enzyme dopa-decarboxylase. Dopamine is 
synthesized in the brain from the amino acid L-tyrosine via the intermediate compound, L-
3,4-dihydroxyphenylalanine (L-dopa). Levodopa is often administered in combination with 
carbidopa or benserazide, which are dopa decarboxylase inhibitors; they allow greater 
concentrations of levodopa entering the brain (Boelen 2009). Levodopa has a short mode 
of action because of its short half-life and due to gradually diminishing ability of the 
presynaptic nerve terminals to store dopamine as the disease progresses. This results in 
wearing off of the medication and causes ON and OFF phases. Levodopa has side effects 
including sleep disturbance, vivid dreams, hallucinations, delusions or organic confusional 
psychosis. Furthermore, levodopa therapy can induce dyskinesias (Fabbrini, Brotchie et al. 
2007). Levodopa is often chosen as treatment for fatigue in people with Parkinson’s 
Disease (Lou, Kearns et al. 2003, Schifitto, Friedman et al. 2008) since it restores 
dopamine levels in the brain and higher dopamine levels are associated with less 
exhaustion (Foley and Fleshner 2008).  
1.8.2 COMT and MOAB inhibitors 
Dopamine is inactivated enzymatically by the action of both MOA, an enzyme associated 
with mitochondria and present in two forms, termed A and B, and COMT, an enzyme 
localized primarily in glial cells in the brain (Watts and Koller 1997). Inhibition of the 
COMT enzyme allows the achievement of more stable and sustained plasma levodopa 
levels, which increases the amount of levodopa that enters the brain. Side effects of this 
drug are dyskinesia and nausea (Movement Disorder Society 2002, Swinn 2005). MOA-B 
blocks the metabolism of dopamine which could enhance endogenous dopamine and 
dopamine from levodopa (Fox, Katzenschlager et al. 2011). Side effects are insomnia, 
hallucinations and vivid dreams (Swinn 2005). Research has shown that modafinil (the 
active component in MOA-B) stimulates, norepinephrine, serotonin (5-
hydroxytryptamine), and dopamine, making it a treatment method for fatigue (Stocchi 
2013, Franssen, Winward et al. 2014). 
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1.8.3 Dopamine agonists 
Dopamine agonists act on pre- and postsynaptic dopamine receptors. Reasons to use 
dopamine agonists are: direct action; more reliable absorption and transport to the brain 
than levodopa; longer half-life than levodopa; no generation of free radicals; possible 
neuroprotective qualities (Movement Disorders Society 2002, Swinn 2005). Side effects 
are: neuropsychiatric complications; sleep disturbance and excessive daytime somnolence; 
postural hypotension (Movement Disorders Society 2002, Swinn 2005). 
1.8.5 Anticholinergics 
Anticholinergics were the first widely accepted treatment for parkinsonism (Movement 
Disorder Society 2002). Anticholinergics block interstratial cholinergic transmission. This 
helps to restore the balance of activity between the cholinergic and dopaminergic system 
which become imbalanced as a result of dopamine loss (Movement Disorder Society 
2002). Patients may experience neuropsychiatric side effects (Movement Disorder Society 
2002, Swinn 2005). 
1.8.6 Surgical treatment  
Surgical treatment for Parkinson’s disease has been performed since the 1940s and 
involved ablative procedures of the thalamus and internal globus pallidus. These surgical 
treatments were replaced by deep brain stimulation in the 1990s (Bronstein, Tagliati et al. 
2011). Deep brain stimulation is a treatment especially for people with advanced 
Parkinson’s disease when the disease and the side effects due to medication are severely 
disabling. The most commonly targeted areas are the motor portions of internal globus 
pallidus and subthalamic nucleus and the thalamus (Fox, Katzenschlager et al. 2011). 
Recent trials have found that deep brain stimulation at either target side was found to 
alleviate parkinsonian motor signs, and to reduce drug-induced side effects (Wichmann 
and Delong 2011). In patients with advanced Parkinson’s disease it improves quality of 
life. The risk of surgical complications is small, however the stimulation may produce 
significant side effects including induction of paresthesias, involuntary movements, 
worsening of gait or speech, gaze deviation or paralysis, and cognitive and mood side 
effects (Wichmann and Delong 2011). 
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1.9 Exercise  
As described, drug treatment can wear off and comes with side effects; furthermore, 
neurosurgical treatment comes with obvious risks and limitations. An alternative treatment 
that possibly slows disease progression down and stimulates movement control that does 
not induce side effects or has obvious risks and limitations is exercise therapy (Falvo, 
Schilling et al. 2008).  
Exercise is defined as a planned, structured physical activity, which aims to improve one or 
more aspects of physical fitness (Morris and Shoo 2004). Physical fitness is defined by the 
American College of Sports Medicine as ‘Physical fitness is the ability to perform 
moderate to vigorous levels of physical activity without undue fatigue and the capability of 
maintaining such ability throughout life’ (ACSM 2005).  
Inactivity is known to raise the risk of chronic condition such as cardiovascular diseases, 
obesity, type-II diabetes, cancer, osteoporosis and fatigue (Berlin, Kop et al. 2006, 
Pedersen and Saltin 2006). Furthermore, inactivity is associated with reduced aerobic 
capacity, atrophy and loss of muscle strength (Convertino 1997, Convertino, Bloomfield et 
al. 1997). It is well-known that exercise has general health benefits including improvement 
of cardiovascular and cerebrovascular health, reduction of osteoporosis and age related 
sarcopenia, improvement of psychological affect, and possibly a general anti-inflammatory 
effect (Ahlskog 2011). It is suggested that on-going vigorous exercise may have a 
neuroprotective effect as well (Ahlskog 2011). 
Research has shown that exercise enhances the synthesis of catecholamines, including 
norepinephrine and dopamine (Chaouloff, Laude et al. 1987). Furthermore, Fisher et al. 
(2004) found an increase in expression of dopamine D2 receptor mRNA and down 
regulation of the dopamine transporter protein within the striatum, changes that are 
consistent with increased dopaminergic signalling in mice that were exercising on a 
treadmill five days a week for 30 days (Fisher, Petzinger et al. 2004). One possible 
mechanism by which exercise may drive activity-dependent neuroplasticity in Parkinson’s 
disease may be through mitigating corticostriatal hyperactivity by modulating 
dopaminergic signalling, and/or diminishing glutamatergic neurotransmission (Petzinger, 
Fisher et al. 2010). Furthermore, physical exercise-induced changes in the concentrations 
of different neurotransmitters, including dopamine, noradrenaline, and serotonin (5-
hydroxytryptamine) (Cordeiro, Guimaraes et al. 2014). This mechanism may explain why 
exercise could be a possible treatment for fatigue. 
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Exercise can be split up into two major forms, aerobic and anaerobic exercise, that have 
different effects on health benefits, Parkinson’s disease symptoms, and fatigue. 
1.9.1 Aerobic exercise 
Aerobic exercise is defined as physical exercise of low to high intensity that depends 
primarily on the aerobic energy-generating process (Plowman and Smith 2008). People 
who do regular activity have a lower risk of many chronic diseases, such as heart disease, 
type 2 diabetes, stroke, and some cancers (NHS 2013). Exercise has been shown to 
improve cognitive function in healthy populations (Guiney and Machado 2013), 
neurological populations (McDonnell, Smith et al. 2011), and has been shown to prevent 
age-related cognitive decline (Bherer, Erickson et al. 2013). Furthermore, it has been 
shown that aerobic exercise improves executive functions (Guiney and Machado 2013) and 
finally, exercise is often used as a treatment method for depressed mood (Silveira, Moraes 
et al. 2013). As described above, animal studies have shown that aerobic exercise increases 
the concentration of dopamine in the striatum of the rat brain (Hattori, Naoi et al. 1994), 
which represents a possible mechanism of the benefits of aerobic exercise for both 
Parkinson’s disease in general and fatigue specifically. As discussed, people with 
Parkinson’s disease have balance and gait issues and a lower quality of life than age 
matched healthy individuals (Schaafsma, Giladi et al. 2003, Allen, Sherrington et al. 2011, 
Hariz and Forsgren 2011). A systematic review and meta-analysis looking into the effects 
of aerobic exercise on Parkinson’s disease included eighteen studies and found a positive 
effect on the motor actions, balance, and gait, but not quality of life (Shu, Yang et al. 
2014). Exercises included walking, treadmill training, aerobic exercise, tai chi, and dance 
showing a range of aerobic exercises with durations ranging from 20 to 60 minutes. 
Furthermore, duration of the exercise programmes varied from 3 to 64 weeks (Shu, Yang 
et al. 2014). As the overall review finds positive effects it would be important to included 
aerobic exercise into exercise programmes delivered to people with Parkinson’s disease; 
however thought should go into looking at optimal intensity, dose and duration of any 
programme. Furthermore, another review did find a positive effect of exercise on quality of 
life (Goodwin, Richards et al. 2008). They included four studies with different exercises, 
with the programme ranging from six to 26 weeks. Again, as studies with different doses 
and durations were included, more research is needed into the doses and durations of an 
optimal exercise programme. 
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1.9.2 Anaerobic exercise 
In strenuous exercise the energy demands can exceed the oxygen supply or its rate of use 
(Grosset 2009, McArdle, Katch et al. 2010). In this type of exercise (anaerobic exercise), 
the respiratory chain cannot process all of the hydrogen joined to the nicotinamide adenine 
dinucleotide (NADH) (McArdle, Katch et al. 2010) and lactate is then produced from the 
pyruvate faster than the body can process it, causing lactate concentrations to rise.  
Anaerobic exercise has shown to improve muscle mass, and neuromuscular performance 
(Taaffe, Duret et al. 1999) in a randomised controlled trial including 53 participants were 
people were randomly assigned to either high intensity progressive resistance training for 
24 weeks or control, which could potentially reduce the risk of falls and fractures in older 
adults, including people with Parkinson’s disease (Taaffe, Duret et al. 1999). Furthermore, 
muscle weakness, often apparent in people with Parkinson’s disease is likely to be 
associated with fatigue in this population (Falvo, Schilling et al. 2008). 
1.9.3 Exercise in Parkinson’s disease 
A systematic review and meta-analysis by Goodwin et al. (2008) that included fourteen 
studies and 495 people with Parkinson’s disease, concluded that exercise had a positive 
effect on physical functioning, health related quality of life, strength, balance and gait, but 
no positive effects on depression and falls (Goodwin, Richards et al. 2008). In this review 
all studies that researched exercise and an outcome that included physical performance of 
functioning, falls or health related quality of life; resulting in a variety of exercise studies 
(in terms of sort of exercise, duration of exercise, disease severity, and number of 
participants) being researched and pooled together, meaning that results should be interpret 
with care. A more recent review of Tomlinson et al. (2012) that included 39 randomised 
controlled trials including 1827 people with Parkinson’s disease investigating 
physiotherapy confirmed the positive effects found in gait, functional mobility and 
physical functioning in the short term (mean follow up < three months). They did not, 
however, find a positive result of physiotherapy on quality of life measured by the 
Parkinson’s disease Questionnaire 39 (Tomlinson, Patel et al. 2012). The authors discuss 
the often inadequate methodological quality and reporting of the trials. Previous studies 
indicate that there is evidence that if the methodological quality of a study is poor (no 
allocation concealment; no blinding), larger effects of intervention is reported than in 
higher quality trials (Egger, Juni et al. 2003). Therefore, it is important to assess 
methodological quality of each trial. Results from trials with a low methodological quality 
should be interpret with caution. The authors suggest that larger randomised controlled 
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trials are needed, particularly focusing on improving trial methodology and reporting, but 
also looking into longer periods of time (Tomlinson, Patel et al. 2012). Systematic reviews 
have been done into resistance training as well. One of the  systematic reviews provides 
evidence that progressive resistance exercise can improve strength and several measures of 
functional ability (Lima, Scianni et al. 2013). The study included only four studies, 
including 92 participants, indicating that the results need to be interpret with caution due to 
the small numbers included, and that research into resistance training is scarce (Lima, 
Scianni et al. 2013) The PEDRO score of the studies ranging between 3 and 8 shows 
relatively poor methodological quality, which means, as indicated above, that results 
should be interpret with care. Finally, in the meta-analyses, only post intervention scores 
were used, discarding any differences between groups at baseline, and two out of four 
interventions used resistance training in combination with balance training or treadmill 
walking, meaning that any improvements in functional ability need to be interpret with 
caution as they might be a result of the treadmill or balance training rather than the 
resistance training. Another recent systematic review by Uhrbrand et al. (2015) 
investigating resistance training, endurance training and other intensive training modalities 
included fifteen studies and suggests that intensive exercise therapy is feasible, safe and 
beneficial in Parkinson’s disease, with strong evidence from a meta-analysis including six 
studies that resistance training can improve muscle strength  (Uhrbrand, Stenager et al. 
2015).  Although this study claims to be the first systematic review into the effect of 
intensive exercise therapy there are some drawbacks to the review. Again, all studies 
investigated exercise programmes with a duration of up to three months, expressing a lack 
of studies looking into longer term programmes; sample size varied from 15 to 108, 
indicating that studies with relatively small sample sizes have been included. Studies with 
small sample sizes, and thus low statistical power, have a reduced change of detecting a 
true effect, so drawing conclusions from these small studies may be questionable; the 
PEDRO scores of the studies varied between 4 and 8 with an average of 5.8, again showing 
relatively poor methodological quality; finally, trials had to be excluded for poor 
description of intensity, frequency, duration and progression of training, which means that 
the literature presented here does not included all interventions. Care must be taken with 
reporting of a trial. A final thing to say is that in the review, conclusions are drawn from 
between two and six studies. For example, it is described that resistance training may 
improve quality of life, however, only two studies measures quality of life, and only one of 
the two studies found a positive effect, indicating that more research is needed into the area 
to draw definite conclusions. Overall, it seems that more research is needed into intensive 
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training to draw any definite conclusions and it is of great importance that the reporting of 
any trials are done using TiDieR guidelines (Hoffmann, Glasziou et al. 2014) so that 
studies can be assessed, repeated and included in reviews. As the results of intensive 
training seem to be positive in people with Parkinson’s disease, it would be important to 
include intensive training elements into an exercise programme in order to investigate this 
further. 
 A review done by Allen et al (2011) looks into participant characteristics, intervention 
delivery, retention rate, adherence and adverse events in trials looking into exercise and 
motor training in people with Parkinson’s disease in 53 trials. This review found that 
overall, trials that assess the effects of exercise and/or motor training, are beneficial in 
improving walking, balance, muscle strength and the performance of functional tasks in 
people with mild to moderate Parkinson’s disease (Allen, Sherrington et al. 2012). The 
review discusses some drawbacks of the trials that were included. Firstly, the average 
intervention duration of all trials was 8.3 weeks (standard deviation was 4.2; range was 2 – 
26 weeks) with an average of around 20 hours of training. As Parkinson’s disease is a 
progressive disorder, sustainable interventions are important as a treatment. Although all 
trials found some benefit of exercise, it is important to research the effects and 
sustainability of an exercise programme lasting for a longer period of time. Furthermore, 
74% of the interventions described involved full-supervision of exercise and/or motor 
training mostly at universities or hospitals. Again, since Parkinson’s disease is a 
progressive disorder, fully supervised programmes are not likely to be realistic as they are 
very costly. Effort should be made to investigate the possibility of a low-supervised 
exercise training in a community setting, to lower burden on the participant (in relation to 
travel). Furthermore, adherence is an important aspect for clinicians/therapist in the 
translation of the research to real life (Allen, Sherrington et al. 2012). Adherence was 
poorly reported, with only 26 studies (49%) of the studies reporting some form of 
adherence. Care must be taken when designing a trial in how adherence is measured with 
strategies in place to improve adherence like participant involvement in goal setting and 
flexibility to allow programs to be modified for individuals (Allen, Sherrington et al. 
2012).  
There are many studies investigating short term (< three months) exercise interventions. 
One study running a ten-month trial community base exercise and wellness program for 
people diagnosed with Parkinson’s disease found improvements in ambulation endurance 
over the ten-month course of their study (Steffen, Petersen et al. 2012). However, in this 
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study only fifteen people with Parkinson’s disease were included, the participants were not 
randomised, and only ten participants completed the exercise programme indicating that 
the results found should be explored further in a larger population with a control group. 
Overall, there is compelling evidence that exercise and physiotherapy is beneficial for 
people with Parkinson’s disease. However, little research has been done into longer term, 
sustainable, exercise interventions. Moving forward, it is important to explore the effects 
of exercise over a longer period (> three months) of time. Furthermore, it is important to 
ensure methodological quality and good reporting of both the intervention and the results, 
so data can be used in informing future studies. As described, most studies have been 
conducted in a specialist setting using intensive supervision. Moving forward, it is 
important to explore more sustainable exercise interventions. 
The mode of delivery of exercise is a relatively unexplored area. In the studies described 
above most studies deliver exercise in a specialist setting (e.g. hospital, physiotherapy). In 
order to make exercise for people with neurological conditions, including Parkinson’s 
disease, feasible for a longer period of time, as it is a progressive disorder and will need 
addressing using exercise indefinitely; low cost, accessible exercise facilities should be 
present in the community setting. 
1.9.4 Exercise for fatigue  
Although the perception of worsened fatigue after overtraining may occur as a 
consequence of afferent inhibition from strained muscles (Andreasen, Stenager et al. 
2011), exercise is often chosen as a treatment method for fatigue in other disorders 
including Chronic Fatigue Syndrome (Whiting, Bagnall et al. 2001, Castell, Kazantzis et 
al. 2011) and Multiple Sclerosis (Andreasen, Stenager et al. 2011, Pilutti, Greenlee et al. 
2013). Andreasen et al (2011) conducted a systematic review looking at the effect of 
exercise therapy on fatigue in Multiple Sclerosis. In ten studies described in the review the 
exercise intervention comprised of endurance training of which some demonstrated a 
substantial effect on fatigue; in three studies, the exercise intervention comprised of 
resistance training, these studies showed promising results in reducing fatigue; finally, 
three studies described a combined training with one study showing no effect, one showing 
an effect, and one showing a trend towards an effect. Overall, the review concludes that 
exercise therapy has the potential to reduce fatigue in people with Multiple Sclerosis 
(Andreasen, Stenager et al. 2011). 
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However, little research has been done into exercise as a treatment method for fatigue in 
people with Parkinson’s disease. A recent study exploring aerobic exercise in 60 people 
with Parkinson’s disease observed that aerobic exercise (three times a week for six 
months) in the community improved fatigue in people with Parkinson’s disease. However, 
they do state that after adjustment for different training methods and settings, calendar 
year, and change in levodopa equivalent, the fatigue score changes to non-significant (Uc, 
Doerschug et al. 2014). Furthermore, a downfall of this study was that they did not have a 
control group, as both groups of participants received an exercise programme (continues or 
interval) and in the final analyses, all patients were grouped together. Interestingly, the 
study found that completers of the intervention were significantly more fatigued than 
dropouts, which may suggest that an exercise intervention might be more suitable for 
participants with a certain level of fatigue. Furthermore, a study investigating fifteen 
people with Parkinson’s disease found an effect of high intensity exercise on fatigue as 
measured by the fatigue severity scale (Kelly, Ford et al. 2014), however this was only a 
small study and it was not a randomised controlled trial lacking, indicating that further 
work in a larger group of people including a control group is needed. 
1.10 Patient views 
Previously, the research agenda has been accused to be mainly led by pharmaceutical and 
medical devices industries instead of addressing the issues that are important for the 
patients (Deane, Flaherty et al. 2014). Qualitative research is needed to explore what is 
important for the patient and for the design of interventions (Deane, Flaherty et al. 2014). 
Qualitative research has been conducted to explore patients’ views on the most bothersome 
symptoms of Parkinson’s disease and on treatment of Parkinson’s disease. Patients with 
Parkinson’s disease listed tremors, lack of mobility, pain, imbalance, lack of 
energy/fatigue, having to give up previously enjoyed activities, dysarthria, and anxiety or 
depression as most troublesome symptoms (Uebelacker, Epstein-Lubow et al. 2014). 
Furthermore, a large study was conducted by Deane et al. (2014) in order to identify the 
top 10 research priorities for the management of Parkinson’s disease. Deane et al. 
identified 94 uncertainties from 4100 responses from patients with Parkinson’s disease, 
carers and health care professionals. They then send these out to 475 participants in order 
to be prioritised. From the responses a top 26 of uncertainties was presented; one of the 
uncertainties listed in this top 26 was: ‘What interventions are effective for reducing or 
managing unexplained fatigue in people with Parkinson’s?’ also indicating that fatigue 
seems to be an important issue for people with Parkinson’s disease. 
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A previous study (The Long-term Individual Fitness Enablement (LIFE) project) looking 
at barriers and facilitators of exercise in people with long term neurological conditions 
revealed that barriers for exercise in people with long term neurological conditions include 
(Elsworth, Dawes et al. 2009): 
- Costs  
- Negative personal experiences and attitudes as well as fear and embarrassment of 
exercising 
- Perception that fitness instructors will lack knowledge about their condition and 
how to help them participate in exercise safely and effectively 
- Transportation and access 
- Equipment (a lack of equipment suitable for and usable by disabled people) 
- A fear of losing balance 
Furthermore, the following facilitators were identified (Elsworth, Dawes et al. 2009): 
- Positive personal attitudes 
- Individually tailored gym programmes 
- An exercise place that actively supports people with similar conditions and 
disabilities 
- An exercise programme that considers individual motivators for exercise, not 
necessarily assuming individuals will be motivated by factors such as weight 
control, body shape or “keeping fit” 
Although barriers concerning community exercise facilities are present, community 
exercise facilities are widely available in the United Kingdom (Winward 2011); therefore, 
exploring ways of making community exercise facilities more accessible for people with 
Parkinson’s disease would be an important aspect into the delivery of long term exercise 
programmes. 
The barriers and facilitator found in the first phase of the LIFE study were incorporated in 
an intervention. A physical activity and support system (PASS) was created addressing 
practical issues as, how to park, how to find and get to the fitness room, where the toilets 
and changing areas are and how to meet the fitness professional. Furthermore, a 
physiotherapist would go through the PASS with the client and would arrange to meet up 
with the client and local fitness professional, providing knowledge and experience of 
neurological conditions, advice on how to modify programmes, knowledge of impairments 
specifically associated with neurological conditions, and an understanding of medications 
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related to these conditions. All these aspects were incorporated in the second part of the 
LIFE study; a pilot study exploring the feasibility and acceptability of a community 
exercise intervention in people with longer-term neurological conditions. Although in this 
study 99 patients with long term neurological conditions including multiple sclerosis, 
Parkinson’s disease, motor neuron disease, cerebral palsy and a number of neuromuscular 
conditions were included; people with Parkinson’s disease made up the largest group of the 
study (n= 39). All participants were encouraged to use local gyms to exercise (the number 
and length of the sessions were determined by the individual).  The intervention 
specifically addressed five key areas: i) access and transport; ii) the fitness instructor; iii) 
the gym; iv) health professional support; v) how to exercise safely. Results show that on 
average, patients attended one session per week over twelve weeks resulting in comparable 
exercise participation to standard GP exercise referral schemes (Elsworth, Winward et al. 
2011, Winward 2011). The physiotherapist gave an average of three 1 hour face-to-face 
and three 5-20 minute phone calls per day (Winward 2011). The study found positive 
changes in mobility outcomes suggestive of a benefit of moderate effect size. 
The study also looked into the effects of this exercise programme on fatigue in the 39 
people with Parkinson’s disease studied. The study found that participants randomised to 
the exercise group attended an average of 15 sessions over 12 weeks and no effects of 
exercise on the Fatigue Severity Scale (self-reported fatigue measure) score was found 
(Winward, Sackley et al. 2012).  A reason for the lack of effect found could be the low 
attendance, not providing sufficient exercise to induce any change. A study exploring 
specific prescribed doses and/or motivational approaches is suggested as further research. 
Following up from this study it would be interesting to explore any longer term effects of 
the exercise trial with a higher dose of exercise sessions per week using the information on 
barriers/facilitators in this specific study. 
1.11 Aims of the thesis  
This chapter described Parkinson’s disease and many issues arising with the disease. 
Fatigue seems to be an important symptom affecting many people with Parkinson’s 
disease. Fatigue may be a direct symptom of Parkinson’s disease or secondary due to other 
complications like depression and due to side effects of medications often prescribed to 
Parkinson’s disease patients, including anti-depressants, anti-hypertensives, and statins 
(Chaudhuri and Behan 2004). This shows that fatigue is a common and debilitating 
symptom in people with Parkinson’s disease and research is needed not only in the concept 
of fatigue, but also in possible treatment methods, like exercise. Therefore, this thesis will 
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aim to explore fatigue and will build results from the LIFE study to investigate exercise as 
a treatment method for fatigue.  
This thesis has three main aims 
 To explore fatigue, including a literature review on current treatment methods of 
fatigue for people with Parkinson’s disease. 
 To determine baseline characteristics of a group of people with Parkinson’s disease 
and explore fatigue in this group. 
 To explore adherence to a six months twice weekly exercise programme and to 
examine the effects of the exercise on general measures and fatigue after six 
months. 
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Chapter 2 Fatigue 
Summary 
This chapter defines and describes fatigue. It briefly touches on central fatigue and how to 
measure this. Since intervention studies investigating fatigue in people with Parkinson’s 
disease normally use self-reported questionnaires to measure fatigue, in this chapter 
different self-reported questionnaires are described. Next, confounding problems that arise 
with fatigue in people with Parkinson’s disease will be discussed. Finally, in order to put 
this information into context, the ICF-model is used. 
2.1 Fatigue defined 
Fatigue in Parkinson’s disease first appears in literature in the article of J.R. Van Meter 
(1950). In this article it is stated that ‘mental or physical fatigue intensifies the symptoms 
of Parkinson’s disease’ (Van Meter 1950).  Fatigue was first described as a specific 
symptom of Parkinson’s disease by Hoehn and Yahr (1976). However, its significance has 
only really been recognised in the last two decades (Fabbrini, Latorre et al. 2013). Despite 
an increasing number of studies into the subject, its pathophysiology is still unknown 
(Kluger, Krupp et al. 2013), and there remains a lot of debate into its relationships with 
other symptoms in people with Parkinson’s disease, for example disease severity has both 
been found related (Herlofson and Larsen 2003, Havlikova, Rosenberger et al. 2008) as 
well as not related (Friedman and Friedman 1993, van Hilten, Weggeman et al. 1993, Abe, 
Takanashi et al. 2000, Lou, Kearns et al. 2001, Shulman, Taback et al. 2001) in different 
studies to fatigue, as will be described later this chapter; as well as measurement 
techniques, including self-reported measures (Kluger, Krupp et al. 2013) and experimental 
technologies including transcranial magnetic stimulation (TMS), and FMRI (Abe, 
Takanashi et al. 2000), all resulting in a range of treatment techniques including drug 
therapy, cognitive behavioural therapy and exercise therapy (Franssen, Winward et al. 
2014). This shows that fatigue needs to be explored further in people with Parkinson’s 
disease in order to inform future treatment techniques. 
Although fatigue seems to have a large impact on people with Parkinson’s disease, 
affecting 40% to 56% of all patients (Herlofson and Larsen 2003, Friedman, Brown et al. 
2007, Okuma, Kamei et al. 2009), the mechanism of fatigue in people with Parkinson’s 
disease is poorly understood (Kluger, Krupp et al. 2013).  
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A feeling of constant exhaustion is a characteristic of central fatigue; this feature is often 
associated with neurological disorders, including Parkinson’s disease (Chaudhuri and 
Behan 2004). 
2.1.1 Central fatigue 
Central fatigue describes fatigue as the failure to initiate and/or sustain both attentional 
tasks and physical activities; the subjective sense of fatigue is perceived at a central level 
(Chaudhuri and Behan 2004). Central fatigue can be present in disorders of the peripheral, 
autonomic and central nervous system (Chaudhuri and Behan 2004). Brief episodes of 
fatigue are normal after a period of stress, following loss of sleep, however, sometimes the 
fatigue is chronic, persistent or relapsing (lasting for >3-6 months), which is extremely 
common in people with Parkinson’s disease (Chaudhuri and Behan 2000). 
2.2 Ways to measure fatigue  
In the paragraphs below different ways of measuring fatigue will be discussed. 
2.2.1 Measuring Central Fatigue 
Central fatigue is studied in healthy people and people with neurological disorders by 
studying central ‘abnormalities’. Neurophysiological studies of healthy human subjects 
using transcranial magnetic stimulation and nerve stimulation reveal changes in motor 
cortex and spinal excitability. These are associated with fatigability during motor tasks and 
suggest that deficits in central drive are responsible for a significant percentage of 
fatigability depending on task demands (Kluger, Krupp et al. 2013). 
Neurophysiologic studies of healthy human subjects using TMS and nerve stimulation 
reveal changes in motor cortex and spinal excitability associated with fatigability during 
motor tasks and suggest that deficits in central drive are responsible for a significant 
percentage of fatigue depending on task demands (Kluger, Krupp et al. 2013). 
Furthermore, Lou et al. (2001) found that the physical fatigue in people with Parkinson’s 
disease is caused by abnormal corticomotor neuron excitability, rather than fatigue by the 
muscle fibre (Lou, Kearns et al. 2001). Finally, Rothwell et al. (2007), investigated 
corticospinal excitability after exercise using TMS and found two differences in people 
with Parkinson’s disease compared to healthy patients: no change in the duration of the 
cortical silent period and no changes in the slope of the input-output curve suggesting an 
abnormal basal ganglia output to the cortex in people with Parkinson’s disease, whereas in 
healthy controls there was a decrease in corticospinal excitability and an increase in the 
duration of the cortical silent period after exercise (Khedr, Galal et al. 2007). Studies in 
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healthy human subjects using TMS and nerve stimulation reveal changes in motor cortex 
and spinal excitability associated with fatigue during motor tasks. Furthermore, fMRI 
studies in Parkinson’s disease have shown that that metabolic activity is reduced in the 
supplementary motor area and premotor areas but increased in the primary motor cortex in 
Parkinson’s disease patients (Friedman, Brown et al. 2007). The imaging techniques 
described above can be expensive, and can only be administered by trained people. 
2.2.2 Measuring self-reported fatigue 
In most studies investigating ways to treat fatigue both in Parkinson’s disease (Abe, 
Takanashi et al. 2001, Ondo, Fayle et al. 2005, Leentjens, Scholtissen et al. 2006, 
Mendonca, Menezes et al. 2007, Schifitto, Friedman et al. 2008, Lou, Dimitrova et al. 
2009, Ghahari, Leigh Packer et al. 2010, Tyne, Taylor et al. 2010, Ondo, Shinawi et al. 
2011, Drijgers, Verhey et al. 2012, Postuma, Lang et al. 2012, Winward, Sackley et al. 
2012, Rios Romenets, Creti et al. 2013, Stocchi 2013) as well as in other patient 
populations like Multiple Sclerosis (Surakka, Romberg et al. 2004, White, McCoy et al. 
2004), self-reported questionnaires are used to describe fatigue. Self-reported 
questionnaires measure fatigue experienced by the patient and is often defined as an 
overwhelming sense of tiredness, lack of energy and feeling of exhaustion (Friedman and 
Friedman 1993, Zwarts, Bleijenberg et al. 2008). Different scales are used in different 
studies to measure fatigue. A review by Tyson and Brown on fatigue scales in neurological 
conditions states that none of the by them selected tools met all the criteria required to 
demonstrate robust psychometrics and utility (Tyson and Brown 2014). A review on 
Fatigue Rating Scales used for Parkinson’s disease discussed nine different scales to 
measure fatigue (Friedman, Alves et al. 2010), demonstrating the lack of consensus on how 
to measure fatigue. In this review it was concluded that two scales meet the criteria for the 
designation of ‘recommended’ as defined by the Movement Disorders Society for rating 
fatigue severity: the Fatigue Severity Scale and the Multidimensional Fatigue Inventory 
(Friedman, Alves et al. 2010).  Therefore, these two scales will be discussed in more detail 
below. Additionally, there is one Parkinson’s disease specific fatigue scale, the Parkinson 
Fatigue Scale, which will also be described. 
The Multidimensional Fatigue Inventory: The Multidimensional Fatigue Inventory is a 20-
item self-report measure including different dimensions. The scale is short with good 
psychometric properties (Smets, Garssen et al. 1995). It is shown to have good 
psychometric properties in non-Parkinson’s disease populations (Whitehead 2009), and in 
one study investigating validity of the scale in people with Parkinson’s disease (Elbers, van 
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Wegen et al. 2012). Disadvantages are that the scale does not define fatigue. Furthermore, 
discrimination between fatigued and non-fatigued Parkinson’s disease patients has not 
been demonstrated (Friedman, Alves et al. 2010). The scale was considered appropriate for 
rating fatigue severity by the Movement Disorders Society (Friedman, Alves et al. 2010). 
The Parkinson Fatigue Scale: In 2005, Brown et al. developed a Parkinson’s disease 
specific fatigue scale, the Parkinson Fatigue Scale. This scale aimed to distinguish between 
people with Parkinsonism who considered they had fatigue and those who did not; and 
between those with problematic and non-problematic levels of fatigue (Brown, Dittner et 
al. 2005). The scale is a 16-item self-reported questionnaire with response options: strongly 
disagree, disagree, do not agree or disagree, agree, and strongly agree (Brown, Dittner et 
al. 2005). Responsiveness to change has not yet been evaluated in Parkinson’s disease, 
furthermore a major disadvantage of this scale is that further studies are needed to evaluate 
its measurement properties in Parkinson’s disease (Friedman, Alves et al. 2010). 
Fatigue Severity Scale: The Fatigue Severity Scale is a uni-dimensional questionnaire 
assessing the effect of fatigue on daily living by use of nine statements which are scored on 
a seven-point Likert scale ranging from totally disagree (1) to totally agree (7) (Krupp, 
LaRocca et al. 1989, Elbers, Rietberg et al. 2012). The scale measures physical fatigue, 
mental fatigue and social aspects, they are not divided in different domains (Friedman, 
Alves et al. 2010). The items cover motivation; physical function; responsibilities; work, 
family or social life; exercise; how easily fatigued; frequency of problem; and priority of 
symptoms (Tyson and Brown 2014).  Studies show that this questionnaire has a good 
internal consistency, and test-retest reliability in different patient groups with neurological 
disorders (Herlofson and Larsen 2003, Horemans, Nollet et al. 2004) including Parkinson’s 
disease (Hagell, Hoglund et al. 2006, Friedman, Alves et al. 2010). The Fatigue Severity 
Scale is appropriate to detect changes in fatigue over time (Whitehead 2009). The scale is 
brief and easy to administer, and it has shown sensitivity to change in previous clinical 
trials. Disadvantages for the Fatigue Severity Scale include that the scale does not provide 
a definition of fatigue and only few studies assessed its psychometric properties in 
Parkinson’s disease (Friedman, Alves et al. 2010).The scale was considered appropriate for 
rating fatigue severity by the Movement Disorder Society (Friedman, Alves et al. 2010). 
Furthermore, it is the most commonly used scale, making it an attractive scale to use in 
studies as they can be used meta-analyses (Friedman, Alves et al. 2010). 
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2.3 Fatigue and confounding problems and fatigue and its relationship to other symptoms 
of Parkinson’s disease 
As mentioned before, fatigue has become recognised as an important symptom of 
Parkinson’s disease over the last two decades, resulting in numerous studies into its 
relationship with other symptoms, including depression, sleepiness, and quality of life. 
Below, research on these relationships will be discussed.  
2.3.1 Fatigue and depression 
As described in Chapter 1, depression is very common in people with Parkinson’s disease 
and affects up to 50% of the patients (Dooneief, Mirabello et al. 1992). Fatigue is one of 
the symptoms included in the criteria for Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition diagnoses of anxiety and depressive disorders, in addition to the 
fundamental affective changes (Lamers, Hickie et al. 2013). Although fatigue is defined in 
different ways in depressive disorders, fatigue appears to be one of the more important and 
difficult to treat aspects of depression in general (Friedman, Brown et al. 2007). This 
shows that that fatigue could be a result of depression in people with Parkinson’s disease. 
A long term study into the relationship between fatigue and depression  found that fatigue 
is related to depression (Alves, Wentzel-Larsen et al. 2004). In this study 233 people with 
Parkinson’s disease were included in 1993 and were followed up for eight years, with 111 
people being followed up in 1997 and 78 people in 2001. The study found significant 
higher depression scores in fatigued patients versus non fatigued patients (Alves, Wentzel-
Larsen et al. 2004). However, they did find a high number of fatigued patients that were 
not depressed (Alves, Wentzel-Larsen et al. 2004). Furthermore, several studies that 
investigate fatigue in a cohort of Parkinson’s disease patients without depression find that 
fatigue is present in 41-50% of the patients (Karlsen, Larsen et al. 1999, Herlofson and 
Larsen 2002, Okuma, Kamei et al. 2009). In the study of Karlsen et al. 233 patients with 
Parkinson’s disease were examined and result showed that fatigued patients were more 
depressed; again, once patients with depression were excluded, the number of patients that 
were fatigued remained high (43.5%) (Karlsen, Larsen et al. 1999). Herlofson and Larsen 
looked into fatigue in non-depressed patients with Parkinson’s disease and found that in 66 
people, 33 people were fatigued, indicating that fatigue is present in non-depressed patients 
with Parkinson’s disease (Herlofson and Larsen 2002). Finally, in the study of Okuma et 
al. 361 Japanese people with Parkinson’s disease were assessed and fatigue was present in 
41.8% and a significant higher depression was found in fatigued people (Okuma, Kamei et 
al. 2009), however, a logistic regression did not find depression as a significant factor in 
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relation to fatigue (Okuma, Kamei et al. 2009). These results suggest that even though 
fatigue can be a result of depression in people with Parkinson’s disease, it is also an 
independent symptom, found in people with Parkinson’s disease, separate from depression.  
2.3.2 Fatigue and sleepiness 
Excessive daytime sleepiness is present in 8-50% of patients with Parkinson’s Disease 
(Friedman, Brown et al. 2007). Symptoms of fatigue and sleep dysfunction overlap 
sufficiently to potentially confound studies of fatigue (Friedman, Brown et al. 2007). 
Parkinson’s disease patients however, manage to distinguish between fatigue and 
sleepiness. Where sleep will refresh people with sleepiness, people with fatigue remain 
fatigued after sleep. Studies suggest that fatigue and the degree of sleepiness in Parkinson’s 
disease patients are unrelated (Karlsen, Larsen et al. 1999, Alves, Wentzel-Larsen et al. 
2004). Comparable to depression described above, in the study of Karlsen et al. patients 
with sleepiness were excluded from the cohort, and it was found that 43.5% of the cohort 
was fatigued, indicating that fatigue is present in people without sleepiness. Similarly, 
Alves et al. excluded all people with sleepiness from their cohort and found that the 
prevalence rate of fatigue remained high across all years (32.1% in 1993; 38.9% in 2001), 
again indicating that fatigue is present in people with Parkinson’s disease separate from 
sleepiness.  
2.3.3 Fatigue and disease severity 
In a review of fatigue in neurological disorders, it is described that the severity of fatigue is 
not indicative of the nature or the severity of underlying disease (Chaudhuri and Behan 
2004). However, the relation between fatigue and disease severity is debated in the 
literature. Some studies have found that patients with fatigue had more severe disease 
status (Herlofson and Larsen 2002, Havlikova, Rosenberger et al. 2008). In the study of 
Herlofson et al. 66 patients were included and a significant difference was found between 
fatigued (50% of the patients) and non fatigued patient on the UPDRS III score (Herlofson 
and Larsen 2002). Havlikova et al. studies 78 people with Parkinson’s disease and found a 
significant correlation between the UPDRS scale and four out of five domains of the 
multidimensional fatigue inventory (Havlikova, van Dijk et al. 2008). Other studies have 
found that disease severity did not correlate with fatigue (Friedman and Friedman 1993, 
van Hilten, Weggeman et al. 1993, Abe, Takanashi et al. 2000, Lou, Kearns et al. 2001, 
Shulman, Taback et al. 2001). Overall, to date no conclusion can be drawn on the 
relationship between fatigue and disease severity in people with Parkinson’s disease. 
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2.3.4 Fatigue and Quality of Life 
Quality of life is defined by the World Health Organization as a state of complete physical, 
mental and social well-being (World Health Organization 1997). A variety of studies have 
investigated the influence of fatigue on quality of life. Herlofson & Larsen (2003) found 
that severity of fatigue showed a strong correlation with the Parkinson’s disease 
Questionnaire 39 and several domains of the Short Form 36 (SF-36), which are both self-
administered questionnaires measuring quality of life. Havlikova et al. (2008) found that 
fatigue predicted worsening on all quality of life domains as measured by the Parkinson’s 
disease Questionnaire 39 (Havlikova, Rosenberger et al. 2008). Overall, it can be 
concluded that fatigue has got a negative influence on quality of life in people with 
Parkinson’s disease, demonstrating the importance of addressing fatigue. 
2.3.5 Fatigue and physical activity levels 
Due to physical activities and mental changes, many people with Parkinson’s disease lead 
a sedentary lifestyle (van Nimwegen, Speelman et al. 2013). Furthermore, a study into 
exercise and fatigue in 39 people with Parkinson’s disease revealed that people who were 
more fatigued were more likely to be less active (Winward, Sackley et al. 2012). 
Furthermore, several large cohort studies have shown that fatigue is associated with a more 
sedentary lifestyle (Friedman, Brown et al. 2007). It is unclear whether physical inactivity 
is a result of fatigue or whether physical inactivity causes fatigue (Rongen-van Dartel, 
Repping-Wuts et al. 2014). 
2.4 ICF-Model 
The issues concerning fatigue that are described above can be put in a model that provides 
a framework for approaching the questions of what is important to study (Threats 2002). 
The International Classifaction of Functioning , Disability and Health (ICF) model ICF-
model describes a situation of an individual with different health related domains within 
the context of environmental and personal factors (Davis 2006). Factors in the ICF model 
are functioning and disability, including body functions and structures, activity and 
participation, and contextual factors, including environmental and personal factors (Davis 
2006). The ICF-model offers a global approach to thinking about health and health-related 
states. It provides a common language for describing health, functioning and disability 
(Rosenbaum and Stewart 2004).  
All motor, non-motor symptoms arising in people with Parkinson’s disease and quality of 
life are put together by means of the ICF-model with fatigue as the main issue. This gives 
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Fatigue 
Body function and 
structures 
-Disease Severity  
-Strength 
-Endurance 
-Depression 
-Sleepiness 
Activities 
-Mobility 
-Activity levels 
-Deconditioning 
Participation 
-Quality of Life 
Environmental factors 
Sleep environment 
Personal factors 
Age, medication, gender 
an overview on all relations together, shown in Figure 3. The model shows the great 
complexity around fatigue, by showing that neither fatigue, nor any of the issues that may 
be involved with fatigue stand on its own.  
 
 
 
 
 
Figure 3: ICF model applied to fatigue in people with Parkinson’s disease 
2.5 Treatments for fatigue in people with Parkinson’s disease  
From this chapter it can be concluded that fatigue is a complex phenomenon due to the 
unknown pathophysiology, the numerous co-factors influencing fatigue, and the numerous 
methods to measure fatigue. Nonetheless, an increasing number of studies address fatigue 
and explore different ways of treating fatigue, therefore it is important to get a clear picture 
of treatment methods in fatigue to find out which methods might be more effective than 
others. The next chapter will present a systematic review of different treatment methods 
used to treat fatigue in people with Parkinson’s disease. 
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Chapter 3: Interventions for fatigue in Parkinson's disease: A systematic review and meta‐
analysis  
Summary 
This chapter is a systematic review and meta-analysis evaluating the different ways that 
have been used to treat fatigue in people with Parkinson’s disease. A search was 
conducted of PubMed, Cinahl, Psychinfo, EMBASE, and Web of Knowledge up to 
November 2013. Fourteen studies with a total of 1890 patients were included in the 
systematic review, with eleven studies exploring drugs, such as amphetamines, dopamines, 
caffeine, and memantine. One study explored doxepin and cognitive behavioural therapy; 
one study focused on cognitive behavioural therapy and one study investigated exercise as 
a treatment method for fatigue. Methodological quality was assessed using the PEDro 
scale. For meta-analyses, studies were weighted on variance. Effect sizes were calculated 
with 95% confidence interval (CI); overall effect was presented by means of a Z-score; 
heterogeneity was investigated using the I2. Three articles (investigating amphetamines) 
were appropriate for meta-analysis,which was performed according to scales used: 
Multidimensional Fatigue Inventory: mean difference, –6.13 (95%CI: –14.63-2.37, Z 5 
1.41, P 5 0.16; I2 5 0); Fatigue Severity Scale: mean difference, –4.00 (95%CI: –8.72-
0.72, Z 5 1.66, P 5 0.10; I2 5 0), indicating that further research to develop treatment 
methods for fatigue in people with Parkinson’s disease is necessary. 
3.1 Introduction 
Studies show that non motor symptoms may have an impact on the lives of patients with 
Parkinson’s disease (Herlofson and Larsen 2002), contributing to disability, reduced 
quality of life, and shortened life expectancy (Chaudhuri, Healy et al. 2006). One of the 
factors reducing quality of life in people with Parkinson’s disease is fatigue (Herlofson and 
Larsen 2002, Havlikova, van Dijk et al. 2008, Miwa and Miwa 2011). Fatigue appears to 
be a common and disabling symptom for people with Parkinson’s disease affecting all 
aspects of life including activities of daily living, work and social activities, and is often 
overlooked (Herlofson and Larsen 2003, Winward, Sackley et al. 2012).  
Fatigue affects up to 58% of all people with Parkinson’s disease (Alves, Wentzel-Larsen et 
al. 2004, Friedman, Alves et al. 2010), and more than half rank it as one of their three 
worst symptoms (Garber and Friedman 2003). The aetiology and pathophysiology of 
fatigue in Parkinson’s disease remains unclear . Considering the impact of increased 
fatigue levels in this population, evidence for treatments to reduce its impact will provide 
   
32 
 
useful information to inform evidence based clinical practice and guide rehabilitation 
programmes. 
As described in the previous chapter, fatigue can be measured in different ways. Since 
studies into fatigue in people with Parkinson’s disease generally use self-administered 
questionnaires, the focus in the chapter will be on subjective fatigue as measured by 
questionnaires.  
Evidence for treatment effects is limited (Seppi, Weintraub et al. 2011). A recent non–
motor symptom review by Seppi et al. (2011) included evidence for treating fatigue in 
Parkinson’s disease. The review included only three studies and concluded that evidence 
was insufficient for the use of the pharmacological treatments, methylphenidate and 
modafinil, for fatigue (Seppi, Weintraub et al. 2011). The review found looked into the 
effects of methylphenidate and modafinil on fatigue in people with Parkinson’s disease 
(Seppi, Weintraub et al. 2011). The included study with regards to methylphenidate was a 
randomised controlled trial in 36 people looking into the effects of methylphenidate as a 
treatment method for fatigue and found a positive effect of the drug on fatigue scores 
(Mendonca, Menezes et al. 2007). The review found two randomised controlled trials 
looking into modafinil as a treatment method. One study, including 19 fatigued people 
with Parkinson’s disease did not find an improvement over time using modafinil (Lou, 
Dimitrova et al. 2009); the other study, including 13 patients with fatigue received either 
modafinil or placebo for nine weeks and found no effects on fatigue (Tyne, Taylor et al. 
2010). The small number of studies included in this review shows that more research into 
fatigue in people with Parkinson’s disease is needed. However, the literature has to be 
explored further to investigate whether any additional trials have investigated fatigue, 
either as a main outcome, or a secondary outcome. Overall, there are a number of different 
treatment methods for fatigue in people with Parkinson’s disease investigated including 
drug treatment (as described above) (Seppi, Weintraub et al. 2011), and exercise training 
(Winward, Sackley et al. 2012); however, there is no clear consensus to guide clinicians. 
3.1.1 Aim of this systematic review and meta-analysis 
The aim of this systematic review was to conduct a review and meta-analysis in people 
with Parkinson’s disease investigating any interventions addressing fatigue comparing to 
any control group in a randomised controlled setting, with self-reported fatigue as an 
outcome measure, in order to establish the evidence of effectiveness of the treatment 
methods.  
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3.2 Methods 
This systematic review and meta-analysis was conducted in accordance with the PRISMA 
guidelines (appendix 2) (Moher, Liberati et al. 2009), no review protocol was published. 
3.2.1 Literature search 
In order to reduce the chance that relevant papers will be discarded, two people (CW, MF) 
independently searched the electronic databases Pubmed, Psychinfo, Cinahl, Embase and 
Web of Knowledge for articles published from the inception of each database up to and 
including November 2013. An example of a search strategy can be found in appendix 3. 
References found in the retrieved articles where checked and on-going trials were 
identified via www.clinicaltrials.gov. The search included the following key words: 
Parkinson’s disease, parkinsonian disorders, Parkinson’s, fatigue.  Only articles published 
in English and Dutch were included. Authors were not contacted to establish additional 
studies. 
3.2.2 Study selection 
Two people (CW and MF) independently evaluated titles and abstracts to determine 
eligibility. Full text was then obtained and reviewed to decide whether the inclusion 
criteria were met. In the case of lack of consensus a third reviewer’s (HD) input was 
sought. Studies were only included in the review if all criteria were met; Inclusion criteria 
were: (a) population described by authors as ‘Parkinson’s disease’ (patients of all ages and 
any duration of Parkinson’s disease were included; studies were included if they focused 
just on people with Parkinson’s disease, or if people with Parkinson’s disease were 
included and data on this subgroup was provided, in order to ensure all patients with 
Parkinson’s disease were included in the current review); (b) the study was a randomised 
controlled trial (to limit bias and improve reliability and accuracy of conclusions (Akobeng 
2005)); (c) to ensure inclusion of enough papers, studies were included in which there was 
a comparison of any intervention aiming at reducing fatigue with another intervention or 
control state, any length of study and length of follow up were included; (d) a validated 
fatigue specific measure was used, either as a separate questionnaire, or as a specific 
fatigue subscale of a larger questionnaire, (e) the study was double blind, or where this was 
not possible, single blind to ensure strong methodological quality. Studies intended to be 
double blind, but failed to be so, were excluded from the review. 
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Studies were excluded if: (a) fatigue was not mentioned in the abstract; (b) explicitly stated 
that the population was a Parkinson related disorder and not idiopathic Parkinson’s disease, 
(c) data after a crossover of patients were not used to avoid a carry-over effect. 
Studies were included in a meta-analysis if usable data were available (i.e. number of 
participants and mean (SD) scores). 
3.2.3 Data extraction 
A spread sheet was created, piloted and then applied to abstract the relevant data from the 
included articles. Four data extractors assessed the papers and extracted data from eligible 
studies. The extracted data were compared to establish reliability and mistakes were 
rectified and disagreements were discussed. 
Data extracted were: (1) characteristics of the trial’s participants including information on 
number of participants, participants age, disease duration, drugs taken, sponsor, and 
inclusion and exclusion criteria; (2)  characteristics of intervention including amount, 
duration, number of drop-outs; (3) type of outcome measure (including fatigue specific 
measure with its outcomes (confidence interval, mean, standard deviation, and p-value) at 
baseline and after the intervention); adverse events; remarks as necessary. If data was not 
available in the publication, the authors were contacted to provide data. One author 
provided the team with data, other authors did not respond. 
3.2.4 Risk of bias 
Bias at study level was assessed using the PEDro scale (The George Institute for Global 
Health 2012). On this scale items are scored 0 for absent, 1 for present and a score out of 
eleven is obtained (The George Institute for Global Health 2012). Two authors (CW and 
MF) used the PEDro scale, one of the authors (CW) also authored of one of the included 
studies, therefore MF scored this study. Only studies scoring excellent methodological 
quality were included in any meta-analyses. Any disagreements on scoring were discussed 
with a third reviewer (HD). Potential publication bias was investigated using funnel plots. 
3.2.5 Data synthesis and analysis 
The primary outcome measure was the difference in fatigue score on any used self-
reported fatigue measure. 
Studies investigating similar interventions (e.g. using drugs from the same group) were 
eligible for meta-analysis. Meta-analysis was performed using RevMan V 5.1 (Review 
Manager (RevMan)) [Computer program]. Version 5.1. Copenhagen: The Nordic 
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Cochrane Centre, The Cochrane Collaboration, 2011) (Cochrane 2011). A significance 
level of p=0.05 was set. 
In the meta-analyses, data from similar studies were pooled together. The meta-analyses 
were performed by computing mean differences using a random effect model. In this 
model inter-study treatment effect variance is estimated (DerSimonian and Kacker 2007). 
This model, was used since it is assumed that there is not one true effect size shared by all 
studies (caused by differences in study population, interventions received, and follow up 
length) (Borenstein 2007, Riley, Higgins et al. 2011). When different scales were used to 
measure the same outcome, standardised mean differences were calculated. Studies were 
weighed on variance, the less variance, the bigger the weighting (Collaboration 2002). 
Effect sizes were calculated with 95% confidence interval, overall effect was presented by 
means of a Z-score (which can be thought of as describing the data in standard deviation 
units) (Freemantle and Geddes 1998). Heterogeneity, a measure of how much of the 
variability in treatment effect estimates is due to real study differences, and how much was 
due to change, was investigated with the I2 statistic (Higgins, Thompson et al. 2003). 
Pooled analyses with a substantial (more than 50%) heterogeneity were not reported. In 
order to investigate comparable outcomes where possible, subgroup analyses were done 
separately for uni-dimensional and multi-dimensional fatigue questionnaires where mean 
differences were calculated.  
3.3 Results 
A total of 14 studies (total number of participants = 1,890) were included in the review. In 
total 972 studies were identified through database searches. No unpublished relevant 
studies satisfied the criteria for inclusion. Two studies included (Rascol, Fitzer-Attas et al. 
2011, Stocchi 2013) the same dataset; therefore, one dataset was used (See Figure 4). 
Three studies investigating amphetamines were eligible for meta-analysis.  
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Figure 4: PRISMA flow diagram  
Flow diagram showing the database search for interventions to treat fatigue in people with 
Parkinson’s disease.  
* Studies may be excluded for more then one reason.
Articles included based on title: 
(n=181) 
Articles found (n=972)  
Excluded based on title (n=791) 
 
Included in review (n=14) 
Included in meta-analysis (n=3) 
 
Articles included based on full text: 
(n=15) 
 
Articles included based on abstract: 
(n=33) 
Excluded based on abstract (n=148)* 
 No Parkinson’s disease(n=6) 
 No intervention (n=92) 
 No fatigue (n=50) 
 Study is ongoing (n=1) 
 
Excluded based on full text (n=18) 
 Did not measure fatigue (n=12) 
 No intervention (n=6) 
Excluded because of double data (n=1) 
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3.3.1 Study characteristics 
All 14 studies selected for the review were studies published in English. From the 14 
studies found, 11 used a pharmacological treatment (Abe, Takanashi et al. 2001, Ondo, 
Fayle et al. 2005, Leentjens, Scholtissen et al. 2006, Mendonca, Menezes et al. 2007, 
Schifitto, Friedman et al. 2008, Lou, Dimitrova et al. 2009, Tyne, Taylor et al. 2010, Ondo, 
Shinawi et al. 2011, Drijgers, Verhey et al. 2012, Rios Romenets, Creti et al. 2013, Stocchi 
2013), one used an online self-management intervention (Ghahari, Leigh Packer et al. 
2010), one used a caffeine treatment (Postuma, Lang et al. 2012) and one used an exercise 
intervention (Winward, Sackley et al. 2012). Drugs and hormones used were Pergolide 
(n=1) (Abe, Takanashi et al. 2001), pramipexole (n=1) (Drijgers, Verhey et al. 2012), acute 
tryptophan depletion (n=1) (Leentjens, Scholtissen et al. 2006), modafinil (n=3) (Ondo, 
Fayle et al. 2005, Lou, Dimitrova et al. 2009, Tyne, Taylor et al. 2010), methylphenidate 
(n=1) (Mendonca, Menezes et al. 2007), memantine (n=1) (Ondo, Shinawi et al. 2011), 
rasagiline (n=1) (Stocchi 2013), carbidopa-levodopa (n=1) (Schifitto, Friedman et al. 
2008), doxepin (n=1) (Rios Romenets, Creti et al. 2013). The study size varied from eight 
to 1176. The age in the studies ranged from 50 to 82. Disease duration varied from 5 
months to 9.1 years. Drugs taken, but not investigated, were: dopaminergics, catechol-O-
methyl transferase (COMT) inhibitors, monoamine oxidase (MAO-B) inhibitor, and 
anticholerinergics. Outcome measures used were Fatigue Severity Questionnaire (n=1) 
(Abe, Takanashi et al. 2001), Profile of Mood States (fatigue subscale) (n=2) (Leentjens, 
Scholtissen et al. 2006, Drijgers, Verhey et al. 2012), fatigue impact scale (n=1) (Ghahari, 
Leigh Packer et al. 2010), Parkinson’s Fatigue Scale (n=1) (Stocchi 2013), 
Multidimensional Fatigue Inventory (n=2) (Mendonca, Menezes et al. 2007, Lou, 
Dimitrova et al. 2009), Fatigue Severity Scale (n=8) (Ondo, Fayle et al. 2005, Mendonca, 
Menezes et al. 2007, Schifitto, Friedman et al. 2008, Tyne, Taylor et al. 2010, Ondo, 
Shinawi et al. 2011, Postuma, Lang et al. 2012, Winward, Sackley et al. 2012, Rios 
Romenets, Creti et al. 2013) (see Table 1). 
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Table 1: Basic characteristics of included studies 
Author Year N Intervention Outcome 
measure used 
Intervention 
period 
PEDro 
score 
Disease Duration 
(in years) 
Drugs taken 
   Active Control    Active Control  
Abe, K., M. 
Takanashi, et al. 
2001 41 Pergolide Mesilate 
990 ± 357 µg/day 
Bromocriptine* 
7.9 ± 2.5 mg/day 
Fatigue severity 
questionnaire 
5 weeks 6 6.0 6.3 Dopaminergics 
Drijgers, R.L., 
Verhey, F.R.J., et al. 
2012 25 Pramipexole 
500 µg 
OR 
Methylphenidate 
10 mg 
Placebo Profile of mood 
status; fatigue 
subscale 
1.5 hours 11 5.0**  Dopaminergics; 
COMT inhibitor; 
MAO-B inhibitor; 
anticholerinergics 
Ghahari, S., T. Leigh 
Packer, et al. 
 
2010 6 Fatigue self-
management 
programme 
OR 
Information only 
No intervention Fatigue impact 
scale 
7 weeks 8 No data   
Leentjens, A. F., B. 
Scholtissen, et al. 
2006 15 Acute tryptophan 
depletion 
75 g amino-acid 
mixture 3g/100g 
tryptophan, was left 
out 
Placebo 
75 g amino-acid 
mixture, 
tryptophan was 
not left out 
Profile of mood 
status 
6 hours 11 No data  NMDA agonist; 
dopamine agonist; 
Lou, J. S., D. M. 
Dimitrova, et al. 
2009 19 Modafinil 
100 mg twice a day 
Placebo Multidimension
al fatigue 
inventory 
2 months 11 4 8 dopamine 
agonists; 
carbidopa/levodo
pa; COMT 
inhibitor 
Mendonca, D. A., K. 
Menezes, et al. 
2007 36 Methylphenidate 
10 mg 3 times a day 
Placebo Fatigue severity 
scale; 
multidimension
al fatigue 
inventory 
6 weeks 11 3.5 9.1 dopaminergics 
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Table 1 (continued): Basic characteristics of included studies 
Author Year N Intervention Outcome 
measure used 
Intervention 
period 
PEDro 
score 
Disease Duration 
(in years) 
Drugs taken 
   Active Control    Active Control  
Ondo, W. G., R. 
Fayle, et al. 
2005 40 Modafinil 
Up to 200 mg twice 
a day 
Placebo Fatigue Severity 
Scale 
4 weeks 11 6.5 7.0 Dopaminergics 
Ondo, W. G., 
Shinawi, L. et al. 
2011  Memantine 20 
mg/day 
Placebo Fatigue Severity 
Scale 
8 weeks 11 No data  Dopaminergics 
Postuma, R.B, Lang, 
A.E. et al. 
2012 61 Caffeine 
Up to 200mg twice 
a day 
Placebo Fatigue Severity 
Scale 
6 weeks 11 8.0 7.8 Dopaminergics 
Rios Romenets, S., 
Creti, L. 
2013  Cognitive 
behavioural 
therapy/ bright light 
therapy 
OR 
Doxepin 
10mg/day 
Placebo Fatigue Severity 
Scale 
6 weeks 9 5.2 
 
OR 
5.2 
4.8 dopaminergics 
Schifitto, G. J. H. 
Friedman, et al. 
2008 361 Carbidopa-
levodopa 
37.5/150mg 
OR 
Carbidopa-
levodopa 75/300mg 
OR 
Cabidopa-levodopa 
150/600mg 
Placebo Fatigue Severity 
Scale 
40 weeks 11 .5 .5 No medication 
Stocchi et al. 2013 110
5 
Rasagiline 
1mg/day 
OR 
Rasagiline 
2 mg/day 
Delayed 
start 
intervention 
Parkinson fatigue 
scale 
72 weeks 11 <18 
months 
 No medication 
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Table 1 (continued): Basic characteristics of included studies 
Author Year N Intervention Outcome 
measure used 
Intervention 
period 
PEDro 
score 
Disease Duration 
(in years) 
Drugs taken 
   Active Control    Active Control  
Tyne, H. L., J. 
Taylor, et al. 
2010 13 Modafinil 
Up to 400 mg/day 
Placebo Fatigue severity 
scale 
9 weeks 11 No data  Dopaminergics; 
dopamine 
agonists 
Winward, C., C. 
Sackley, et al. 
2012 39 Exercise Delayed 
start 
exercise 
Fatigue severity 
scale 
12 weeks 9 5.7 5.9 Dopaminergics; 
dopamine 
agonists 
 
*: both groups received an active (but different) intervention. **: data not available for separate groups  
   
41 
 
3.3.2 Methodological quality and bias 
Ten studies (Ondo, Fayle et al. 2005, Leentjens, Scholtissen et al. 2006, Mendonca, 
Menezes et al. 2007, Schifitto, Friedman et al. 2008, Lou, Dimitrova et al. 2009, Tyne, 
Taylor et al. 2010, Ondo, Shinawi et al. 2011, Drijgers, Verhey et al. 2012, Postuma, Lang 
et al. 2012, Stocchi 2013) were of excellent methodological quality as scored by the PEDro 
scale (11/11). Three studies (Ghahari, Leigh Packer et al. 2010, Winward, Sackley et al. 
2012, Rios Romenets, Creti et al. 2013) were of good methodological quality (8/11; 9/11; 
9/11). These studies did not achieve an excellent PEDro score due to an inability to blind 
the participants and therapists (Winward, Sackley et al. 2012) the assessors and therapists 
(Rios Romenets, Creti et al. 2013), or the assessors, therapists and participants (Ghahari, 
Leigh Packer et al. 2010). The study of Abe et al. (2001) (Abe, Takanashi et al. 2001) was 
of fair methodological quality and scored 6/11 on the PEDro scale with points 2,3, and 5-7 
missing; however, not all information necessary for scoring was provided in the article. 
Funnel plots should have data points from a sufficient number of trials to be able to 
demonstrate publication bias (The Cochrane Collaboration 2011). Since only a limited 
number of trials were found, no tests were done for publication bias. 
3.3.3 Outcomes 
An overview of the outcomes of the studies can be found in Table 2. Studies investigating 
multiple arms are included in the table more than once. Abe et al. (2001) found a 
significant effect of taking pergolide mesilate compared to bromocriptine. Drijgers et al. 
(2012) found a significant effect of treatment with pramipexole vs placebo and 
pramipexole vs methylphenidate. Lou et al. (2009) found a significant effect of modafinil 
over placebo. Medonca et al. (2006) found a significant result two fatigue scales when 
comparing methylphenidate to placebo. Rios Romenets et al. (2013) also found a 
significant effect for their treatment group with doxepin vs placebo on fatigue, no 
significant effect was found for the Cognitive Behavioural Therapy and light therapy. 
Finally, Stocchi et al. (2013) found a significant effect for taking rasagiline vs 
placebo.Ghahari et al. (2010); Leentes et al. (2006); Ondo et al. (2005); Ondo et al. (2010); 
Postuma et al. (2013); Schifitto et al. (2011); Tyne et al (2010); and Winward et al. (2012) 
did not find any significant differences between the experimental group and the control 
group in treatment of fatigue (see Table 2). 
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Table 2: Outcomes studies 
Study Intervention Pre 
Control 
Mean (SD) 
Pre 
Experimental 
Mean (SD) 
Post 
Control 
Mean (SD) 
Post 
Experimental 
Mean (SD) 
p-value 
Abe, K., Tahanashi, M. et al. 
(2001) 
Pergolide mesilate 
vs placebo 
4.8 (0.9) 5.1 (0.7) 4.7 (0.8) 4.4 (0.55) <0.05 
Drijgers, R.L., Verhey, F.R.J. 
et al. (2012) M 
Pramipexole vs 
placebo 
78.0 (10.0)  
 
75.6 (11.6)  70.7 (13.9)  
 
62.6 (16.3)  <0.05 
 
Drijgers, R.L., Verhey, F.R.J. 
et al. (2012) M 
Pramipexole vs 
mehtylphenidate 
77.1 (10.1)  75.6 (11.6) 73.0 (13.4)  62.6 (16.3)  <0.05  
 
Ghahari, S., Leigh Packer, T. 
et al. (2010) 
Behavioural 
program vs control 
83.5 (46.0) 77.3 (47.2) 81.5 (71.4) 72.3 (45.6) >0.05 
 
Leentjens, A. F., Scholtissen, 
B. et al. (2006) 
Acute tryptophan 
depletion vs 
placebo 
59 (14.0) 58 (13.7) 56 (15.2) 65 (15.4) >0.05 
Lou, J.S., Dimitrova, D.M. et 
al. (2009) 
Modfinil vs 
placebo 
63.5 (4.8) 55.8 (5.1) 61.0 (4.8) 54.5 (5.12) <0.05 
Medonca, D.A., Menezes, K. 
et al. (2007) (FSS) M 
Methylphenidate 
vs placebo 
45.1 (6.5) 43.8 (6.7) 43.2 (8.4) 37.3 (9.5) <0.05 
Medonca, D.A., Menezes, K. 
et al. (2007) (MFI) M 
Methylphenidate 
vs placebo 
51.7 (16.1) 51.0 (10.8) 48.5 (16.5) 42.6 (15.6) <0.05 
Ondo, W.G., Fayle, R. et al. 
(2005) 
Modfinil vs 
placebo 
36.8 (12.8) 37.6 (14.1) 37.8 (10.8) 36.8 (12.7) >0.05 
Ondo, W. G., Shinawi, L. et 
al. (2010) 
Memantine vs 
placebo 
37.2 (14.3) 37.6 (14.2) 35.7 (16.9) 37.4 (17.7) >0.05  
 
Postuma, R. B., Lang, A.E. et 
al. (2013) 
Caffeine vs 
placebo 
   -2.85  
(-7.73,2.06)* 
>0.05 
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Table 2 (continued): Outcomes studies   
Study Intervention Pre 
Control 
Mean (SD) 
Pre 
Experimental 
Mean (SD) 
Post 
Control 
Mean (SD) 
Post 
Experimental 
Mean (SD) 
p-value 
Rios Romenets, S., Creti, L. 
(2013) 
Doxepin vs 
placebo 
  0 (5.8)** -17.7 (14.3)** <0.05 
 
Stocchi, F. et al. (2013) M Rasagiline 1mg vs 
placebo 
  0.17 (0.03)** 0.03 (0.04)** >0.05 
Stocchi, F. et al. (2013) M Rasagiline 2 mg 
vs placebo 
  0.17 (0.03)** -0.02 (0.04)** >0.05 
Schifitto, G., Friedman J.H. et 
al (2011) M 
Levodopa 150 mg 
vs placebo 
  0.75 (1.39)** 0.30 (1.08)** >0.05 
Schifitto, G., Friedman J.H. et 
al (2011) M 
Levodopa 300 mg 
vs placebo 
  0.75 (1.39)** 0.36 (1.11)** >0.05 
Schifitto, G., Friedman J.H. et 
al (2011) M 
Levodopa 600 mg 
vs placebo 
  0.75 (1.39)** 0.33 (1.04)** >0.05 
Tyne, H. L., Taylor, J. et al. 
(2010) 
Modafinil vs 
placebo 
5.4 (3)*** 6.1 (2)*** 5.1 (3)*** 5.7 (3)*** >0.05 
Winward, C., Sackley, C. et 
al. (2012) 
Exercise vs 
control 
4.15 (1.49) 3.9 (1.41) 3.72 (1.46) 3.5 (1.30) >0.05 
 
*Reported as mean and 95% confidence interval; **Reported as change score baseline vs end score; ***Medium (range) instead of Mean (SD) 
Abbreviations: SD: Standard Deviation; FSS: Fatigue Severity Scale; MFI: Multidimensional Fatigue Inventory; M: indicates multiple arm trials which appear more 
than once in the table  
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3.3.4 Adverse events 
All studies investigating amphetamines report adverse events. Leentjes et al. (2006) 
mention that six people experienced nausea. In the study of Lou et al. (2009) three subjects 
in the experimental group drop out due to blood in urine, memory loss and loss of balance, 
frequent urination, soft stool and flatulence, and early wakefulness. Medonca et al (2007) 
describe that three people in each group dropped out due to adverse events. In the 
experimental group complaints were backache, difficulty sleeping, feeling more 
bradykinetic, being mildly short of breath and feeling dizzy. Furthermore, a side effects 
questionnaire (including 20 side effects) was completed. Six people in experimental group 
mentioned side effects; five people in the placebo group mentioned side effects. In Ondo et 
al. (2005) adverse events in the modafinil group were a dry mouth (n=1), dizziness (n=1), 
back pain (n=1), nausea and anxiety (n=1). Adverse events in the placebo group were 
hypotension (n=1), renal calcinosis (n=1) and blurred vision (n=1). In Ondo et al. (2011) 
four people in the memantine group dropped out due to shoulder pain (n=1), lethargy 
(n=1), dyskinesia (n=1), nausea/confusion (n=1), anxiety (n=1); further adverse events in 
the experimental group were: sedation (n=2), confusion (n=1), pain (n=1), obsessive 
thinking (n=1), lethargy (n=1), and dyskinesia (n=1); finally, adverse events in the placebo 
group were nausea (n=3), dizziness (n=2), nervousness (n=1), hypertension (n=1), limb 
numbness (n=1), anxiety (n=1), weight loss (n=1), and jerking (n=1). Drijgers et al. (2012) 
were the only study using dopamine agonists who mentioned adverse events. Two 
participants dropped out due to dizziness, panic and nausea; the other studies (Abe et al 
(2001); Schifitto et al (2008); Stocchi et al. (2013)) did not mention any adverse events. 
Gahari et al (2010) and Winward et al (2012) did not report any adverse events.  As the 
interventions using drugs exhibit more adverse events than the online management and 
exercise programmes, non-drug interventions could be a better choice as treatment for 
fatigue in people with Parkinson’s disease. However, it must be noted, that although the 
adverse events were not reported in the studies, adverse events may have occurred. A 
review investigating exercise trials in people with Parkinson’s disease remark that adverse 
events are not often reported in trials (Goodwin, Richards et al. 2008). In future, authors 
should adhere to the TIDieR guidelines in order to be able to draw clear conclusions on 
safety of exercise trials.  
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3.3.5 Meta-analysis 
In the amphetamine group three studies were included (Lou et al (2009); Medonca et al. 
(2007); Ondo et al. (2005)). Two different fatigue scales were used (Multidimensional 
Fatigue Inventory, multi-dimensional; and Fatigue Severity Scale, uni-dimensional).The 
whole group included 45 people in the experimental group and 45 in the control group. 
Two separate analyses were done on the whole group. In the first analysis Lou et al.; Ondo 
et al.; and data from Medonca et al. on the Multidimensional Fatigue Inventory were 
included. The mean difference was -0.25 with a confidence interval of -0.67 to 0.16, the I2 
was 0 % and the z score of the overall effect was 1.20 (p=0.23) (see Figure 5). In the second 
analysis, data from Lou et al; Ondo et al; and data from Medonca et al. on the Fatigue 
Severity Scale were included. Here, the mean difference was -0.36 with a confidence 
interval of -0.78 to 0.06, the I2 was 0% and the z score of the overall effect was 1.67 
(p=0.09) (see Figure 6).  
 
 
 
 
 
Figure 5: Forest plot amphetamines  
(Medonca Multidimensional Fatigue Inventory) 
 
 
 
Figure 6: Forest plot subgroup analysis amphetamines Multidimensional Fatigue Inventory 
Furthermore, sub analyses on the two different fatigue scales were undertaken. For the 
analysis of the Multidimensional Fatigue Inventory Lou et al. (2009) & Medonca et al. 
(2007) were combined; there were 26 people were in the experimental group, 27 in the 
control group. The mean difference was -6.13 with a confidence interval of -14.63 to 2.37, 
the I2 was 0% and the z score of the overall effect was 1.41 (p=0.16) (see Figure 7).  
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For the analysis of the Fatigue Severity Scale Ondo et al. (2005) and Medonca et al. (2007) 
were combined; there were 36 people in the experimental group and 35 people in the 
control group. The mean difference and confidence interval was -4.00 (-8.72, 0.72). I2 was 
0% and the Z score of the overall effect was 1.66 (p=0.10) (see Figure 8). 
 
Figure 7: Forest plot amphetamines  
(Medonca Fatigue Severity Scale data) 
 
 
 
Figure 8: Forest plot subgroup analysis amphetamines Fatigue Severity Scale 
3.4 Discussion 
Individually the studies of Medonca et al. (amphetamines), Abe et al.,  Drijgers et al. 
(2012), Rios Romenets et al., and Stocchi (2014) (dopamine) showed a treatment effect 
(Mendonca, Menezes et al. 2007, Drijgers, Verhey et al. 2012, Rios Romenets, Creti et al. 
2013, Stocchi 2013). No non-pharmacological studies showed a treatment effect. Because 
of heterogeneity (in outcome measures, different drugs and dosages, and duration of 
studies), data from the dopamine studies could not be pooled. When data from studies 
investigating amphetamines were pooled, no treatment effect was shown. This review adds 
additional research evidence to Seppi et al. (2011) and has resulted in the inclusion of a 
further eleven articles with a meta-analysis. 
In general the medications used were well tolerated. If adverse events were reported it was 
stated that no differences were found in adverse events between the treatment group and 
the placebo group, which indicates that the used methods were safe to use. No adverse 
events were reported in the exercise study of Winward et al (2012), but adverse events are 
often inadequately reported (Goodwin, Richards et al. 2008, Allen, Sherrington et al. 
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2012). Apart from Drijgers et al. (2012) the studies on dopamine agonists do not report 
their adverse events. A review on treatments of Parkinson’s disease states that well 
reported adverse events using dopamine agonists are nausea, vomiting, hypotension and 
psychosis (Movement Disorders Society 2002, Movement Disorders Society 2002). 
Overall, studies investigating drugs to treat fatigue, seem to find a number of adverse 
events, whereas the studies of Gahari et al. and Winward et al. investigating respectively 
an online self-management programme, and an exercise programme did not find report any 
adverse events. A review on exercise in people with Parkinson’s disease stated that adverse 
events are generally not reported in the exercise studies (Goodwin, Richards et al. 2008), 
meaning that they either do not happen, or are not reported, which has to be explored 
further in order to draw any conclusions on safety of exercise trials.  
Different mechanisms for treating fatigue are proposed. Studies directly addressing fatigue 
include treatment with pergolide mesilate (Abe, Takanashi et al. 2001), an online self-
management programme (Ghahari, Leigh Packer et al. 2010), modafinil (Lou, Dimitrova et 
al. 2009, Tyne, Taylor et al. 2010), methylphenidate (Mendonca, Menezes et al. 2007), 
levodopa (Schifitto, Friedman et al. 2008) and exercise (Winward, Sackley et al. 2012). 
Different mechanisms are behind these choices of treatment methods. Three studies did not 
explain an underlying mechanism (Schifitto, Friedman et al. 2008, Tyne, Taylor et al. 
2010, Winward, Sackley et al. 2012). Other studies described their method in detail. Abe et 
al (2001) describes a mechanism where patients with fatigue have shown reduced glucose 
metabolism or reduced isotope uptake, which may be addressed by dopamine which can 
improve frontal lobe function and may improve fatigue in that way (Abe, Takanashi et al. 
2001). Schifitto et al. 2008 used a similar treatment method, so it can be concluded that a 
similar hypothesis underlies their intervention. Since glucose metabolism is the process 
through which glucose is oxidized to carbon dioxide and water as a metabolic fuel (i.e. to 
provide energy) (McArdle 2010), a reduction in glucose metabolism may explain fatigue. 
Furthermore, glucose is the main fuel for the brain (McArdle, Katch et al. 2010) indicating 
that fatigue in people with Parkinson’s disease could have a central origin. Lou et al. 
(2009) describe that modafinil is a central nervous stimulant whose mechanism is 
associated with an activation of the tuberomamillary nucleus and orexin-containing 
neurons (Lou, Dimitrova et al. 2009). Tyne et al. (2010), also use modafinil to treat fatigue, 
so it can be expected that the same hypothesis underlies their research. Finally, Medonca et 
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al. (2007) explain that methylphenidate is a central nervous stimulant and is an antagonist 
of dopamine and norepinephrine transporters on the presynaptic neuronal cell membrane. 
Reduced reuptake results in an increase in extracellular levels of both neurotransmitters 
(Mendonca, Menezes et al. 2007). Although, Winward et al. (2012) do not describe a 
reasoning for using exercise as a treatment method for fatigue in people with Parkinson’s 
disease, it can be hypothesised that they choose this method as it was previously found that 
exercise has  the potential to induce a positive effect on fatigue in people with Multiple 
Sclerosis (Andreasen, Stenager et al. 2011, Latimer-Cheung, Pilutti et al. 2013), and 
animal models imply that exercise might be effective in treating fatigue in people with 
Parkinson’s disease (Friedman, Brown et al. 2007).Other treatment methods focused on 
treatment of excessive daytime sleepiness (Ondo, Fayle et al. 2005), insomnia (Rios 
Romenets, Creti et al. 2013), depression (Leentjens, Scholtissen et al. 2006) or general 
treatment of Parkinson’s disease (Ondo, Shinawi et al. 2011, Rascol, Fitzer-Attas et al. 
2011, Drijgers, Verhey et al. 2012, Postuma, Lang et al. 2012). The different explanations 
of fatigue in people with Parkinson’s disease, and the many ways to treat fatigue, shows 
there is no consensus yet on what fatigue is and how it should be treated. Therefore, more 
research is necessary into the mechanisms behind fatigue, and treatment of fatigue in 
people with Parkinson’s disease. 
Apart from the study of Schifito et al (2008) and Stocchi (2013), participants in all other 
studies continued to take their routine medication. As described, drugs such as dopamine 
agonists could influence fatigue, and mono-amine oxidase inhibitor can have 
amphetamine-like effects, which may introduce bias; results should therefore be 
interpreted with care. 
The difficulty in defining fatigue is one reason for the multitude of measures (Friedman, 
Alves et al. 2010) and there is little evidence to guide which measurement instrument to 
use (Friedman, Brown et al. 2007). Although the scales in the included studies used 
validated scales, different scales measure different aspects of fatigue (Aaronson, Teel et al. 
1999), therefore caution is needed when pooling data together. Further research and 
agreement is needed on evaluating the best method of measuring fatigue in people with 
Parkinson’s disease in order to have a standardized measure for this phenomenon. In this 
review however, the majority of the studies (eight) explored fatigue using the fatigue 
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severity scale. Indeed, literature indicates that the fatigue severity scale is the most used 
scale to explore fatigue in chronic diseases . 
It should be noted that a number of studies had to be excluded from the review because 
validated fatigue measurement tools had not been used, and/or other parameters including 
sleep could not be separated out from measurement of fatigue, thereby limiting findings 
(Adler and Thorpy 2005, Ray Chaudhuri, Martinez-Martin et al. 2013). This is an 
important finding as at first glance the literature appears to be rich with studies 
investigating the impact of interventions on fatigue. This limitation due to inadequate case 
definition and a reliable, validated measure appears to severely limit advancement of 
understanding in this area. 
Ten out of the fourteen included studies show an excellent methodological quality as 
scored by the PEDro scale, although the study of Abe et al. (2006) only showed a fair 
methodological quality. This study was included in the meta-analysis and therefore caution 
is necessary when interpreting of the results. However, it is worth mentioning Abe at al. is 
the oldest study found in this review and it has been shown that methodological quality of 
studies has improved over the last decade (Moseley, Herbert et al. 2002). One of the 
studies included in the review (Winward, Sackley et al. 2012) was written by authors of 
this review (CW, HD, DW), however, the PEDro scoring was done by one of the authors 
that was not involved in that particular study (MF).  
One final problem in translating findings from studies on people with Parkinson’s disease 
is the diagnosis of Parkinson’s disease (Tolosa, Wenning et al. 2006). This difficulty in 
diagnosis contributes to the fact that the results in this systematic review need to be 
interpreted with caution. A commonly used diagnosis of idiopathic Parkinson’s disease is 
provided by the brain bank clinical diagnostic criteria (Hughes, Daniel et al. 1992). 
However, only a limited number of studies used this criterion in their inclusion criteria 
(Hughes, Daniel et al. 1992, Alves, Wentzel-Larsen et al. 2004, Adler and Thorpy 2005, 
Ondo, Fayle et al. 2005, Lou, Dimitrova et al. 2009, Ghahari, Leigh Packer et al. 2010, 
Tyne, Taylor et al. 2010, Ray Chaudhuri, Martinez-Martin et al. 2013). Studies should try 
to include people diagnosed with idiopathic Parkinson’s disease to increase heterogeneity 
of the study sample.  
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3.5 Limitations 
There are some limitations to this review and meta-analysis. First of all, the selection was 
limited to studies in English and Dutch which may have caused language bias with 
potentially relevant studies published in other languages being missed. Second, although 
the authors excluded measures of physical fatigue, previous research states the overlap 
between mental fatigue and physical fatigue may not be clear on rating scales, additionally 
sleep may be a confounding factor as well (Friedman, Alves et al. 2010). All this taken 
together shows that it is hard to define and measure fatigue and this may have created 
problems with including studies in the current review. Finally, different fatigue scales were 
used in different studies, so results from the meta-analysis should be interpreted carefully. 
Moving forward, it would be important to use one standard fatigue scale to make it 
possible to pool findings. As discussed earlier, the fatigue severity scale is the most used 
fatigue scale making it a favourable choice of measure in future research. 
3.6 Conclusion 
Different methods of treating fatigue in people with Parkinson’s disease are currently being 
used. Drug therapy is the most common way of treating fatigue in Parkinson’s disease.  
After analysis, no significant effects were found on treatment of fatigue in people with 
Parkinson’s disease with either amphetamines or dopamine agonists. This shows that more 
research is necessary into treatment methods of fatigue in people with Parkinson’s disease. 
Consensus into determining the best way to measure fatigue in people with Parkinson’s 
disease would further improve research in this area.  
The review showed that most interventional studies focus on mood, depression and 
sleepiness, only one intervention looked into relationships between physical activity, 
exercise tolerance and self-reported fatigue even though there is evidence to believe that 
exercise is likely to diminish fatigue. The question whether exercise is a possible treatment 
for fatigue in people with Parkinson’s disease has not been explored thoroughly enough to 
provide a definite answer.  Although Winward et al. 2012 did not find a positive 
relationship between exercise and fatigue in people with Parkinson’s disease, the authors 
indicate that the lack of finding could be attributed to the low levels of attendance (on 
average once a week) and they suggest that future studies should explore the effect of 
specific doses of prescribed exercise (Winward, Sackley et al. 2012). Only one exercise 
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study was found directed at treating fatigue in people with Parkinson’s disease showing the 
field is relatively unexplored, and more research into exercise type, dosage, and duration 
could add to providing a clearer picture on the effects of exercise on fatigue in people with 
Parkinson’s disease.  
As discussed previously fatigue is a complex phenomenon due to the unknown 
pathophysiology, the numerous co-factors influencing fatigue, and the numerous methods 
to measure fatigue; it would be important to first explore fatigue further in relation to 
physical activity and exercise tolerance in order to explore the  possibilities of an exercise 
intervention to treat fatigue in people with Parkinson’s disease. 
The next Chapter will explore relationships between self-reported fatigue and physical 
activity and exercise tolerance. 
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Chapter 4: Fatigue, baseline correlations 
Summary 
First, as a sub-study, the day to day reliability of the activity monitor (GeneActiv) was 
assessed. For this sub-study, 30 patients were included and results show that there is no 
difference in activity between the days of the week. Furthermore, this chapter is a cross 
sectional study investigating associations between self-reported fatigue and a set of 
measures including: disease severity, quality of life, mobility, physical activity, and 
exercise capacity. For the cross-sectional study, 89 patients were included. Significant 
Pearson correlations were found between the self-reported fatigue and self-reported 
fatigue during the exercise tolerance test (RPEbreath (r=-0.282; p=0.024)); (RPElegs r=-
0.261; p=0.033)); respiratory exchange rate (r=-0.309; p=0.002) and GENEActiv light 
activity (-0.209; p=0.049). The possible correlation between and self-reported fatigue 
exercise capacity may implicate that if exercise capacity (measured as respiratory 
exchange ratio) is improved by for example an exercise programme, self-reported fatigue 
may be improved as well. 
4.1. Introduction 
As described previously, fatigue is a major issue in people with Parkinson’s disease. 
Despite the high prevalence of fatigue, the systematic review and meta-analysis (Chapter 
3) concluded that currently there is no effective way of treating fatigue in people with 
Parkinson’s disease (Franssen, Winward et al. 2014), supporting the need to better 
understand this symptom in order to develop effective interventions.  
Although fatigue in relation to psychometrics has been well studied and described in 
people with Parkinson’s disease including quality of life (Havlikova, Rosenberger et al. 
2008, Elbers, van Wegen et al. 2014), sleepiness (Karlsen, Larsen et al. 1999, Alves, 
Wentzel-Larsen et al. 2004, Friedman, Brown et al. 2007), and depression (Karlsen, Larsen 
et al. 1999, Alves, Wentzel-Larsen et al. 2004, Okuma, Kamei et al. 2009) as described in 
Chapter 2. Fatigue and quality of life seem to be correlated as shown in the study of 
Herlofson and Larsen, where 66 participants were included and fatigue related to a lower 
quality of life as well as in the study of Elbers et al. in which 153 participants were 
included and results showed that participants that experienced more fatigue, reported lower 
levels of quality of life. It must be noted however, that the authors showed that the 
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relationship between fatigue and quality of life was confounded by depression and anxiety. 
Studies suggest that fatigue and the degree of sleepiness in Parkinson’s disease patients are 
unrelated (Karlsen, Larsen et al. 1999, Alves, Wentzel-Larsen et al. 2004). In the study of 
Karlsen et al. patients with sleepiness were excluded from the cohort of participants, and it 
was found that 43.5% of the cohort was fatigued, indicating that fatigue is present in 
people without sleepiness. Similarly, Alves et al. excluded all people with sleepiness from 
their cohort and found that the prevalence rate of fatigue remained high across all years 
(32.1% in 1993; 38.9% in 2001), again indicating that fatigue is present in people with 
Parkinson’s disease separate from sleepiness.  Finally, although depression seems to be 
related to fatigue, studies show that non-depressed participants still show a high percentage 
of fatigue. A long term study into the relationship between fatigue and depression  found 
that fatigue is related to depression (Alves, Wentzel-Larsen et al. 2004). In this study 233 
people with Parkinson’s disease were included in 1993 and were followed up for eight 
years, with 111 people being followed up in 1997 and 78 people in 2001. The study found 
significant higher depression scores in fatigued patients versus non fatigued patients 
(Alves, Wentzel-Larsen et al. 2004). However, they did find a high number of fatigued 
patients that were not depressed (Alves, Wentzel-Larsen et al. 2004). Furthermore, , 
several studies that investigate fatigue in a cohort of Parkinson’s disease patients without 
depression find that fatigue is present in 41-50% of the patients (Karlsen, Larsen et al. 
1999, Herlofson and Larsen 2002, Okuma, Kamei et al. 2009). In the study of Karlsen et 
al. 233 patients with Parkinson’s disease were examined and result showed that fatigued 
patients were more depressed; again, once patients with depression were excluded, the 
number of patients that were fatigued remained high (43.5%) (Karlsen, Larsen et al. 1999). 
Herlofson and Larsen looked into fatigue in non-depressed patients with Parkinson’s 
disease and found that in 66 people, 33 people were fatigued, indicating that fatigue is 
present in non-depressed patients with Parkinson’s disease (Herlofson and Larsen 2002). 
Finally, in the study of Okuma et al. 361 Japanese people with Parkinson’s disease were 
assessed and fatigue was present in 41.8% and a significant higher depression was found in 
fatigued people (Okuma, Kamei et al. 2009), however, a logistic regression did not find 
depression as a significant factor in relation to fatigue (Okuma, Kamei et al. 2009). 
However, fatigue in relation to measures of physical performance has been studied less.  
   
54 
  
 
 
In Chapter 2, the possible relation between fatigue and disease severity is described. Some 
studies have found that patients with self-reported fatigue had more severe disease status 
(Herlofson and Larsen 2002, Havlikova, Rosenberger et al. 2008), where other studies 
have found that disease severity did not correlate with fatigue (Friedman and Friedman 
1993, van Hilten, Weggeman et al. 1993, Abe, Takanashi et al. 2000, Lou, Kearns et al. 
2001, Shulman, Taback et al. 2001) as described in Chapter 2. Because it is still unclear 
what the relation between self-reported fatigue and disease severity is, more research is 
required; since there is more research leaning towards a relationship between the two, it is 
expected that a self-reported fatigue and disease severity will correlate. As described 
previously in Chapter 2, it is expected that self-reported fatigue correlates to self-reported 
quality of life (Herlofson and Larsen 2003, Havlikova, Rosenberger et al. 2008). 
Research into fatigue in relation to mobility, physical activity and exercise tolerance in 
people with Parkinson’s disease is scarce. Research in stroke has shown that mobility is 
likely not to be related to self-reported fatigue (Michael, Allen et al. 2006). Furthermore, 
previous research in a small sample size indicated that fatigue is related to both exercise 
tolerance and physical activity (Garber and Friedman 2003). In the study of Garber and 
Friedman, only 37 patients with Parkinson’s disease were assessed on disease severity, 
fatigue, functional capacity, physical activity, and mobility. They found increased levels of 
fatigue were associated with decreased levels of leisure physical activity, lower frequency 
of vigorous physical activity, less time spent moving about performing daily tasks each 
day, lower diastolic blood pressure and VO2max, and longer Up and Go performance time 
(Garber and Friedman 2003). In this study only a small sample size was included which 
can be an issue in cross sectional studies which may not represent the general group (Mann 
2003). Furthermore, they used a questionnaire to assess physical activity. Questionnaires 
assessing physical activity have been shown to have limitations in terms of their reliability 
and validity, activity monitors could give a more accurate indication of physical activity 
(Prince, Adamo et al. 2008). A study using a larger sample size, could give more 
generalizable results; furthermore, using activity monitors could give a more accurate 
indication of physical activity, than using just questionnaires. 
To date, it is unclear whether it is possible to improve self-reported fatigue in people with 
Parkinson’s disease. In order to better understand relationships between self-reported 
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fatigue and exercise this chapter aims to explore the correlations between self-reported 
fatigue and physical measures including disease severity, aerobic capacity and mobility 
that can be improved using an exercise programme. 
Although cross sectional studies are limited by the fact that they are carried out at one time 
point and give no indication of the sequence of events, they can investigate associations 
between risk factors and the outcome of interest (Levin 2006). The sample and response 
rate determine how well results can be generalised to the population as a whole (Levin 
2006).  
4.1.1 Aims 
 to explore relationships between self-reported fatigue and activity levels in people 
with Parkinson’s disease; 
 to explore relationships between self-reported fatigue and exercise tolerance in 
people with Parkinson’s disease  
4.2 Methods 
4.2.1 Participants 
A cross sectional study was conducted. Patients with idiopathic Parkinson’s disease were 
recruited between December 2011 and August 2013 as part of a single-blinded 
Randomised Controlled Trial (Clinical Trial Gov number: NCT01439022; Research Ethics 
Committee reference: 11/SC/0267; funding: National Institute for Health Research). 
(Participant flow and drop out throughout the whole trial will be described in Chapter 5). 
Recruitment of participants was facilitated by the National Institute for Health Research 
Clinical Research network: The Dementias and neurodegeneration research network. 
Possible participants were approached by means of promotion by the neurologist and 
Parkinson’s nurses; at local Parkinson’s meetings; and by means of invitation letters from 
GP surgeries. Inclusion criteria for the study were: (i) diagnosis of idiopathic Parkinson’s 
disease (as defined by the United Kingdom Parkinson’s disease Society Brain Bank 
clinical diagnostic criteria (see appendix 1) (Hughes, Daniel et al. 1992)); (ii) able to walk 
≥100 meters. Exclusion criteria were: (i) dementia; (ii) history of additional prior 
neurological condition; (iii) severe depression or psychosis or a mental state that would 
preclude consistent active involvement with the study over its duration; (iv) cardiac 
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precautions that would prevent the subject from completing the full battery of outcome 
measures; (v) any known contraindication to exercise; (vi) reduced cognitive function of 
any cause (MMSE < 23); (vii) an orthopaedic condition that limited independent walking. 
After agreeing to take part in the study, participants came to the laboratory for one visit, 
where the main assessor took written informed consent prior to participation of all 
participants, in accordance to the Declaration of Helsinki. Participants’ medication was 
continued as normal and was recorded.  
4.2.2 Measures 
4.2.2.1 Fatigue 
In order to establish fatigue, that is listed as the health condition in the ICF-model 
described in Figure 3, a self-reported fatigue measure was chosen. Measures of self-
reported fatigue have been described in Chapter 2. For this study, the Fatigue Severity 
Scales (FSS) was chosen as outcome measure to assess subjective fatigue (see appendix 4) 
over the The Multidimensional Fatigue Inventory and the Parkinson’s Fatigue scale as the 
scale is brief and easy to administer; it has shown sensitivity to change in previous clinical 
trials; and it is most commonly used to assess fatigue in people with Parkinson’s disease 
(Fabbrini, Latorre et al. 2013). The items cover motivation; physical function; 
responsibilities; work, family or social life; exercise; how easily fatigued; frequency of 
problem; and priority of symptoms (Krupp, LaRocca et al. 1989). 
4.2.2.2 Disease severity 
In order to establish the level of severity of Parkinson’s disease of the participants, disease 
severity, that is described in the ICF-model under body function and structures, was 
measured. For assessing the disease severity and progression in Parkinson’s disease 
patients two scales are commonly used: the Movement Disorder Sponsored Unified 
Parkinson Disease Rating Scale (MDS-UPDRS) (see appendix 5) and the Hoehn and Yahr 
scale (Dibble, Cavanaugh et al. 2010). The Hoehn and Yahr scale is widely utilized and 
accepted (Goetz, Poewe et al. 2004) and included in the MDS-UPDRS. The MDS-UPDRS 
is shown to be a valid and reliable questionnaire (Winter, von Campenhausen et al. 2011). 
It focuses on impairments associated with Parkinson’s disease (Dibble, Cavanaugh et al. 
2010). The MDS-UPDRS is the most widely used clinical rating scale for Parkinson’s 
disease and it is provided with clear and detailed descriptions of methods for data 
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acquisition (Goetz, Tilley et al. 2008).  The questionnaire contains four parts: part I mainly 
includes participation as described in the ICF-model and covers non-motor experiences of 
daily living, the first six questions are administered by the researcher; the other questions 
are self-administered. Part II covers activities as listed in the ICF model and concerns 
motor experiences of daily living and is completely self-administered. Part III, that covers 
body function and structures as listed in the ICF-model, is a motor examination and part 
four includes questions about motor complications, both sections (three and four) are 
administered by the researcher (Goetz 2011). Each question has 5 response possibilities: 0 
(normal); 1 (slight); 2 (mild); 3 (moderate); and 4 (severe). The time required to complete 
all parts of the questionnaire is approximately 40 minutes. The scale ranges from 0 to 132 
and the lower the score, the less disability. The scale has a floor, but no ceiling effect 
(Goetz, Tilley et al. 2008). The scale has shown to have excellent factor validity if all parts 
are considered separately (Goetz, Tilley et al. 2008). Throughout this thesis, part III of the 
MDS-UPDRS will be analysed and discussed. Part III of the MDS-UPDRS was selected 
because it focuses on motor symptoms which are likely to change with an exercise 
intervention (Ridgel, Vitek et al. 2009, Uc, Doerschug et al. 2014). Furthermore, this part 
of the MDS-UPDRS was chosen over the Hoehn and Yahr scale because the Hoehn and 
Yahr scale measures unilateral versus bilateral signs and presence or absence of gait 
balance impairments.  Therefore, an increment in the Hoehn and Yahr scale does not 
necessarily represent a higher degree of overall motor dysfunction (Goetz, Poewe et al. 
2004). Furthermore, the Hoehn and Yahr scale seems relatively insensitive to treatment 
induced change, especially in the lower categories (Goetz, Poewe et al. 2004), which is the 
target population of this study. 
4.2.2.3 Two minute walk test 
A walk test was used as an indicator of the functional ability of the participants. Mobility is 
falls under activities in the ICF-model. Walk tests can be administered as a means of 
evaluating functional status and to monitor the effectiveness of an intervention (Solway, 
Brooks et al. 2001). The 12-minute walk test (12MWT) was originally developed to assess 
physical fitness in healthy young men (Brooks, Parsons et al. 2004). It is a useful and 
reproducible measure of exercise tolerance (Butland, Pang et al. 1982). More recently, 
shorter versions of this test, the six- and two-minute walk test (6MWT; 2MWT), have been 
developed (Butland, Pang et al. 1982). In all tests participants walk between two markers 
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on a measured trail, and try to cover as much ground as possible in a set time frame (e.g. 
two, six or twelve minutes) (Brooks, Parsons et al. 2004). In other patient populations and 
in Parkinson’s disease, the 2MWT is shown to be a reliable, feasible and efficient measure 
(Light, Behrman et al. 1997, Brooks, Hunter et al. 2002, Brooks, Parsons et al. 2004). A 
recent systematic review described the psychometric properties of the 2MWT and found 
that the 2MWT could be a valid walk-test for individuals with neurological conditions by 
correlating the 2MWT with the 6MWT, 12MWT, 10 meter walk test, the SF-36 and the 
modified Barthel Index (Pin 2014). In this research the 2MWT was chosen as a measure of 
functional ability. 
4.2.2.4 Quality of life 
Quality of life, as described under participation in the ICF-model, was measured using a 
self-administered questionnaire, the short form 36 (SF-36) (appendix 6). The SF-36 is 
widely used (Leonardi, Raggi et al. 2012) and the validity of this questionnaire has been 
tested repeatedly (Dibble, Cavanaugh et al. 2010).  The SF-36 gives information on eight 
different domains (Jenkinson, Layte et al. 1997). These domains are: physical functioning, 
role-physical, bodily pain, general health, vitality, social functioning, role-emotional and 
mental health (Ware 2014). The SF-36 has been recommended for use in Parkinson’s 
disease (Martinez-Martin, Jeukens-Visser et al. 2011). Compared to healthy participants, 
people with Parkinson’s disease generally report far greater levels of disability in terms of 
functioning and well-being (Jenkinson, Peto et al. 1995). (Martinez-Martin, Jeukens-Visser 
et al. 2011). Other quality of life questionnaires that are frequently used include the 
EuroQol 5D 5L and the Parkinson’s disease specific one Parkinson’s Disease Quest 39. 
The EuroQol 5D 5L is brief and easy to administer, however it is not likely to detect 
change (Marra, Woolcott et al. 2005). Generic quality of life scale might overlook 
important specific aspect that could be influenced by having Parkinson’s disease 
(Jenkinson, Fitzpatrick et al. 1997). There are Parkinson’s disease specific questionnaires 
that measure quality of life, including the Parkinson’s Disease Quest 39, however, generic 
scales have a large amount of reference data, are widely available and utilized in many 
Parkinson’s disease studies (Martinez-Martin, Jeukens-Visser et al. 2011). 
   
59 
  
 
 
4.2.2.5 Physical Activity Questionnaire in the Elderly  
To monitor physical activity levels in the participants (described under activities in the 
ICF-model), a physical activity questionnaire was used. The Physical Activity 
Questionnaire in the Elderly (PASE) (appendix 7) is a questionnaire which looks at leisure 
time, household and work-related activities and physical activity recall over the last week. 
It is an easily scored, quick to tool to assess physical activity in an elderly population 
(Schuit, Schouten et al. 1997). The overall score ranges from 0 to 400 or more, with a 
higher score indicating more activity. Studies have shown that this questionnaire is reliable 
and valid (Washburn, Smith et al. 1993, Liu, Buffart et al. 2011). Also test-retest reliability 
was shown to be good (Liu, Buffart et al. 2011). A downside of the PASE is that the 
questionnaire may overestimate women’s physical activity as compared to men since 
women normally have a greater engagement in heavy housework and taking care of others 
(Schuit, Schouten et al. 1997) (appendix 7). There are currently no Parkinson’s disease 
specific questionnaires to measure physical activity levels. Other questionnaires used in 
studies in people with Parkinson’s disease are for example the Yale Physical Activity 
survey (Garber and Friedman 2003, Delikanaki-Skaribas, Trail et al. 2009, Nocera, Amano 
et al. 2013) and Godin Leisure Activity Questionnaire (Garber and Friedman 2003, 
Nocera, Amano et al. 2013). Although the Yale Physical Activity Survey showed good 
correlations with VO2max, but accuracy in assessing low-intensity activities, activities likely 
to be conducted by people with Parkinson’s disease, is not established (Bonnefoy, 
Normand et al. 2001). Furthermore, both the Yale Physical Activity Survey and the Yale 
Physical Activity survey are both not specifically tailored to elderly people, which is likely 
to be the core group of participants in this study, whereas the PASE is specifically 
designed for an elderly population. 
4.2.2.6 Activity monitor (GENEActiv) 
Another measure to establish physical activity patterns (described under activities in the 
ICF-model) is an activity monitor. The GENEActiv is a wrist worn activity monitor. The 
GENEActiv, was worn by the participants around the wrist for seven days following an 
assessment. The GENEAactiv is a triaxial acceleration sensor which is lightweight, 
waterproof. It sampled at 100Hz for seven days. The participants sent the monitor back in a 
pre-stamped, addressed envelope. The data was then downloaded from the device onto the 
computer and transformed into a 60-second epoch excel file. An Excel Macro was 
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designed by GENEActiv (GENEActiv 2014) which generated minutes per day spent 
sedentary, performing light, moderate or vigorous activities (Welch, Bassett et al. 2014). 
The file that was collected from the participants was run through this Macro to calculate a 
total weekly activity count. Finally, one outcome was calculated by averaging the data 
across the days. 
4.2.2.7 Exercise tolerance 
Exercise tolerance, which falls under body function and structures in the ICF-model, is 
described by means of aerobic capacity. Aerobic capacity of the participants was 
determined using a modified Sjostrand cycle ergometer test (Sjostrand 1947). Participants 
were thoroughly screened before the fitness test including the Physical Activity Readiness 
Questionnaire (appendix 8) (Glendhill 2002) and blood pressure measurement (ACSM 
2009), and a 12-lead Electrocardiogram. Electrocardiograms were assessed following a set 
of criteria, any values found in the electrocardiograms that were outside the set parameters 
were run past the study neurologist. Following advice from the neurologist, the participants 
were either asked to perform the cycle ergometer test, or their general practitioner (GP) 
was asked to give advice on the participant performing the ergometer test. Exclusion 
criteria for the exercise test were: systolic blood pressure > 180 mmHg; diastolic blood 
pressure > 100 mmHg; a known heart murmur, stents fitted, and advice from the GP not to 
do the exercise test. Prior to testing sessions, participants were asked to refrain from the 
consumption of alcohol, cigarettes, food, caffeine and to avoid exercise for a period of 
three hours. Each participant received a full description of the exercise test procedure and 
was familiarised with Borg’s rating of perceived exertion (RPE) CR10 Scale (0-10) using a 
set text (see appendix 9) (Borg 1998). Saddle heights were adjusted to accommodate knee 
flexion (170° to 175°).  Feet were supported in the pedals by toe clips, and straps. 
All participants underwent an incremental cycle ergometer exercise test (Lode Excalibur 
Sport, Gronigen, Netherlands) of two minute stages, after an initial one minute of unloaded 
cycling. Workload was progressed based on the modified Sjostrand protocol (increasing 
workload initially by 50 Watts and then by 25 Watts). The test ended at volitional 
exhaustion or if the participant was unable to maintain a cadence of 50 rpm. The criteria 
for true maximal effort included a plateau in  max; maximal heart rate > 95% of age 2OV
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predicted maximum; and respiratory exchange ratio >1.06 (Winter 2007). Verbal 
encouragement was given throughout. 
Pulmonary gas exchange was measured breath-by-breath using an automated metabolic 
analysis system (Cortex Metalyzer, Leipzig Germany). The system was calibrated prior to 
each test in accordance to manufacturer’s instructions. All participants wore a face mask 
covering the nose and mouth connected to a low-resistance volume transducer (Triple V, 
Hoechberg, Germany). Heart rate was recorded continuously throughout the testing 
protocol using short-range telemetry (Polar S810, Finland). The respiratory exchange ratio 
is the radio of carbon dioxide (VCO2) output over oxygen (VO2) uptake (Cooper and 
Storer 2001) and maximum respiratory exchange ratio was averaged over the last 30 
seconds of the test. End exercise respiratory exchange ratio can be used to represent 
objective maximal effort (Cooper and Storer 2001). Trained people show lower respiratory 
exchange ratios than untrained people for a given workforce (Ramos-Jiménez, Hernández-
Torres et al. 2008). 
4.2.2.8 Self-reported fatigue during exercise tolerance 
As a marker of single-activity self-reported fatigue, the CR10 rating of perceived exertion 
scale was used to measure leg fatigue and breathlessness at the end of each stage, which 
previously has been done in Multiple Sclerosis (Dawes, Collett et al. 2014). The original 
rate of perceived exertion scale was a 15-point scale from 6 to 20 reflecting the range of 
heart rate in a healthy group of young subjects during maximal exercise on a cycle 
ergometer. The ratio scales method showed that the perception of exertion grew with the 
physical work load (Borg 1990). The CR10 rate of perceived exertion is a category ratio 
scale from 1 to 10 with 1 being no effort and 10 being maximal effort (Borg 1998) and it 
has shown reasonable validity, sensitivity and reliability as a subjective measure in the 
healthy population. Although reliability in Parkinson’s disease has not been researched 
specifically, the scale is found to be valid in other clinical populations like in people with 
chronic lower back pain (Dawes, Barker et al. 2005). It is easy to use because of its 
simplicity. It enables determination of both relative and absolute subjective levels (Noble 
and Robertson 1996). To standardise the procedure and improve accuracy of the rate of 
perceived exertion scale it was important that participants understood both the verbal 
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anchors and the numerical value. The following instructions were given to each participant 
(ACSM 2014): 
“_________(name), during the exercise test we want you to pay close attention to how 
hard the exercise is. In particular we want to know how hard you are breathing, and the 
sensations that you are feeling in your legs. I’ll be asking you to select a number from this 
scale from 1 to 10. Each number represents the amount of effort that you can feel in your 
breathing or legs. The words are there to help you choose a number. Try not to 
underestimate or overestimate your feelings of exertion. So, while you are resting, looking 
at the scale, how would you describe your breathing now? (Pause) And using the same 
scale, how would you describe the feelings in your legs? 
4.2.2.9 Other measures 
All measures described above were collected as part of a larger randomised controlled trial 
(Clinical Trial Gov number: NCT01439022; Ethics number: 11/SC/02/67). This trial 
included other measures not described and discussed in this thesis. 
4.2.3 Data handling and analyses 
Data were analysed using IBM SPSS Statistics 22. Descriptive statistics (means and 
standard deviations) were generated to describe the characteristics of the participants.  
4.2.3.1 GENEActiv day to day reliability 
The GENEActiv devices were given to the participants on different days of the week; 
hence the start day was different for different participants. Furthermore, data collected 
from the GENEAactiv devices did not always contain data of six full days. In order to 
establish whether incomplete data (ie. if data collection of less than six days occurred) 
could be used, it was investigated whether there were systematic differences in day of the 
week in the number of minutes per activity. Furthermore, it was necessary to consider 
possible differences between different days of the week included in this dataset since 
previous research suggests there may be differences in activities during weekdays 
compared to weekend days (Jago, Anderson et al. 2005, Treuth, Catellier et al. 2007, 
Corder, Craggs et al. 2013). In a subgroup of the participants, day to day variability in the 
GENEActiv data was investigated. For this, averages of each activity of each day (all data 
captured by the GENEActiv was included if there was three days or more worth of data) 
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were compared in 30 subjects to establish whether there was a difference in activity 
between the days. A one-way-ANOVA was performed to establish any differences. 
Previous research has shown that a minimum of 3-4 days is required to achieve 80% 
reliability, which was the proportion of total variance accounted for by inter-individual 
sources (Matthews, Ainsworth et al. 2002). Therefore, it was decided that it was valid to 
average at least three days, regardless of when the days were in the week, as overall 
outcome measure for the GENEActiv in case no differences were found in the ANOVA. 
4.2.3.2 Correlations 
Associations were explored using Pearson correlation coefficients. Subjective fatigue 
(Fatigue Severity Scale) was plotted against the other fatigue measures as a scatterplot to 
examine for systematic bias, random error and heteroscedasticity. Significance was set as 
p>0.05. 
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4.4 Results 
4.4.1 GENEActiv day-to-day reliability 
Table 3 presents an overview of the average total number of minutes per day per activity 
(sedentary, light, moderate and vigorous). The ANOVA revealed no significant difference 
between days for each activity.  
Table 3: Overview of average minutes per day spent sedentary; doing light, moderate or vigorous 
activity as measured by the GENEActiv and p-values for comparisons per day 
 Sedentary 
Mean (SD) 
Minutes 
Light 
Mean (SD) 
Minutes 
Moderate 
Mean (SD) 
Minutes 
Vigorous 
Mean (SD) 
Minutes 
Monday (n=31) 777 (117) 81 (55) 80 (71) 1 (4) 
Tuesday (n=25) 755 (131) 93 (57) 98 (79) 1 (2) 
Wednesday (n=28) 773 (156) 92 (56) 92 (85) 3 (10) 
Thursday (n=17) 752 (154) 86 (49) 85 (66) 1 (3) 
Friday (n=25) 736 (113) 93 (55) 101 (68) 2 (4) 
Saturday (n=30) 795 (145) 91 (57) 74 (65) 1 (1) 
Sunday (n=31) 771 (123) 81 (63) 72 (59) 1 (4) 
p-value ANOVA 0.772 0.947 0.653 0.621 
Abbreviations: SD: Standard Deviation. 
4.4.2 Demographics 
In total 105 participants were included in the study (the power calculation for the trial will 
be provided in Chapter 5). Eighty three participants were able to participate following in- 
and exclusion criteria as described under heading 4.2.2.7. Table 4 gives an overview of the 
baseline descriptive statistics of all 105 participants (apart from heart rate (n=83)). 
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Table 4: Baseline descriptive statistics (n=105) 
Variable Mean (SD) 
 
Range 
Gender Male =61  
Age (Years) 66.9 (7.8) 39-86 
Years of PD 5.0 (4.1) 0-18.0 
UPDRS III (range 0-132) 18 (10) 0-57 
2 MWT (meters) 141 (24) 66-221 
SF-36 PH (range 0-100) 63 (18) 21-92 
SF-36 MH (range 0-100) 70 (17) 28-93 
Heart rate (bpm) 129 (24) 39-183 
Abbreviations: SD: Standard Deviation; PD: Parkinson’s disease; UPDRS III: Movement Disorder 
Society Sponsored Revision of the Unified Parkinson’s Disease Rating Scale section three; SF-36: 
Short Form 36; PH:  Physical Health; MH: Mental Health. 
Of all 105 participants sixty-nine participants were on dopamine medication; 23 
participants took dopamine agonists; one participant took glutamate agonists; two 
participants took anticholinergics; six people were one Monamine Oxidase Type B 
inhibitor (MOAB) medication and six people were not on drugs to treat Parkinson’s 
disease. Sixty-nine participants were prescribed one Parkinson’s disease specific drug were 
the other 30 participants on Parkinson’s disease drugs took a mixture of several 
Parkinson’s disease drugs. Furthermore, 45 participants were taking both Parkinson’s 
disease as well as non-Parkinson’s disease drugs and three people did not take any 
Parkinson’s disease specific medication but did take other drugs.  
Non Parkinson’s disease drugs included anti-depressants (n=12); anti-hypertensives 
(n=27); cholesterol lowering drugs (n=17); bowel and urinary tract medication (n=28); 
anti-sickness drugs (n=5); drugs for thyroid disorder (n=8); drugs for bi-polar disorder 
(n=1); drugs for pancreatic insufficiency (n=1); drugs for tachycardia (n=1); drugs for 
stomach ulcers (n=2); drugs for insomnia (n=1); drugs for diabetes (n=3); drugs for 
arthritis (n=1); drugs for gout (n=2); drugs for migraine (n=1); and drugs for chronic 
obstructive pulmonary disease (n=1). Table 5 gives an overview of mean and standard 
deviation (SD) of self-reported fatigue; physical activity and exercise tolerance. 
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Table 5: Measures of fatigue, physical activity and exercise tolerance showing mean, standard 
deviation (SD) and range of the scale 
Variable Mean (SD) Range 
FSS (range: 1-7) (n=105) 3.8 (1.4) 1.1-7 
GENEActiv sedentary (minutes) (n=89) 766 (139) 346-1134 
GENEActiv light (minutes) (n=89) 88 (43) 16-238 
GENEActiv moderate (minutes) (n=89) 90 (80) 5-424 
GENEActiv vigorous (minutes) (n=89) 4 (17) 0-147 
RER (range: 0.85-1.5) (n=82) 1.2 (0.1) 0.9-1.4 
RPE breath (range: 0-10) (n=83) 6 (2) 0-10 
RPE legs (range (0-10) (n=82) 7 (2) 2-10 
(ml*kg*min-1) (n=83) 23 (7) 9-43 
*Abbreviations: SD: Standard Deviation; FSS: Fatigue Severity Scales; RER: Respiratory 
Exchange Ratio; RPE: Rate of Perceived Exertion. 
4.4.3 Correlations 
Table 6 displays Pearson correlations between self-reported fatigue measures of physical 
activity and exercise tolerance. Significant Pearson correlations (small to moderate effect 
sizes) were found between the self-reported fatigue (Fatigue Severity Scale) and self-
reported fatigue during the exercise tolerance test (fatigue severity scale and rate of 
perceived exertion for breathing (r=-0.282; p=0.024)); fatigue severity scale and rate of 
perceived exertion for the legs (r=-0.261; p=0.033); maximum respiratory exchange ratio 
(r=-0.309; p=0.002) (see Figure 9). Furthermore, a significant Pearson correlation was 
found between self-reported fatigue and GENEActiv light activity (-0.209; p=0.049). 
Table 6: Pearson correlations with self-reported fatigue (Fatigue Severity Scale) 
Variable FSS 
Pearson r 
 
p-value 
GENEActiv sedentary (n=89) 0.040 0.710 
GENEActiv light activity (n=89) -0.209* 0.049 
GENEActiv moderate activity (n=89) -0.121 0.258 
RER (n=83) -0.309 0.051 
RPE breath (n=82) -0.282* 0.010 
RPE legs (n=82) -0.261* 0.018 
(ml*kg*min-1) -0.179 0.076 
*Pearson r is significant (p<0.05); abbreviations: FSS: Fatigue Severity Scale; RER: Respiratory 
Exchange Ratio; RPE: Rate of Perceived Exertion 
2OV
2OV
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Figure 9: Strongest Pearson correlation: Fatigue Severity Scale and the Respiratory Exchange Ratio 
(r=-0.309; p=0.004) 
No significant correlations were found between self-reported fatigue (Fatigue Severity 
Scale) and VO2max (r=-0.179; p=0.076) and self- reported fatigue and sedentary time and 
moderate activity (r=-0.121; p=0.258) as measured by the GENEActiv (see Table 6). 
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4.5 Discussion 
In current research fatigue in Parkinson’s disease is mostly measured using self-reported 
questionnaires. This study found that 41% of participants was fatigued (Fatigue Severity 
Scale score>4), which is slightly lower than most studies (Herlofson and Larsen 2003, 
Okuma, Kamei et al. 2009, Friedman, Abrantes et al. 2011) but still shows fatigue is 
present in a large portion of the participants, hence this shows that fatigue is an important 
issue to address. A possible explanation for the relatively low number of people classified 
as fatigued in this study is that the participants in this study were recruited as part of a 
larger randomised controlled trial where exercise was investigated. It is possible that 
recruitment bias has been a problem here. As mentioned, in cross sectional studies it is 
important to have a representative sample (Levin 2006), which may not be the case here as 
participants were recruited for an exercise study, possibly resulting in a skewed sample of 
participants. Research has often found that participants that are recruited for general and 
physical activity studies differ from the general population (van Heuvelen, Hochstenbach 
et al. 2005, Martinson, Crain et al. 2010). 
4.5.1 Relationships between self-reported fatigue and activity levels 
Different correlations were found between self-reported fatigue (as measured by the 
Fatigue Severity Scale) and activity levels (as measured by the GENEActiv). Whilst there 
was a correlation between fatigue and light activity, no other correlations were found. 
People that were more fatigued performed less light activity; however, they were not 
necessarily more sedentary or performing less moderate activities. This suggests that 
regardless of their fatigue, people with Parkinson’s disease do not seem to do more or less 
activity. Previous research has found inconclusive results regarding the relationship 
between fatigue and physical activity. Where one study investigating the effects of 
physical activity levels in people with Parkinson’s disease found no correlation between 
the two, another study investigation looking into fatigue and activity levels found that 
people with more severe self-reported fatigue were more sedentary (Garber and Friedman 
2003, Rocha dos Santos, Barbieri et al. 2014). It may be important to split physical activity 
into different components, in order to better establish what people with Parkinson’s disease 
do during a day, and what influence this has on fatigue and vice versa. 
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4.5.2 Relationships between self-reported fatigue and exercise tolerance  
Results from this study from the peak recordings of both rate of perceived exertion and 
respiratory exchange ratio suggest that participants had a normal exercise response and 
relationship between objective and subjective measures during it. A true maximal aerobic 
capacity (VO2 max) is defined as a maximal heart rate (HRmax) > 85% of age-adjusted 
predicted HRmax and a respiratory exchange ratio > 1.10 (Katzel, Sorkin et al. 2011). Only 
37 participants reached an age predicted HRmax of >85% and a respiratory exchange ratio 
of >1.10. Medications such as β-blockers will affect some physical test results (ACSM 
2014), therefore, rate of perceived exertion was taken into account as well. Rate of 
perceived exertion at the end of the test was on average 7 (rate of perceived exertion for 
the legs) and 6 (rate of perceived exertion for breathing) out of 10 suggesting that neither 
leg fatigue nor breathlessness were the reason for terminating the acute exercise 
intervention. As only four people performing the exercise test were on β-blockers, no 
further analyses have been done to look into the effects of β-blockers on the data. This data 
is in line with other neurological populations and suggests that either motivation or an 
inability to move was the limiting factor during an endurance test (Weiser, Kinsman et al. 
1973, Noble and Robertson 1996, Dawes, Collett et al. 2014). This study found a negative 
correlation between self-reported fatigue and the respiratory exchange ratio, indicating that 
people that report lower fatigue were able to work harder than people that reported higher 
levels of fatigue. There is one previous study that investigated the correlation of self-
reported fatigue (using the Fatigue Severity Scale) and exercise tolerance in patients with 
Parkinson’s disease in 37 subjects (Garber and Friedman 2003). Garber et al (2003) 
hypothesized that people who are more fatigued have poorer functional capacity which 
their findings confirmed (Garber and Friedman 2003). The current study was conducted in 
a much larger sample size which allows for a better generalisability.  
This study found that self-reported fatigue measured during exercise tolerance (measured 
as rate of perceived exertion) and self-reported fatigue over a longer period of time (as 
measured by the Fatigue Severity Scale) correlated well. Furthermore, exercise tolerance 
and self-reported fatigue (as measured by the Fatigue Severity Scale) correlated with one 
another. Since previous research has shown that it is possible to increase aerobic capacity 
(Bergen, Toole et al. 2002, Uc, Doerschug et al. 2014) and respiratory exchange ratio 
(Friedlander, Casazza et al. 1997, Bergman and Brooks 1999) in people with Parkinson’s 
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disease and exercise tolerance and self-reported fatigue may be related, it is plausible that 
an increase in exercise tolerance could lead to a possible decrease in self-reported fatigue. 
Furthermore, previously it has been discussed that fatigue could be related to depression, 
and quality of life and a lower physical activity. Previous research has shown that aerobic 
exercise could improve depression (Daley 2008), and increase quality of life (Goodwin, 
Richards et al. 2008), which could have a positive effect on self-reported fatigue. 
4.5.3 Limitations 
There are some limitations to the study. Firstly, confounding factors of fatigue like 
depression and sleep disorder are not specifically addressed by separate questionnaires, 
however, previous studies show that fatigue is present regardless of the presence of 
depression and sleep disorders (van Hilten, Weggeman et al. 1993, Karlsen, Larsen et al. 
1999, Herlofson and Larsen 2002, Alves, Wentzel-Larsen et al. 2004, Herlofson, Ongre et 
al. 2012). Secondly, there is still no universally accepted measure of fatigue in people with 
Parkinson’s disease. The Fatigue Severity Scale is, however, used in several studies of 
people with Parkinson’s disease (Alves, Wentzel-Larsen et al. 2004, Tyne, Taylor et al. 
2010, Valko, Waldvogel et al. 2010, Elbers, Rietberg et al. 2012). Finally, patients 
recruited for this study were part of a larger exercise study. It is likely that the sample 
described here is not a representative sample as participants were recruited for a specific 
purpose, which was a trial investigating exercise, and it is highly likely that the participants 
were either already doing exercises, or were interested in doing exercise, which may not 
represent all patients with Parkinson’s disease. Furthermore, only people with Parkinson’s 
disease that were able to walk on their own for at least 100 meters were included, which 
only represent a group of people with Parkinson’s disease.  
Finally, as discussed in Chapter 3, different drugs can have an influence on fatigue in 
people with Parkinson’s disease. For example, Abe et al (2001) describes a mechanism 
where patients with fatigue have shown reduced glucose metabolism or reduced isotope 
uptake, which may be addressed by dopamine which can improve frontal lobe function and 
may improve fatigue in that way (Abe, Takanashi et al. 2001). Although drugs could have 
an influence on fatigue, no further analyses have been done into any differences between 
participants on and participants not on drugs, the main reason being that only two 
participants were not taking any medication at all. In future studies, it would be interesting 
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to look at the different effects of drugs on the relationship between fatigue and exercise 
parameters. 
4.5.4 Conclusion 
Both the current study, as well as outcomes from previous studies regarding the Fatigue 
Severity Scale, seem to correlate with measures for aerobic capacity (Garber and Friedman 
2003). However, in the current study, respiratory exchange ratio was described as a factor 
of fatigue which represents how hard people relatively work (Cooper and Storer 2001), 
rather than just presenting aerobic capacity. This may be an important factor in developing 
treatment programmes for treating fatigue in people with Parkinson’s disease. The possible 
correlation between the respiratory exchange rate and t self-reported fatigue may implicate 
that if respiratory exchange ratio is improved (lower respiratory exchange ratio at the same 
workload) (Jeukendrup, Mensink et al. 1997, Bergman and Brooks 1999, Ramos-Jiménez, 
Hernández-Torres et al. 2008) by for example an exercise programme, as previously shown 
in studies (Friedlander, Casazza et al. 1997, Bergman and Brooks 1999), self-reported 
fatigue could be improved as well.  
The next chapter will explore the effects of an exercise programme on fatigue and other 
measures in people with Parkinson’s disease to address the question whether an 
improvement in fitness could diminish fatigue. 
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Chapter 5 Randomised controlled trial investigating exercise as a treatment 
for fatigue in people with Parkinson’s disease 
Summary  
The previous chapter indicated that exercise may improve fatigue in people with 
Parkinson’s disease. This chapter is a randomised controlled trial looking into the effects 
of exercise on fatigue in people with Parkinson’s disease. In the trial, 105 people were 
included and allocated to either an exercise programme (twice a week for six months; 
n=54) or a control intervention (handwriting exercises twice a week for six months; 
n=51). The main finding was that the exercise programme showed an improvement in the 
UPDRS (Cohen’s d = 0.25). No strong effect of the exercise programme on fatigue was 
detected (Cohen’s d = 0.17). Finally, high adherence (twenty-four participants attended at 
least 76% of all prescribed sessions) and few adverse events showed that the exercise 
programme is feasible. 
5.1 Introduction 
Following on from the previous chapter were a correlation was found between respiratory 
exchange rate and self-reported fatigue, this chapter will build on these results and will 
explore the effects of an exercise programme to treat fatigue in people with Parkinson’s 
disease.   
5.1.1 Exercise for fatigue 
In the literature, studies investigating treatment methods for fatigue measure fatigue using 
self-reported questionnaires. Exercise as a treatment method for this self-reported fatigue 
was described in Chapter 1. In summary, exercise is often chosen as a treatment method 
for fatigue in other disorders such as Multiple Sclerosis (Andreasen, Stenager et al. 2011, 
Pilutti, Greenlee et al. 2013). Findings from studies on exercise, including yoga, aerobic 
exercise, strength exercise, to improve fatigue in Multiple Sclerosis have shown that 
exercise may have a small influence on reducing fatigue (Oken, Kishiyama et al. 2004, 
Surakka, Romberg et al. 2004, Pilutti, Greenlee et al. 2013). However, little research has 
explored the impact of exercise as a treatment method for fatigue in people with 
Parkinson’s disease. 
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5.1.2 Exercise for fatigue in Parkinson’s disease 
In Chapter 1 the possible benefits of both aerobic and anaerobic exercise on Parkinson’s 
disease and fatigue have been described. In brief, animal studies have shown that aerobic 
exercise increases the concentration of dopamine in the striatum of the rat brain (Hattori, 
Naoi et al. 1994), which represents a possible mechanism of the benefits of exercise for 
both symptoms of Parkinson’s disease in general and fatigue specifically. Previous studies 
have also shown that forty minutes of active assisted cycling can increase aerobic capacity 
(Ridgel, Peacock et al. 2012). Furthermore, a study by Hass et al. (2007) concluded that 24 
sessions of whole body resistance training improved muscular fitness in people with 
Parkinson’s disease (Hass, Collins et al. 2007). Therefore, an exercise programme 
including both aerobic and anaerobic exercise may be beneficial for treating fatigue in 
people with Parkinson’s disease. 
In Parkinson’s disease there is little research into exercise as a treatment method for self-
reported fatigue. One exercise study that investigated the effects of exercise on self-
reported fatigue was conducted by Winward and colleagues (Winward, Sackley et al. 
2012). The current was part of a larger study, the Long-Term Individual Fitness 
Enablement (LIFE) project, run by the same group that developed the study described in 
this thesis. In the study, participants with long-term neurological conditions were asked to 
exercise in a gym-based setting and were instructed to do exercises following current 
guidance (five aerobic sessions and two strength sessions per week) (Elsworth, Winward et 
al. 2011). 39 participants with Parkinson’s disease were included (control group n=19; 
intervention group n=20). The study found that in the intervention group a mean of 15 
exercise sessions were attended with 55% attending 1 or more times per week (Winward, 
Sackley et al. 2012).  The intervention group was further divided into fatigued (Fatigue 
Severity Score >4) and non-fatigued participants and only two people out of eight 
classified as fatigue managed to attend the exercise programme once a week. The study 
found no effects of a twelve week exercise programme on the Fatigue Severity Scale score 
(Winward, Sackley et al. 2012), which may be explained by the low attendance; however, 
reasons of low attendance have not been discussed in the paper. In a more recent study 
exploring aerobic exercise in the community, people with Parkinson’s disease, 60 patients 
were asked to exercise three times a week for 45 minutes over six months. The study 
observed that aerobic exercise in the community improved self-reported fatigue in people 
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with Parkinson’s disease (Uc, Doerschug et al. 2014). An interesting finding in this study 
was that there were difference in fatigue level at the start between completers of the 
intervention and dropouts out the intervention, with the completers being significant more 
fatigued at baseline. This may imply that there is a good chance for improvement of the 
level of fatigue in this group. Overall, more research is needed to establish whether 
exercise could be a treatment method for fatigue in people with Parkinson’s disease and 
whether it may be effective in people with a certain level of fatigue. 
As described in Chapter 4, a higher aerobic capacity correlates significantly with lower 
self-reported fatigue. This may imply that an improvement in aerobic capacity may lead to 
an improvement in self-reported fatigue. Previous studies, including a systematic review 
including fifteen studies looking at resistance training, endurance training and other 
intensive training modalities in Parkinson's disease found an improvement in aerobic 
capacity following an exercise programme (Bergen, Toole et al. 2002, Ridgel, Vitek et al. 
2009, Uhrbrand, Stenager et al. 2015), therefore it is expected that an exercise programme 
will increase aerobic capacity which in turn may improve self-reported fatigue. 
5.1.3 Duration of exercise programme 
A systematic review and meta-analysis including fourteen paper researching of exercise 
programmes of up to twelve weeks (Goodwin, Richards et al. 2008, Allen, Sherrington et 
al. 2012), showed that exercise is beneficial with regards to physical functioning, health-
related quality of life, strength, balance and gait speed for people with Parkinson’s Disease 
(Goodwin, Richards et al. 2008). Previous work conducted within this group involved a 
twelve week community based exercise programme in people with long-term neurological 
conditions. In this trial, participants went to Inclusive Exercise Initiative gyms that offer an 
inclusive exercise environment, an accessible fitness facility, equipment designed and 
tested for use by people with disabilities, and fitness staff with expertise in exercise 
prescription. Participants had to self-direct their exercises to meet their own fitness goals 
for twelve weeks (Elsworth, Winward et al. 2011). The study found positive results in 
attendance and suggested a future study looking at long-term effects up to at least six 
months to confirm any benefit (Elsworth, Winward et al. 2011). One recent study by 
Schenkman et al (2012) investigating a 16 months exercise trial, followed up 96 
participants out of 121 participants at 16 months (79.3% retention rate) which suggests that 
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a longer-term programme is feasible. The programme compared three interventions. The 
first intervention consisted of a supervised flexibility/balance/function exercise group. The 
second group was a supervised aerobic exercise group. Both groups received supervised 
exercise three days a week for four months; in month five, supervision was tapered and 
after that they received one supervised session per month. Finally, there was a control 
group that exercised under supervision during an initial session and then once a month for 
16 months. The participants were asked to keep an exercise diary that was reviewed once a 
month. Their programme lacked a non-exercising control group, but saw no reduction in 
UPDRS score in both their exercise groups, which one would normally expect in 
Parkinson’s disease due to the progressiveness of the disorder (Schenkman, Hall et al. 
2012). Since the benefits of longer term exercise programmes have not been established 
thoroughly, a six months exercise intervention was developed.  
5.1.4 Community exercise 
In spite of the well-known benefits of exercise in people with Parkinson’s disease it is 
apparent that there are barriers to participation. Previous research, as described in Chapter 
1, has shown that people with disabilities have identified the following barriers for 
exercise, including community exercise (Elsworth, Dawes et al. 2009): 
- Costs  
- Negative personal experiences and attitudes as well as fear and embarrassment of 
exercising 
- Perception that fitness instructors will lack knowledge about their condition and 
how to help them participate in exercise safely and effectively 
- Transportation and access 
- Equipment (a lack of equipment suitable for and usable by disabled people) 
- A fear of losing balance 
Furthermore, the following facilitators were identified (Elsworth, Dawes et al. 2009): 
- Positive personal attitudes 
- Individually tailored gym programmes 
- An exercise place that actively supports people with similar conditions and 
disabilities 
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- An exercise programme that considers individual motivators for exercise, not 
necessarily assuming individuals will be motivated by factors such as weight 
control, body shape or “keeping fit” 
The barriers and facilitators described were taken into account when developing the current 
exercise programme. The programme had to be low-cost, accessible, tailored to the 
individual, and nearby their home.  
Although barriers concerning community exercise facilities are present, community 
exercise facilities are widely available in the United Kingdom (Elsworth, Winward et al. 
2011, Winward 2011). A pilot study exploring the feasibility and acceptability of a 
community exercise intervention in people with longer-term neurological conditions found 
that adherence to a twelve week programme was good with participant attending an 
average of 15 exercise sessions over twelve weeks (Elsworth, Winward et al. 2011, 
Winward 2011). Therefore, it is expected that a 24 week community based programme in 
people with Parkinson’s disease will show similar results in terms of adherence. 
The study also found that participants required on average three physiotherapy support 
sessions in a twelve week period (Winward 2011), therefore the programme was developed 
with participants receiving support once a month from an exercise expert. 
The aim for the control group was not to provide exercises in a gym setting, but to provide 
the same support that the participants in the exercise group received (Boutron, Moher et al. 
2008). Therefore, the participants in the control group received the same number of 
support sessions as the participants in the exercise group received. 
The components described above were incorporated into an intervention consisting of a 
randomised controlled trial investigating a community based six months exercise 
programme. 
5.1.4 Aims 
 To investigate the effects of a community based six months exercise programme on 
fatigue in people with Parkinson’s disease using an randomised controlled trial 
 To explore the adherence to and safety of a community based six months exercise 
programme in people with Parkinson’s disease 
 To explore what baseline characteristics could predict adherence to the programme.  
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 To explore whether participants who attended more sessions of the implemented 
exercise programme benefitted from larger potential benefits. 
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5.2 Methods 
The study as described below is set up as an external randomised controlled pilot trial. 
Since the study is set up as a randomised trial, CONSORT guidelines for reporting 
randomised trials (see appendix 10) were followed in reporting the trial and the results 
(Schulz, Altman et al. 2010) (divided over this chapter and the previous chapter).  
The intervention is described following TiDier guidelines (see appendix 11) (Hoffmann, 
Glasziou et al. 2014). The TiDier guidelines have been implemented to improve the 
completeness of reporting and the replicability of interventions (Hoffmann, Glasziou et al. 
2014). Below, the rationale of the components of the trial is described. 
This study was a phase II single blind pilot randomised controlled trial. Participants, 
including in- and exclusion criteria were described in Chapter 4. No changes were made to 
the methods after commencement of the trial. 
5.2.1 Power calculation 
As a pilot trial no formal power calculation has been used to direct the sample size, 
however data from short term exercise studies of the primary outcome measure (of the trial 
this thesis is based on; the two minute walk test) suggest that effect sizes from changes in 
motor symptoms observed in the two minute walk test of 0.3 can be expected for exercise 
one time per week to 0.8 for three times per week, with clinically meaningful change in the 
elderly of twelve meters or an effect size of 0.55. Thus it is likely that 80 subjects in total 
would be sufficient to detect an effect size of 0.55 with a power of 80% and alpha of 0.05. 
Allowing for attrition, in 99 participants there were five people dropping out during a 
twelve week intervention, thus it was expected that in six months 100 people would allow 
for attrition. 
5.2.2 Randomisation and assessments 
The participants were assessed at baseline and then at three (halfway through the 
intervention), six (at the end of the intervention) and twelve months. Participants recruited 
to the study were allocated the next available study number by the blinded assessor. The 
study number related to a computer-generated randomization list drawn up by the Oxford 
Clinical Trials Unit (Nuffield Department of Primary Care Health Sciences, Oxford 
University), that randomised individuals (1:1) into either intervention (exercise) or control 
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(handwriting) groups. The Oxford Clinical Trials Unit used minimisation techniques for 
randomisation to allow for balancing medication and gender at baseline were used. The list 
was held by the principal investigator who informed the physiotherapist and exercise 
professional supporting the intervention of group allocation. The project’s physiotherapist, 
exercise expert and the participants were not blinded to group allocation. Group allocation 
was concealed from the assessor until the end of the study. 
All assessments were conducted at the Movement Science Lab (Oxford Brookes 
University) by the same blinded assessor, and patients were reminded throughout the trial 
that the assessor was blinded to the allocated intervention. 
5.2.3 Interventions 
When and how much: The intervention took place twice a week over a period of six 
months with each session lasting 60 minutes. Both groups were asked to continue other 
daily activities as they usually would, including any exercise which was part of their 
routing before the start of the trial. After the six month assessment no further instruction on 
exercise (or hand writing practice) was given. Both groups were instructed to perform daily 
activities as they usual would; including any exercises that were part of their routine before 
the start of the trial. 
5.2.3.1 Experimental Group 
Where: The gym-based exercise sessions were delivered in exercise facilities, in 
Oxfordshire and Berkshire, under the supervision of an exercise expert. Participants were 
able to choose participating facilities nearby their home to minimise travel burden (which 
has been identified as a barrier in previous research (Elsworth, Dawes et al. 2009)).  
How and who provided: The projects’ physiotherapist attended the initial session and 
ensured that the exercises were appropriate throughout the exercise programme. This first 
session was also aimed at putting the participant at ease; to get them familiar with the gym; 
and to introduce them to the staff normally present in the gym, which were identified as 
barriers for people with neurological illnesses to exercise in a gym facility (Elsworth, 
Winward et al. 2011). Other staff members working in the gym were fully informed about 
the study prior to any participants beginning the intervention. Exercise prescription was 
provided by an exercise professional (registry of exercise professional’s level 4 
qualification in exercise for long term neurological conditions). The project physiotherapist 
   
80 
  
 
 
ensured that safe exercise prescription was achieved at all times and ensured that any 
medical/medication issues were best addressed. The participants could contact the projects’ 
exercise expert if anything unusual happened or when they needed more assistance. 
When and how much: The exercise programme totalled 48, 60 minutes sessions over a 24 
week period (2 times a week).  
What: An exercise programme combining aerobic components (as discussed in Chapter 1, 
aerobic exercises may be beneficial in improving balance, gait, physical function, and 
quality of life in individuals with Parkinson’s disease (Hackney and Earhart 2009, 
Canning, Allen et al. 2012, Li, Harmer et al. 2012), and anaerobic exercise (as discussed in 
Chapter 1 resistance training (anaerobic exercise) is the only form of exercise that 
increases muscle size and strength (ACSM 2014). Anaerobic exercise has shown to 
improve muscle mass, neuromuscular performance (Taaffe, Duret et al. 1999) which could 
potentially reduce the risk of falls and fractures in older adults, including people with 
Parkinson’s disease (Falvo, Schilling et al. 2008).  
At the start of each session, each participant performed 30 minutes of aerobic training and 
was able to choose from a treadmill, bicycle ergometer, cross-trainer or rowing ergometer, 
if the equipment was available. After an initial warm up of 10 minutes, the participant was 
instructed to exercise so that their heart rate was maintained in an aerobic training zone for 
20 minutes (55-85 percentage age predicted maximal heart rate) following  prescription 
guidelines (ACSM 2009) rather than using the exercise tolerance data to determine 
exercise intensity. Speed and resistance were manipulated to maintain the participant’s 
heart rate within an aerobic zone (medication affecting heart rate was considered). 
Participants recorded the type of equipment used and actual duration, as well as rating of 
perceived exertion (RPE, CR10 scale) (Borg 1998) and heart rate in their diaries. 
After the aerobic exercise, there were 30 minutes of anaerobic training. Strength was 
trained on resistance equipment, performed at an initial resistance so ten repetitions could 
be performed. Leg extension was performed on a seated leg press and squats performed 
using a chair. Functional core stability/mobility was trained during upper limb training. 
Upper limb/trunk exercises included: Double arm pull-down, a double arm lateral raise and 
single arm rotation performed seated, or standing as able.  
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Tailoring: At the monthly support session, exercise intensities and progression were 
monitored. The interventions were personalised and progressed according to the following 
protocols. At the initial session the exercise professional or physiotherapist set the exercise 
intensity so that the participants achieved 55-85 percentage age predicted maximal heart 
rate (ACSM 2009), for the duration of the aerobic training, participants were then taught to 
manipulate speed or resistance in order to maintain the exercise intensity. Exercise 
tolerance data could be used to assess exercise intensity, however it was decided to keep to 
the ACSM guidelines. For the anaerobic exercises, initial resistance was selected so ten 
repetitions could be performed. The exercise professional or physiotherapist instructed the 
participants that when two full sets of ten could be performed at a given resistance, within 
two minutes, to increase resistance. This would lead to a resultant decrease in repetitions 
and then the protocol would be repeated. 
How well: In order to be able to define adherence to the programme participants were 
provided with an exercise booklet to fill out (see appendix 12). For aerobic exercise, time 
(in minutes) and machine were noted down. Furthermore, rate of perceived exertion and 
heart rate were recorded in the exercise booklet. For the anaerobic training, the volume of 
work done was reported by noting down the resistance weight and the number of 
repetitions.  
All travel and gym costs were met by the study. 
5.2.3.2 Control Group 
Patient and public involvement was used to create an effective control group where people 
would adhere to a certain programme. Possibilities of an active control group were 
explored during user group meetings where people with Parkinson’s disease identified 
handwriting as a major issue. A programme aimed at handwriting could engage people and 
would create an active control group without implementing exercise.  
What and where: The control group received a hand writing programme based on the 
Parkinson’s Disease Society’s guidance information sheet for handwriting (PDS 2008). 
Participants were provided with a handwriting programme to complete at their home (in 
Oxfordshire or Berkshire), 60 minutes twice weekly for six months.  
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Who provided and how: The control group were monitored and supported by an exercise 
expert. They would get a first visit with the exercise expert and were provided with four 
booklets each containing two 60 minute handwriting sessions. The exercise expert would 
explain what was expected from the participant (filling out one booklet per week, 
containing two sessions of 60 minutes of handwriting exercises) and the exercise expert 
would go through the first book with the participant to ensure they knew how to complete 
the work books. They would then be visited by the exercise expert every month to be 
provided with a new set of booklets and they could contact the exercise expert or 
physiotherapist if they needed more advice or had any concerns.  
When and how much: The handwriting program also totalled 48 sessions over a 24 week 
period (2x a week). The 60minute session consisted of the following, Warm up exercises 
for both hands (wriggling figures, making a fist, touching figure with thumb, circling 
wrists, shrugging shoulders and stretching hands), then a variety of writing activities (eg 
copying shapes, writing pangrams, writing a post card, filling in a form) and finished with 
hand exercises (rolling putty, using pegs, placing sticks in a jar, and ball drop and catch). 
Writing activities varied from work book to work book in order to maintain interest.   
Tailoring: There was no formal tailoring or progression, as all participants in the 
handwriting group followed the same work books. However, participant could monitor 
their own performance using ‘The quick brown fox jumps over the lazy dog’ pangram 
which was performed every session and feedback was given by the exercise expert or 
physiotherapist at the monthly support sessions.  
How well: As with the exercise group, diaries were used by participants in the control 
group to record their practice. 
5.2.4 Measures 
Measures have been described in Chapter 4. No changes in outcome measures were made 
after commencement of the trial. Below, the measures used are listed. 
Primary outcome measure: 
Self-reported fatigue was assessed using the Fatigue Severity Scale (FSS) (Krupp, 
LaRocca et al. 1989) 
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Secondary outcome measures: 
Disease severity was measured by the Movement Disorder Society Unified Parkinson’s 
Disease Rating Scale part III (UPDRS-III) (Winter, von Campenhausen et al. 2011).  
To measure mobility, the two-minute walk test (2MWT) was conducted in which 
participants were asked to walk at a normal comfortable speed on a track of 16 meters for 
two minutes; the distance covered was measured (Brooks, Parsons et al. 2004).  
The Short Form 36 (SF-36) was used to measure quality of life (Ware 2014). 
In order to assess activity levels of the participants, the Physical Activity Scale for the 
Elderly (PASE) was conducted (Schuit, Schouten et al. 1997). For seven days following an 
assessment the participants wore an accelerometer  (GENEActiv) (Welch, Bassett et al. 
2014) on their wrist for a week. Outcome scores reflecting sedentary activity, light activity 
and moderate activity were calculated by averaging the data across the days of data 
collection (Welch, Bassett et al. 2014, Pavey, Gomersall et al. 2015). 
Aerobic capacity of the participants, by averaging VO2 over the highest 30 seconds of the 
test. Maximum respiratory exchange ratio was calculated from the ratio of  to ; 
averaged over the last 30 seconds of the test.  The CR10 Rating of Perceived Exertion 
scale was used to measure leg fatigue and breathlessness at the end of each stage, which 
previously has been done in Multiple Sclerosis (Dawes, Collett et al. 2014). 
5.2.5 Data handling and analyses 
Data were analysed using IBM SPSS Statistics 22. In order to investigate any changes over 
time all people were included in an intention to treat analysis.  
5.2.5.1 Demographics 
Mean and standard deviation (SD) were calculated for both groups the exercise group and 
the control group at baseline as well as twelve and twenty-four weeks after the 
commencement of the trial. Two tailed Independent t-tests were performed to establish any 
differences in primary and secondary outcomes between the exercise group and control 
group at baseline. 
2COV 2OV
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5.2.5.2 Effects of the intervention 
The effects of the intervention were expressed over time (baseline versus 24 weeks) 
between the groups as Cohen’s D and 95% confidence interval. Significance was 
established if the 95% confidence interval does not cross 0. The Cohen’s D was calculated 
using a linear mixed model. A linear mixed model was used instead of an ANOVA’s and a 
regression model because of the advantage that all data collected can be used, and missing 
data does not result in exclusion of complete subjects (Seltman 2014). 
5.2.5.3 Adherence and safety 
Feasibility of the intervention was measured in terms of adherence and adverse events. 
Adherence in the exercise group was determined by counting the number of sessions 
participants had undertaken during the intervention. For the exercise intervention a session 
would count as going to the gym and attempting to perform the aerobic exercises, the 
anaerobic exercises, or both. Besides number of sessions the participants attended in the 
gym, sub-analyses were performed on the time spent on aerobic exercise (in minutes), and 
whether or not they performed anaerobic exercise (yes/no per exercise).  
Adherence of the control group was determined by counting the number of sessions 
participants had completed in their booklet. A session was counted as completed if over 
50% of the session was completed. 
The exercise expert in collaboration with the physiotherapist would ask the participants 
whether or not any adverse events and serious adverse events had taken place in between 
visits. Furthermore, any other adverse events and serious adverse events that became 
apparent during any contact with a participant were recorded throughout the trial. 
5.2.5.4 Progression of exercises 
To assess anaerobic exercise progression over time the average volume (kilograms times 
repetitions) of all participants was calculated per session. Progression was then presented 
as change score from baseline. Aerobic exercise progression is not measured as intensity 
did not have to be reported in the exercise diary. 
5.2.5.5 Predictors of adherence 
Outcomes from baseline measures as described in Chapter 4 (Chapter 4: Table 4 and Table 
5 ) were correlated with number of gym sessions attended. 
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5.2.5.6 Sub-analyses of the effects of intervention 
In order to investigate the relationship between attended gym sessions and the outcomes of 
the exercise programme, a sub analysis was performed of participants that were 
randomised into the exercise group. All participants who were non-compliant (defined as 
attending ‘0’ or ‘1’ session) were assigned a number of ‘0’ sessions. Pearson’s correlations 
were performed between number of sessions attended and change data. Change data was 
defined as: Change data = 24 weeks assessment – baseline assessment. 
Finally, the effects of the intervention were expressed over time (baseline versus 24 weeks) 
within the exercise group as Cohen’s D and 95% confidence interval. Significance was 
established if the 95% confidence interval does not cross 0. 
5.2.6 Correlations at 6 months 
Finally, significant correlations found in Chapter 4 regarding self-reported fatigue and 
physical activity, exercise tolerance and fatigue reported during exercise tolerance were 
explored after the intervention using Pearson’s correlations. 
5. 3 Results 
5.3.1 Participant flow and dropout 
The flow diagram in Figure 10 shows the flow of participants through the study. 
A total of 170 people expressed an initial interest in the study. 107 people were screened 
for eligibility and 105 people were included in the study. 54 participants were allocated to 
the exercise group; 51 patients were allocated to the control group. 
Eighty-six people were followed up on after twelve weeks, resulting in a retention rate of 
82%. Reasons for loss to follow up were: i) too ill to attend further sessions (n=3); ii) re-
diagnosed (dementia n=1; multiple system atrophy n=1); iii) withdrew consent (n=8); 
reasons: medical reasons (n=4); too busy (n=3); not interested anymore (n=1)); iv) 
unavailable to come in on time (i.e. twelve weeks after the start ± two weeks) (n=4); v); 
vii) passed away (n=1).  
91 people were followed up on after 24 weeks resulting in a retention rate of 87% 
(compared to the baseline appointment). Reasons for loss to follow up were: i) too ill to 
come in (n=3); ii) re-diagnosed (dementia n=1; multiple system atrophy n=1); iii) 
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withdrew consent (n=8); vi) passed away (n=1). These were the same reasons as the 
reasons for loss to follow up at twelve weeks. 
5.3.2 Demographics 
Descriptive statistics are presented in Table 7. In the table, numbers found at three months 
are included, however, as exercise interventions lasting three months have been explored 
previously, this thesis focuses at the outcomes at six months, which has not been explored 
much, and therefore, further analyses were performed comparing data from the baseline 
and six months into the trial. 
All variables except from the 2MWT were similar at baseline between the two intervention 
groups. 
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12 weeks assessment (n=43) 
Loss to follow up at 24 weeks (n=6) 
- Medical reasons (n=1) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=0) 
- Passed away (n=0) 
Discontinued intervention (n=9) 
- Medical reasons (n=0) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=0) 
- Passed away (n=0) 
- Not interested (n=7) 
Loss to follow up at 12 weeks (n=11) 
- Medical reasons (n=2) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=3) 
- Passed away (n=1) 
Discontinued intervention (n=13) 
- Medical reasons (n=2) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=2) 
- Passed away (n=1) 
- Not interested (n=3) 
 
Loss to follow up at 24 weeks (n=8) 
- Medical reasons (n=2) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=0) 
- Passed away (n=1) 
Discontinued intervention (n=18) 
- Medical reasons (n=2) 
- Re-diagnosed (n=0) 
- Withdrew (n=4) 
- Not available (n=0) 
- Passed away (n=0) 
- Not interested (n=16) 
Adherence for participants (n=37) 
<25% (n=1) 
26-50% (n=4) 
51-75% (n=7) 
>76% (n=25) 
Excluded (n=2) 
-Not meeting inclusion criteria (n=2) 
-Failed to give consent (n=0) 
-declined to participate (n=0) 
 
24 weeks assessment (n=45) 
24 weeks assessment (n=46) 
Loss to follow up at 12 weeks (n=7) 
- Medical reasons (n=1) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=1) 
- Passed away (n=0) 
Discontinued intervention (n=9) 
- Medical reasons (n=0) 
- Re-diagnosed (n=1) 
- Withdrew (n=4) 
- Not available (n=1) 
- Passed away (n=0) 
- Not interested (n=3) 
12 weeks assessment (n=44) 
Expressed an interest (n=170) 
Assessed for eligibility (n=107) 
Randomized (n=105) 
Allocated to Exercise (n=54) 
-Received allocated intervention (n=54) 
-Did not receive allocated intervention (n=0) 
Allocated to Handwriting (n=51) 
-Received allocated intervention (n=50) 
-Did not received allocated intervention (n=1*) 
*Received wrong intervention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Flow diagram of Participants through the study 
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Table 7: Descriptive statistics: Mean and Standard Deviation (SD) for assessment 1, 2 and 3 for 
both groups (exercise and control). 
p-values are reported for differences at assessment one between the exercise and control group as 
determined by t-test. 
Variable Assessment Exercise 
Mean (SD) 
Control 
Mean (SD) 
p-value 
(difference at 
baseline) 
Age 1 66 (9) 68 (7) 0.254 
     
Years since 
diagnosis 
1 4.8 (4.1) 5.3 (4.1) 0.547 
     
Weight 1 76.9 (16.6) (n=54) 78.1 (14.1) (n=51) 0.693 
 2 77.2 (15.6) (n=42) 76.6 (14.6) (n=44)  
 3 76.8 (15.8) (n=45) 76.5 (15.0) (n=45)  
     
UPDRS part III 1 17 (10) (n=54) 19 (10) (n=51) 0.214 
 2 14 (10) (n=42) 18 (10) (n=44)  
 3 14 (9) (n=45) 19 (9) (n=45)  
     
2 Minute Walk 
Test 
1 146.5 (23.9) 
(n=54) 
137.0 (22.7) (n=51) 0.041 
(metres) 2 152.6 (21.3) 
(n=42) 
135.6 (25.9) (n=44)  
 3 147.8 (30.6) 
(n=45) 
138.0 (25.0) (n=45)  
     
SF-36  1 70 (18) (54) 68 (17) (n=51) 0.579 
Mental Health 2 73 (16) (n=43) 70 (16) (n=44)  
 3 70 (18) (n=46) 66 (19) (n=45)  
     
SF-36  1 64 (18) (n=54) 61 (19) (n=51) 0.384 
Physical Health 2 66 (17) (n=43) 61 (19) (n=44)  
 3 64 (18) (n=46) 60 (21) (n=45)  
     
PASE 1  66 (35) (n=40) 64 (33) (n=48) 0.803 
 2  76 (43) (n=32) 77 (31) (n=39)  
 3  78 (41) (n=39) 74 (40) (n=33)  
Abbreviations: UPDRS part III: Movement Disorders Society Unified Parkinson’s Disease Rating Scale part 
III; SF-36: Short Form 36; PASE: Physical Activity Scale for the Elderly. Assessment 1: baseline 
assessment; Assessment 2: 12 weeks assessment; Assessment 3: 24 weeks assessment. 
Mean and SD for all fatigue measures for the three assessments for both the exercise group 
and the control group are presented in Table 8. 
  
   
89 
  
 
 
Table 8: Measures of fatigue, physical activity and exercise tolerance 
Mean and Standard Deviation (SD) for assessment 1, 2 and 3 for both groups (exercise and 
control). P-values are reported for differences at assessment one between the exercise and control 
group as determined by a t-test. 
Variable Assessment Exercise 
Mean (SD) 
Control 
Mean (SD) 
p-value 
FSS 1 3.6 (1.4) (n=54) 3.9 (1.4) (n=51) 0.239 
 2 3.5 (1.4) (n=44) 3.4 (1.4) (n=44)  
 3 3.3 (1.5) (n=46) 3.5 (1.5) (n=45)  
     
GA: Sedentary 1 762 (156) (n=45) 770 (121) (n=44) 0.768 
(Minutes) 2 745 (147) (n=37) 789 (139) (n=35)  
 3 760 (142) (n=34) 784 (153) (n=35)  
     
GA: light 1 86 (42) (n=45) 90 (72) (n=44) 0.695 
(Minutes) 2 80 (40) (n=37) 84 (47) (n=35)  
 3 74 (36) (n=34) 79 (74) (n=35)  
     
GA: moderate 1 92 (88) (n=45) 87 (72) (n=44) 0.759 
(Minutes) 2 83 (80) (n=37) 78 (68) (n=35)  
 3 73 (57) (n=34) 79 (74) (n=35)  
     
 1 21.3 (7.2) (n=43) 20.6 (7.1) (n=39) 0.779 
 2 21.1 (6.6) (n=34) 20.2 (6.8) (n=32)  
 3 21.4 (5.8) (n=31) 20.4 (7.7) (n=31)  
     
RER 1 1.18 (0.10) (n=43) 1.17 (0.14) (n=39) 0.633 
 2 1.23 (0.10) (n=34) 1.18 (0.14) (n=32)  
 3 1.19 (0.09) (n=31) 1.19 (0.14) (n=31)  
     
RPElegs 1 7 (3) (n=43) 7 (2) (n=39) 0.928 
 2 8 (2) (n=34) 7 (2) (n=32)  
 3 8 (2) (n=31) 8 (2) (n=31)  
     
RPEbreath 1 6 (2) (n=43) 7 (2) (n=39) 0.972 
 2 7 (2) (n=34) 7 (2) (n=32)  
 3 7 (2) (n=31) 7 (2) (n=31)  
Abbreviations: FSS: Fatigue Severity Scale; GA: GENEActiv; : Ratio of Oxygen consumption; RER: 
respiratory exchange ratio; RPElegs: Rate of perceived exertion for the legs; RPEbreath: Rate of perceived 
exertion for the breathing. Assessment 1: baseline assessment; Assessment 2: 12 weeks assessment; 
Assessment 3: 24 weeks assessment. 
5.3.3 Effects of the intervention 
Effect sizes are reported in Table 9. Cohen suggested that d=0.2 be considered a 'small' 
effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. The data shows 
2OV
2OV
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small effects sizes for the 2 MWT (d=0.25) and for the MDS-UPDRS part III (d=0.27), all 
other effect sizes were smaller than 0.2.  
Table 9: Effect sizes over time of the difference (assessment 1 and assessment 3) between the 
groups (exercise and handwriting) (n: see table 8) 
Variable Cohen’s d 95% confidence interval 
2 MWT 0.27*  0.04 – 0.51 
UPDRS-III 0.25*  0.02 – 0.49 
SF-36 Mental Health 0.12 -0.11 – 0.36 
SF-36 Physical Health 0.07 -0.16 – 0.30 
PASE 0.06 -0.16 – 0.28 
* significant (95% confidence interval does not cross 0).  
Abbreviations: 2 MWT: 2 minute walk test; UPDRS III: Movement Disorders Society Unified Parkinson’s 
Disease Rating Scale part III; SF36: Short Form 36; Phys: Physical; Men: Mental; PASE: Physical Activity 
Scale for the Elderly. 
Effect sizes for the fatigue measures are reported in Table 10. All effect sizes were smaller 
than 0.2. Effect size for the Fatigue Severity Scale (d=0.17) approached 0.2.  
Table 10: Effect sizes over time (assessment 1 and assessment 3) between the two groups (exercise 
and handwriting) for the fatigue, physical activity and exercise tolerance (n: see table 8). 
Variable Cohen’s d 95% confidence interval 
FSS 0.17 -0.19 – 0.41 
 0.08 -0.11 – 0.27 
RER 0.10 -0.12 – 0.32 
GENEActiv Sedentary 0.07 -0.15 – 0.29 
GENEActiv  Light 0.09 -0.13 – 0.31 
GENEActiv  Moderate 0.01 -0.21 – 0.23 
Abbreviations: FSS: Fatigue Severity Scale; : Ratio of Oxygen consumption; RER: Respiratory 
Exchange Ratio 
5.3.4 Progression in the exercise programme 
Figure 11 shows average progression over time of the exercises per session. All exercises 
show a positive trend towards progression over the number of sessions.  
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adhered to some extend to the exercise programme. These 37 participants (68%) attended 
an average of 37 (SD=10) of 48 sessions. The minimum number of sessions attended was 
nine and the maximum was 47 sessions. One participant attended fewer than 25% of the 
sessions; four participants attended between 26% and 50%; eight participants attended 
between 51% and 75%; and 24 participants attended over 75% of the prescribed exercise 
sessions. 
During the attended sessions participants completed an average of 30 minutes (SD = 3 
minutes) of the 30 minutes prescribed aerobic exercise. Regarding anaerobic exercises, 
participants performed  the leg press on average 33 sessions; leg extension nine sessions; 
sit-to-stand 31 session; double arm pull down 35 session; rotation wood chop 29 session; 
and arm raise 34 sessions out of 48 session. 
5.3.6 Adherence to control programme 
In total 51 participants were randomised into the control group. Of these participants, 
twelve participants were non-compliant. One person completed 25% of the sessions; four 
participants completed between 26 and 50% of the sessions; six participants completed 
between 51 and 75% of the sessions; and 28 participants completed at least 76% of the 
prescribed sessions.  
5.3.7 Adverse events 
In total, eight adverse events were reported in the exercise group. Only two adverse events 
were related to the intervention. One participant suffered from an abnormal heart rate 
response during the intervention; one participant felt faint during exercise which was later 
classified by the consultant as orthostatic hypotension. The latter participant did continue 
the intervention. As a result of adverse events two participants allocated to the exercise 
group withdrew consent before starting the intervention period. One of them suffered a 
severe fall which led to three weeks hospitalization; the other person withdrew because of 
severe depression. One participant died early on in the intervention period due to unrelated 
issues. Three participants suffered falls unrelated to the exercise intervention. One person 
broke their leg unrelated to the intervention.  
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5.3.8 Parameters relating to adherence to exercise sessions 
The following descriptive measures positively related (Pearson r) to the number of sessions 
participants attended: 2MWT (r=0.370; p=0.008); SF-36 Physical Health (r=0.415; 
p=0.003). However, the following descriptive measures did not relate to the number of 
sessions attended: UPDRS III (r=-0.106; p=0.466); SF-36 Mental Health (r=0.221; 
p=0.126); and PASE (r=0.214; p=0.203) (see Table 11). 
Table 11: Pearson Correlations with number of sessions attended to baseline characteristics 
 Pearson r p-value 
UPDRS III (n=50) -0.106 0.466 
2MWT (n=50) 0.370 0.008 
SF36 Physical Health (n=49) 0.415 0.003 
SF36 Mental Health (n=49) 0.221 0.126 
PASE 0.214 0.203 
Abbreviations: 2MWT: 2 minute walk test; UPDRS III: Movement Disorders Society Unified Parkinson’s 
Disease Rating Scale part III; SF36: Short Form 36; PASE: Physical Activity Scale for the Elderly. 
The number of sessions attended related with  (r=0.387; p=0.014). The correlation 
between number of session attended and self-reported fatigue levels (FSS) approached 
significance (r=-0.278; p=0.051). The following descriptive measures did not relate to the 
number of sessions attended: respiratory exchange ratio (r=0.002; p=0.988); and baseline 
activity levels as monitored by all outcomes of the GENEActiv (sedentary: r=-0.530; 
p=0.740; light: r=0.010; p=0.951; moderate: r=0.027; 0.868) (see Table 12 ). 
Table 12: Pearson correlations with number of sessions attended and physical activity and exercise 
tolerance. 
 Pearson r p-value 
FSS (n=50) -0.278 0.051 
GENEActiv sedentary (n=41) -0.530 0.740 
GENEActiv light (n=41) 0.010 0.951 
GENEActiv moderate (n=41) 0.027 0.868 
 (n=40) 0.387 0.014 
RER (n=40) 0.002 0.988 
Abbreviations: FSS: Fatigue Severity Scale; : Ratio of Oxygen consumption; RER: Respiratory 
Exchange Ratio 
5.3.9 Sub-analyses of participants in the exercise group 
In the sub-analyses, all participants randomised to the exercise group (n=54) were 
included. These data show small effects sizes in UPDRS part III (Cohen’s d=0.24; 95% 
2OV
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confidence interval 0.03-0.45). Effect sizes for SF-36 physical health (Cohen’s d=0.17; 
95% confidence interval -0.04-0.38); and PASE (Cohen’s d=0.17; 95 % confidence 
interval -0.02-0.37) approached 0.2 (see Table 13). 
Table 13: Effect sizes over time (baseline assessment and 24 weeks assessment) in the exercise 
group (n=54) 
Variable Cohen’s d 95% confidence interval 
UPDRS III 0.24  0.03 – 0.45 
2 MWT 0.10 -0.11 – 0.31 
SF-36 Mental Health 0.09 -0.12 – 0.29 
SF-36 Physical Health 0.17 -0.04 – 0.38 
PASE 0.17 -0.02 – 0.37 
Abbreviations: 2MWT: 2 minute walk test; UPDRS III: Movement Disorders Society Unified Parkinson’s 
Disease Rating Scale part III; SF36: Short Form 36; Phys: Physical; Men: Mental; PASE: Physical Activity 
Scale for the Elderly. 
For fatigue, small effect sizes were found in light activity (d=0.3); and moderate activity 
(d=0.27) (see Table 14). 
Table 14: Effect sizes for fatigue, physical activity and exercise tolerance over time (baseline 
assessment and 24 weeks assessment) in the exercise group (n=54) 
Variable Cohen’s d 95% confidence interval 
FSS 0.14 -0.06 – 0.35 
 0.08 -0.11 – 0.27 
RER 0.08 -0.11 – 0.27 
Sedentary 0.14 -0.05 – 0.33 
Light 0.30  0.10 – 0.49 
Moderate 0.27  0.08 – 0.47 
Abbreviations: FSS: Fatigue Severity Scale; : Ratio of Oxygen consumption ; RER: Respiratory 
Exchange Ratio 
Furthermore, in this subgroup, analyses were performed to explore whether or not 
participants that adhered well to the programme experienced greater benefits compared to 
the participants that did not adhere well to the programme. Correlations of the number of 
sessions and the above mentioned measures are presented in Table 15; two examples of the 
correlations are shown in Figure 12 (number of attended sessions plotted against change 
score of the UPDRS part III) and Figure 13 (number of attended sessions plotted against 
change score of the FSS). There was no significant correlation between number of sessions 
attended and any of the measures explored.  
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Table 15: Pearson correlation coefficients between the number of attended sessions and the change 
score between assessment one and assessment three in the exercise group. 
Variable Number of sessions attended 
Pearson r                            P-value 
UPDRS III (n=42) 0.022 0.891 
2MWT (n=42) 0.235 0.134 
SF36 mental health (n=43) 0.236 0.128 
SF36 physical health (n=43) 0.048 0.759 
Abbreviations: 2MWT: two minute walk test; UPDRS III: Movement Disorders Society Unified Parkinson’s 
Disease Rating Scale part III; SF36: Short Form 36; FSS: Fatigue Severity Scale; RER: Respiratory 
Exchange Ratio. 
Table 16: Pearson correlation coefficients between the number of attended sessions and the fatigue 
change scores between assessment one and assessment three in the exercise group. 
Variable                                                           Number of sessions attended  
                                                                          Pearson  r                            P-value 
FSS (n=43) -0.019 0.901 
GENEActiv sedentary activity (n=26) 0.129 0.530 
GENEActiv light activity (n=26) -0.167 0.414 
GENEActiv moderate activity (n=26) -0.243 0.231 
 (n=29) -0.298 0.116 
RER (n=29) 0.015 0.939 
Abbreviations: FSS: Fatigue Severity Scale; : Ratio of Oxygen consumption; RER: Respiratory 
Exchange Ratio 
 
Figure 12: Scatterplot of the number of session attended and the change in the UPDRS part III (Movement 
Disorders Society Unified Parkinson’s Disease Rating Scale part III) score from baseline assessment to the 
24 weeks assessment. Abbreviations: UPDRS = Unified Parkinson’s Disease Rating Scale 
2OV
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Figure 13: Scatterplot showing the number of session attended and the change in the Fatigue Severity Scale 
from baseline assessment to the 24 weeks assessment. Abbreviations: FSS = Fatigue Severity Scale 
5.3.9 Correlations at 6 months 
No significant correlations were found correlations between self-reported fatigue (Fatigue 
Severity Scale) and measures of physical activity (GENEActiv light), exercise tolerance 
(Respiratory Exchange Ratio), and self-reported fatigue during exercise tolerance (Rate of 
Perceived Exertion) (see Table 17). 
Table 17: Pearson’s correlations between self-reported fatigue (Fatigue Severity Scale) and 
physical activity and exercise tolerance 
Variable FSS 
Pearson r 
 
p-value 
GENEActiv light activity (n=89) 0.123 0.366 
RER (n=83) -0.006 0.963 
RPE breath (n=82) -0.186 0.135 
RPE legs (n=82) -0.083 0.505 
Abbreviations: FSS: Fatigue Severity Scale; RER: Respiratory Exchange Ratio; RPE: Rate of Perceived 
Exertion 
5.4 Discussion  
The scores for self-reported fatigue decreased in both the exercise and the control group 
after the intervention period. A possible explanation for this finding is that simply having 
an organised occupation (i.e. ‘something’ to do), in combination with the attention of an 
exercise expert is sufficient to reduce fatigue. 
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5.4.1 Effects of the exercise intervention 
The main finding in of this study is that the exercise programme produced a small 
improvement in disease severity in the exercise group compared to the control group. This 
is in line with other exercise studies that find improvement in the MDS-UPDRS III 
(Comella, Stebbins et al. 1994, Ridgel, Vitek et al. 2009, Sage and Almeida 2009). Even 
though the current study was community based with a smaller number of sessions per week 
than in the other studies mentioned, there was still a small improvement in the MDS-
UPDRS III indicating that this programme might benefit disease severity. 
Small effect sizes were found over time in the exercise group for both light and moderate 
activity as measured by the GENEActiv. As can be seen in Table 7, these effect sizes show 
that people in the exercise group are likely to be less active over the week. This result may 
be different from what expected, since participants go to the gym, and it is expected that 
this would result in more activity during the day. However, previous research has shown 
that there is a compensatory decline in energy expenditure following imposition of 
physical activity (Epstein and Wing 1980, Goran and Poehlman 1992, Rowland 1998). 
The initial analysis showed a small improvement in the 2MWT in the group receiving the 
exercise intervention, but further analyses showed that the groups were different at 
baseline and the 2MWT did not show an improvement over time as shown in the absence 
of an effect size in the exercise group over time. Other studies investigating the effects of 
exercise on mobility did find an increase in 2MWT (Lauhoff, Murphy et al. 2013) or 
6MWT (Duncan and Earhart 2012, Shulman, Katzel et al. 2013, Kretschmer, Irina et al. 
2014). A possible explanation for small improvement in the 2MWT in the exercise group 
is that at baseline, the participants performed at a level similar to the general older 
population (Bohannon, Wang et al. 2014); therefore, it is likely that there was little room 
for improvement, which would explain the lack of detectable improvement over time.  
This study found no positive increase in the exercise group in  or respiratory exchange 
ratio. This is in contrast to other studies (Bergen, Toole et al. 2002). A possible explanation 
for this finding is similar to that of the 2MWT in that the  and respiratory exchange 
ratio were similar to the general older population to begin with. Furthermore, 68% of the 
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patients attended some of the programme. Since 32% did not attend any exercise sessions, 
this might have influenced overall findings.  
Finally, results show that, when all participants were combined, a progression of exercise 
(expressed as kilograms multiplied by repetitions) is seen. Progression of exercise may 
indicate that the body’s physiological capacities have expanded (ACSM 2014). The 
progression seen in the exercises indicate that exercise could induce an improvement of 
physiological capacities over time in people with Parkinson’s disease. Intensity was not 
reported in the exercise diary, therefore, aerobic exercise progression is not discussed in 
this study. In future studies, intensity should be recorded, so progression of aerobic 
exercise can be reported. If a positive increase in the exercise group in  or respiratory 
exchange ratio had been found, this could have been an indicator of aerobic exercise 
progression, however, no positive increase was found, meaning no conclusions can be 
drawn with regards to aerobic exercise progression. 
5.4.2 Feasibility 
This programme provides evidence of the feasibility of a low cost exercise programme that 
people are likely to adhere to. Part of that important information is adherence to the 
programme (Allen, Sherrington et al. 2012). This is one of the first studies implementing a 
longer term exercise programme in people with Parkinson’s disease. Although overall, 
fifteen participants were non-compliant, 24 participants attended at least 76% of all 
prescribed sessions. These fifteen people were all non-compliant and attended none, or just 
the very first session. This finding shows, that non-compliance can be predicted early on. 
This shows that it is feasible to implement the programme in the community. One thing to 
take into account when discussing the adherence to this programme is that participants for 
this study were recruited specifically for an exercise study. Hence, people were likely to be 
motivated to do exercise before starting this programme. This may give a slightly skewed 
view compared to the general population. However, the number of people adhering to the 
programme is higher than commonly in exercise programmes where the same bias is 
introduced. To measure adherence, self-reported diaries were used, fully acknowledging 
that self-reporting comes with some limitations, including under- or over reporting (Bollen, 
Dean et al. 2014). However, a recent review on self-reported adherence to unsupervised 
home-based rehabilitation exercise programmes states that at present there is no cheap and 
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easily available gold standard measurement of unsupervised exercise-based adherence, 
therefore self-reporting remains a suitable option (Bollen, Dean et al. 2014). A previous 
study using diaries to record attendance and adherence rate (Uc, Doerschug et al. 2014) 
found by using just diaries, an attendance rate of 83%, which shows diaries may be an 
adequate way of self-reporting attendance.  
The small amount of supervision during this exercise programme provides a low cost 
implementable exercise programme for people with Parkinson’s disease. In the past, most 
exercise studies have been executed under strict supervision; hence adherence was often 
higher than in the current study. A systematic review states that adherence is often not 
reported, however, when reported adherence was over 70% and often 100%  (Allen, 
Sherrington et al. 2012). However, programmes with high supervision are costly. Whether 
or not findings from exercise under strict supervision can be generalized to community 
settings where participants receive only little supervision is unclear (Uc, Doerschug et al. 
2014). 
Overall we found similar adherence numbers in both groups, showing that we created an 
effective control group. 
There were a low number of adverse events in this study with only two adverse events 
related to the study. Adverse events are often poorly reported in exercise programmes 
(Allen, Sherrington et al. 2012). In a systematic review that included adverse events, 72% 
of the studies did not report adverse events, in the other fifteen trials, eleven adverse events 
occurred (Allen, Sherrington et al. 2012). Overall, it can be concluded that participants in 
exercise programmes normally do not suffer from adverse events. Exercise programmes 
seem to be safe to implement in people with Parkinson’s disease. 
5.4.3 Predictors of adherence 
The findings presented in the results indicate that participants that perform better at 
baseline on performance tests like the 2MWT, and the aerobic capacity test as indicated by 
, were more likely to attend more sessions prescribed in the exercise programme. 
Furthermore, participants who rated their physical health high on the SF-36 were more 
likely to attend more sessions in the gym; the number of sessions attended did not correlate 
with self-reported mental health of the participants. This is in line with other research into 
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adherence to medication where adherence to medication has shown that a higher quality of 
life correlates with a higher adherence (Carballo, Cadarso-Suarez et al. 2004). The results 
from the current study show that more able participants attend the gym sessions. This is an 
important result and has to be taken into account when interpreting outcomes of an 
exercise programme.  
The relationship between the numbers of sessions attended and fatigue as indicated by the 
Fatigue Severity Scale almost reached significance, indicating that people that are more 
fatigued are less likely to attend many of the prescribed exercise sessions. This result could 
indicate a vicious circle where the participant might be too fatigued to do the exercises, 
whilst not doing any exercise may result in more fatigue. It is important to try and break 
this vicious circle (Falk, Granger et al. 2007). 
5.4.4 Sub-analyses of the exercise group 
Sub-analyses investigating the relationship between attended gym sessions and the 
outcomes of the exercise programme found no significant correlations. This indicates that 
participants who attended more sessions of the exercise programme, did not improve more 
on any of the outcome measures than participants who attend fewer sessions. This finding 
likely links in with the predictors of adherence in that participants that were more likely to 
attend more sessions had a higher performance on tests like the 2MWT, and the aerobic 
capacity test as indicated by . Because of this, it is likely that there was little room for 
improvement in the group of participants that attended more sessions and therefore no 
correlations have been found between the number of sessions and the outcomes measured. 
Finally, sub analyses in the exercise group show a small effect sizes in the MDS-UPDRS 
III which indicates that participants who have been randomised to the exercise group show 
a small improvement in disease severity over time, which is in line with previous studies 
(Comella, Stebbins et al. 1994, Ridgel, Vitek et al. 2009, Sage and Almeida 2009). As 
explained before, this is an important finding since it shows that exercise has the 
possibility of diminishing motor symptoms in people with Parkinson’s disease. The sub-
analyses in the exercise group showed an effect size approaching 0.2 for the PASE. It 
seems that people’s self-reported activity went up slightly in the exercise group. A possible 
reason for the discrepancy between the self-reported measure and the activity monitor may 
be that participants often choose to do the aerobic component of the gym exercises on the 
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bicycle ergometer. Previous research has shown that cycling activity is underestimated by 
a wrist worn accelerometer (Parkka, Ermes et al. 2007). Finally, sub analyses in the 
exercise group showed an effect size approaching 0.2 for the SF-36 physical health, 
showing that exercise possibly improves self-reported physical health. 
Correlations between self-reported fatigue and physical activity, exercise tolerance, and 
self-reported fatigue during exercise tolerance that were shown to be significant at 
baseline, were not significant at 6 months. This indicated that with training it may be 
possible to push people during an exercise tolerance test regardless of their fatigue. 
Furthermore, physical activity may not be influenced by self-reported fatigue after training.  
5.4.5 Limitations 
There are some limitations to this study. First of all, participants were purposively 
recruited to an exercise study, possibly resulting in a skewed sample. This may have 
resulted in the sample in this study being particularly mobile (as indicated by the 2 minute 
walk test). Generalisability to people with Parkinson’s disease has to be done with caution. 
Furthermore, only participants that were able to walk were included in the study. In future 
research it should be explored whether exercise, could be beneficial for people that are less 
mobile, including people in a wheelchair, including exploring the feasibility of community 
delivered exercise to less mobile people with Parkinson’s disease 
5.4.6 Conclusion 
It can be concluded that the exercise programme had a small effect on disease severity in 
favour of the exercise group, however no other benefits were found. A possible 
explanation for this may be the dosage of the exercise programme: Two hours per week 
may not have been enough exercise to show any health benefits (Ringbaek, Broendum et 
al. 2000). Moreover, the fact that the participants overall were highly functioning at the 
start of the programme so that there was little room for improvement. Finally, this study 
shows it is safe and feasible to have patients with Parkinson’s disease exercise in a 
community setting. Although previous research has shown that patients with a neurological 
disorder are less likely to go to the gym due to several barriers, this study showed that with 
a little extra support initially, patients are doing exercise in community based gyms in a 
safe matter. The opportunity for patients to exercise in a community based setting rather 
than either a specialised setting, or for example under constant supervision of a 
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physiotherapist is of great importance as it can reduce the costs of exercise for patients, and 
therefore, the quantity of doing exercise can be increased which is thought to have a 
beneficial impact. Furthermore, doing exercises in a community setting might lower the 
burden of the family, as transport is less likely to be an issue in a community setting 
compared to having to travel to an specialised institution. 
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Chapter 6 Overall Discussion and Conclusion and Future studies 
Summary 
This chapter gives an overall conclusion of the work done for this thesis, based on the aims 
set out in Chapter 1. Furthermore, limitations are discussed and finally possibilities for 
further research are proposed. 
6.1 Exploring fatigue 
This thesis set out to explore fatigue in people with Parkinson’s disease. Fatigue is a 
difficult concept, not only to describe, but also to measure.  
As part of this work, a systematic review and meta-analysis was conducted that provided 
new insights into treatment methods of fatigue in people with Parkinson’s disease. The 
study included fourteen studies investigating interventions for self-reported fatigue in 
people with Parkinson’s disease and concluded that at this point in time, there is no definite 
treatment for fatigue. Consensus into determining the best way to measure fatigue in 
people with Parkinson’s disease would further improve research in this area. As long as 
fatigue is defined and measured in different ways, research is not likely to provide strong 
robust answers regarding treatment of fatigue in people with Parkinson’s disease. Exercise 
seems to be a treatment method used in other areas such as Multiple Sclerosis, but is hardly 
explored in people with Parkinson’s disease. 
6.2 Fatigue in a population of people with Parkinson’s disease 
In order to establish whether an exercise programme could improve self-reported fatigue in 
people with Parkinson’s disease, correlations between self-reported fatigue and physical 
measures including disease severity, aerobic capacity and mobility that can be improved 
using an exercise programme were explored. An association was found between 
respiratory exchange ratio and self-reported fatigue. The correlations found show that if 
respiratory exchange ratio can be improved by for example an exercise programme, self-
reported fatigue may be improved as well.  
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6.3 Adherence to a six months twice weekly exercise programme and the effects of the 
exercise programme 
Finally, this knowledge was implemented and a single blind randomised controlled trial 
was set up to explore whether exercise could be effective as a treatment method for fatigue 
in people with Parkinson’s disease. The study found that out of 54 participants randomised 
to the exercise group, 37 participants adhered to the programme to some extent, with 24 
participants attending at least 75% of all the sessions. Furthermore, there we no adverse 
events related to the intervention, indicating the intervention is feasible to implement. 
The exercise programme had a small effect on disease severity in favour of the exercise 
group, however no other benefits were found. A possible explanation for this may be the 
dosage of the exercise programme, two hours per week may not be enough exercise to 
show any health benefits (Ringbaek, Broendum et al. 2000), and the fact that the 
participants overall were highly functioning at the start of the programme so that there was 
little room for improvement. 
The randomised controlled trial was conducted in a larger team. The focus of this work has 
been fatigue, including the systematic review and meta-analysis exploring fatigue in people 
with Parkinson’s; subsequently, the comparisons at baseline between fatigue and measures 
of physical activity and exercise tolerance; and finally by exploring fatigue in the larger 
randomised controlled trial. 
6.4 Limitations of the work 
Although great effort was made to study fatigue in people with Parkinson’s disease as 
specific as possible, there are limitation to this work. 
As discussed in Chapter 2, fatigue can be a result of depression. Although it is 
acknowledged that fatigue in Parkinson’s disease is present in the absence of depression 
(Karlsen, Larsen et al. 1999, Herlofson and Larsen 2002, Alves, Wentzel-Larsen et al. 
2004, Okuma, Kamei et al. 2009) results from studies also suggest that depression is 
significantly higher in fatigued people with Parkinson’s disease. A limitation of the current 
study is that depression was not explored using a separate questionnaire, meaning that it is 
difficult to draw conclusions about the occurrence of depression in this group of people 
and the relation of the possible presence of depression and fatigue. However, as drugs were 
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recorded as part of the study, it can be concluded that the rate of depressed people was not 
very high, as only 12 participants (11%) were on anti-depressant medication. Going 
forward, it is important to measure confounders of fatigue like depression and sleepiness to 
get a full picture of fatigue in people with Parkinson’s disease.  
Furthermore, fatigue was measured as an average, however, fatigue measured throughout 
the day could give a completer picture of fatigue and can inform the development of any 
future exercise programme’s by taking into account fatigue levels and fluctuations of 
fatigue levels of people with Parkinson’s disease throughout the day. 
6.5 Overall conclusion 
This thesis set out to explore fatigue which is a complex phenomenon and not well studied 
in people with Parkinson’s disease. Even though there are studies exploring different 
treatment methods for fatigue in Parkinson’s disease, the systematic review and meta-
analysis conducted in Chapter 3 showed that currently there seems to be no effective 
treatment for fatigue in people with Parkinson’s disease. This thesis set out to look into the 
possibilities of treating fatigue in people with Parkinson’s disease by means of an exercise 
programme using a single blind randomised controlled trial.  
Fatigue was diminished in both the exercise group and the control group. Although studies 
in Multiple Sclerosis and other populations like cancer have shown a reduction in fatigue 
after exercise, this study failed to show a significant effect of the exercise on fatigue. One 
explanation for this may be that the exercise programme did not seem to affect any of the 
measures, showing that the intensity of the programme may not have been enough to 
improve mobility, aerobic capacity, quality of life or fatigue. 
This is the first study to explore the effects of a combined (aerobic and anaerobic) exercise 
community based longer term (six months) exercise programme on fatigue in people with 
Parkinson’s disease. Results show that both arms of the interventions were adhered to 
reasonably well and small effects were found showing exercise improved disease severity 
in people with Parkinson’s disease; no effects were found in relation to fatigue. 
   
106 
  
 
 
6.6 Future 
This work shows that fatigue in Parkinson’s disease is a complex phenomenon that is 
difficult to address. Further research into understanding fatigue in Parkinson’s disease is an 
important step in order to explore further treatment methods of fatigue. Exploring fatigue 
in more detail and closely throughout days can give a clearer picture of when people are 
fatigued and why; this then could contribute to informing any further treatment 
programmes.  
Furthermore, as mentioned, confounding factors around fatigue like depression and 
sleepiness should be explored in future studies to give a full and clear picture of fatigue. 
Following results found in this study a future study should design an exercise programme 
specifically to treat fatigue in people with Parkinson’s disease. Building on from literature 
in other populations such as Multiple Sclerosis and Cancer an exercise programme should 
be built to specifically address fatigue. As results in this study around fatigue are 
inconclusive, an exercise programme that is intensive enough (three times a week rather 
than two) should be developed. Attendance and progression should be monitored closely 
by means of for example a diary (as used in this study) in order to make correct 
conclusions of the effect of the programme. 
Finally, as this study showed positive effects of exercise on disease severity, a full 
randomised controlled trial should be designed and conducted to establish effectiveness of 
the six months exercise trial in people with Parkinson’s disease. 
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Appendices 
Appendix 1: UK Parkinson’s Disease Society Brain Bang Clinical Diagnostic Criteria 
UK PARKINSON’S DISEASE SOCIETY BRAIN BANK CLINICAL DIAGNOSTIC CRITERIA 
(Hughes, Daniel et al. 1992) 
Step 1. Diagnosis of Parkinsonian Syndrome  
• Bradykinesia  
• At least one of the following  
- Muscular rigidity  
- 4-6 Hz rest tremor  
- postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction  
Step 2 Exclusion criteria for Parkinson’s disease  
• history of repeated strokes with stepwise progression of parkinsonian features  
• history of repeated head injury  
• history of definite encephalitis  
• oculogyric crises  
• neuroleptic treatment at onset of symptoms  
• more than one affected relative  
• sustained remission  
• strictly unilateral features after 3 years  
• supranuclear gaze palsy  
• cerebellar signs  
• early severe autonomic involvement  
• early severe dementia with disturbances of memory, language, and praxis  
• Babinski sign  
• presence of cerebral tumor or communication hydrocephalus on imaging study  
• negative response to large doses of levodopa in absence of malabsorption  
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure  
Step 3 supportive prospective positive criteria for Parkinson’s disease  
Three or more required for diagnosis of definite Parkinson’s disease in combination with step one  
• Unilateral onset  
• Rest tremor present  
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• Progressive disorder  
• Persistent asymmetry affecting side of onset most  
• Excellent response (70-100%) to levodopa  
• Severe levodopa-induced chorea  
• Levodopa response for 5 years or more  
• Clinical course of ten years or more  
 
   
 
 
1
2
4
 
Appendix 2: PRISMA 2009 Checklist 
 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
   
 
 
1
2
5
 
Section/topic  # Checklist item  Reported 
on page #  
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
   
 
 
1
2
6
 
Section/topic  # Checklist item  Reported 
on page #  
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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Appendix 3: Search Strategy Systematic Review and Meta-analysis 
Pubmed search 
1. Parkinson disease [MESH] 
2. “Parkinson disease” 
3. Parkinsonian disorders [MESH] 
4. “Parkinson’s” 
5. Fatigue [MESH] 
6. “fatigue” 
7. 1 OR 2 OR 3 OR 4 
8. 5 OR 6 
7 AND 8 
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Appendix 4: Fatigue Severity Scale 
 
The Fatigue Severity Scale (FSS) is a method of evaluating the impact on fatigue on you. The 
FSS is a short questionnaire that requires you to rate your level of fatigue.  
The FSS questionnaire contains nine statements that rate the severity of your fatigue symptoms. 
Read each statement and circle a number from 1 to 7, based on how accurately it reflects your 
condition during the past week and the extent to which you agree or disagree that the statement 
applies to you. 
A low value indicates strong disagreement with the statement, whereas a high value indicates 
strong agreement. 
 
FSS Questionnaire 
During the past week, I found that: Disagree <-------------------------> Agree 
1. My motivation is lower when I am fatigued 1 2 3 4 5 6 7   
2. Exercise brings on my fatigue 1 2 3 4 5 6 7   
3. I am easily fatigued 1 2 3 4 5 6 7   
4. Fatigue interferes with my physical functioning 1 2 3 4 5 6 7   
5. Fatigue causes frequent problems for me 1 2 3 4 5 6 7   
6. My fatigue prevents sustained physical functioning 1 2 3 4 5 6 7   
7. Fatigue interferes with carrying out certain duties 
and responsibilities 
1 2 3 4 5 6 7   
8. Fatigue is among my three most disabling 
symptoms 
1 2 3 4 5 6 7   
9. Fatigue interferes with my work, family, or social 
life 
1 2 3 4 5 6 7   
          Total Score:    
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Appendix 5:  MDS-UPDRS 
Part III: Motor Examination 
 
Overview: This portion of the scale assesses the motor signs of Parkinson’s Disease. In 
administering Part III of the MDS-UParkinson’s DiseaseRS the examiner should comply with the 
following guidelines: 
 
At the top of the form, mark whether the patient is on medication for treating the symptoms of 
Parkinson's disease and, if on levodopa, the time since the last dose. 
 
Also, if the patient is receiving medication for treating the symptoms of Parkinson’s Disease, 
mark the patient’s clinical state using the following definitions: 
 
ON is the typical functional state when patients are receiving medication and have a good 
response. OFF is the typical functional state when patients have a poor response in spite 
of taking medications. 
 
The investigator should “rate what you see”. Admittedly, concurrent medical problems such as stroke, 
paralysis, arthritis, contracture, and orthopedic problems such as hip or knee replacement and 
scoliosis may interfere with individual items in the motor examination. In situations where it is 
absolutely impossible to test (e.g., amputations, plegia, limb in a cast), use the notation “UR” for 
Unable to Rate. Otherwise, rate the performance of each task as the patient performs in the context of 
co-morbidities. 
 
All items must have an integer rating (no half points, no missing ratings). 
 
Specific instructions are provided for the testing of each item. These should be followed in all 
instances. The investigator demonstrates while describing tasks the patient is to perform and rates 
function immediately thereafter. For Global Spontaneous Movement and Rest Tremor items (3.14 and 
3.1 7), these items have been placed purposefully at the end of the scale because clinical information 
pertinent to the score will be obtained throughout the entire examination. 
 
At the end of the rating, indicate if dyskinesia (chorea or dystonia) was present at the time of the 
examination, and if so, whether these movements interfered with the motor examination. 
 
 
3a  Is the patient on medication for treating the symptoms of Parkinson’s Disease? No
 Yes 
 
 
3b If the patient is receiving medication for treating the symptoms of 
Parkinson’s Disease, mark the patient’s clinical state using the following 
definitions: 
 
ON: On is the typical functional state when patients are receiving medication and have a good 
response. 
 
OFF: Off is the typical functional state when patients have a poor response in spite of taking 
medications. 
 
 
3c  Is the patient on Levodopa ? No Yes 
3.C1 If yes, minutes since last levodopa dose: _____________ 
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3.1 SPEECH SCORE 
    
Instructions to examiner:  Listen to the patient’s free-flowing speech and 
engage in conversation ifnecessary. Suggested topics: ask about the 
patient’s work, hobbies, exercise, or how he got to the doctor’s office. 
Evaluate volume, modulation (prosody) and clarity, including slurring, 
palilalia (repetition of syllables) and tachyphemia (rapid speech, running 
syllables together). 
  
0: Normal: No speech problems.   
1: Slight: Loss of modulation, diction or volume, but still all words easy 
to understand.   
2: Mild: Loss of modulation, diction, or volume, with a few words 
unclear, but the overall sentences easy to follow.   
3: Moderate:  Speech is difficult to understand to the point that some, but 
not most, sentences are poorly understood.   
4: Severe: Most speech is difficult to understand or unintelligible.   
3.2 FACIAL EXPRESSION 
 
Instructions to examiner: Observe the patient sitting at rest for 10 seconds, 
without talking and also while talking. Observe eye-blink frequency, 
masked facies or loss of facial expression, spontaneous smiling and 
parting of lips. 
  
0: Normal: Normal facial expression.   
1: Slight: Minimal masked facies manifested only by decreased frequency 
of blinking.    
2: Mild:  In addition to decreased eye-blink frequency, Masked facies 
present in the lower face as well, namely fewer movements around the 
mouth, such as less  
  
3: Moderate: Masked facies with lips parted some of the time when the 
mouth is at rest.   
4: Severe: Masked facies with lips parted most of the time when the 
mouth is at rest.   
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3.3 RIGIDITY SCORE 
    
Instructions to examiner: Rigidity is judged on slow passive movement of major joints 
with the patient in a relaxed position and the examiner manipulating the limbs and 
neck. First, test without an activation maneuver. Test and rate neck and each limb 
separately. For arms, test the wrist and elbow joints simultaneously. For legs, test the 
hip and knee joints simultaneously. If no rigidity is detected, use an activation 
maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not 
being 
tested. Explain to the patient to go as limp as possible as you test for rigidity. 
  
0: Normal: No rigidity.   
1: Slight: Rigidity only detected with activation maneuver. R 
2: Mild: Rigidity detected without the activation maneuver, but full range of motion is 
easily achieved   
3: Moderate:  Rigidity detected without the activation maneuver; full range of motion 
is achieved with effort L 
4: Severe: Rigidity detected without the activation maneuver and full range of motion 
not achieved   
3.4 FINGER TAPPING 
     
Instructions to examiner: Each hand is tested separately. Demonstrate the task, but do 
not continue to perform the task while the patient is being tested. Instruct the patient 
to tap the index finger on the thumb 10 times as quickly AND as big as possible. Rate 
each side separately, evaluating speed, amplitude, hesitations, halts and decrementing 
amplitude. 
  
0: Normal: No problems.   
1: Slight: Any of the following: a) the regular rhythm is broken with one or two 
interruptions or hesitations of the tapping movement; b) slight slowing; c) the 
amplitude decrements 
R 
2: Mild: Any of the following: a) 3 to 5 interruptions during tapping; b) mild slowing; 
c) the amplitude decrements midway in the 10-tap sequence.   
3: Moderate: Any of the following: a) more than 5 interruptions during tapping or at 
least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the 
amplitude 
decrements starting after the 1st tap. 
L 
4: Severe: Cannot or can only barely perform the task because of slowing, 
interruptions ordecrements.   
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3.5 HAND MOVEMENTS SCORE 
    
Instructions to examiner: Test each hand separately. Demonstrate the task, but do not 
continue to perform the task while the patient is being tested. Instruct the patient to make a 
tight fist with the arm bent at the elbow so that the palm faces the examiner. Have the 
patient open the hand 10 times as fully AND as quickly as possible. If the patient fails to 
make a tight fist or to open the hand fully, remind him/ her to do so. Rate each side 
separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude. 
  
    
0: Normal: No problem.   
1: Slight: Any of the following: a) the regular rhythm is broken with one or two 
interruptions orhesitations of the movement; b) slight slowing; c) the amplitude decrements 
nearthe end of the task. 
R 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild 
slowing; the amplitude decrements midway in the task.   
3:Moderate:  Any of the following: a) more than 5 interruptions during the movement or at 
least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the 
amplitude decrements starting after the 1st open-and-close sequence. 
L 
4: Severe:Cannot or can only barely perform the task because of slowing, interruptions or 
decrements.   
3.6 PRONATION-SUPINATION MOVEMENT OF HANDS  
 
Instructions to examiner:  Test each hand separately. Demonstrate the task, but do not 
continue to perform task while the patient is being tested. Instruct the patient to extend the 
arm out in front of his/her body with the palms down; then to turn the palm up and down 
alternately 10 times as fast and as fully as possible. Rate each side separately, evaluating 
speed, amplitude, hesitations, halts and decrementing amplitude. 
 
0: Normal: No problems. 
 
1: Slight: Any of the following: a) the regular rhythm is broken with one or two 
interruptions or          hesitations of the movement; b) slight slowing; c) the amplitude 
decrements near the end of the sequence. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movement; b) mild 
slowing; c) the amplitude decrements midway in the sequence. 
 
3: Moderate: Any of the following: a) more than 5 interruptions during the movement or at 
least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the 
amplitude decrements starting after the 1st supination-pronation sequence. 
 
4: Severe: Cannot or can only barely perform the task because of slowing, interruptions, or 
decrements 
  
R  
 
 
 
 
 
L 
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3.7 TOE TAPPING SCORE 
    
Instructions to examiner: Have the patient sit in a straight-backed chair with arms, both feet 
on the floor. Test each foot separately. Demonstrate the task, but do not continue to perform 
the task while the patient is being tested. Instruct the patient to place the heel on the ground 
in a comfortable position and then tap the toes 10 times as big and as fast as possible. Rate 
each side separately, evaluating  speed, amplitude, hesitations, halts and decrementing 
amplitude   
    
0: Normal: No problem.   
1: Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions 
or hesitations of the tapping  movement; b) slight slowing; c) the amplitude decrements near 
the end of ten taps. 
R 
2: Mild: Any of the following: a) 3 to 5 interruptions during the tapping movements; b) mild 
slowing; the amplitude decrements midway in the task.   
3:Moderate:  Any of the following: a) more than 5 interruptions during the tapping 
movement or at least one longer arrest (freeze) in ongoing movement; b) moderate slowing; 
c) the amplitude decrements starting after the 1st tap. 
L 
4: Severe: Cannot or can only barely perform the task because of slowing, interruptions or 
decrements.   
3.8 LEG AGILITY  
 
Instructions to examiner:  Have the patient sit in a straight-backed chair with arms. The 
patient should have both feet comfortably on the floor. Test each leg separately. Demonstrate 
the task, but do not continue to perform the task while the patient is being tested. Instruct the 
patient to place the foot on the ground in a comfortable position and then raise and stomp the 
foot on the ground 10 times as high and as fast as possible. Rate each side separately, 
evaluating speed, amplitude, hesitations, halts and decrementing amplitude.  
 
0: Normal: No problems. 
 
1: Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions 
or          hesitations of the movement; b) slight slowing; c) the amplitude decrements near the 
end of the task. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movement; b) mild slowing; 
c) the amplitude decrements midway in the task. 
 
3: Moderate: Any of the following: a) more than 5 interruptions during the movement or at 
least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the amplitude 
decrements starting after the first tap. 
 
4: Severe: Cannot or can only barely perform the task because of slowing, interruptions, or 
decrements 
  
R  
 
 
 
 
 
L 
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3.9 ARISING FROM CHAIR SCORE 
    
Instructions to examiner: Have the patient sit in a straight-backed chair with arms, with both 
feet on the floor and sitting back in the chair (if the patient is not too short). Ask the patient to 
cross his/her arms across the chest and then to stand up. If the patient is not successful, repeat 
this attempt a maximum of two more times. If still unsuccessful, allow the patient to move 
forward in the chair to arise with arms folded across the chest. Allow only one attempt in this 
situation. If unsuccessful, allow the patient to push off using his/her hands on the arms of the 
chair. Allow a maximum of three trials of pushing off. If still not successful, assist the patient 
to arise. After the patient stands up, observe the posture for item 3.13   
    
0: Normal: No problems. Able to arise quickly without hesitation.   
1: Slight: Arising is slower than normal; or may need more than one attempt; or may need to 
move forward in the chair to arise. No need to use the arms of the chair.  
2: Mild: Pushes self up from arms of chair without difficulty.   
3:Moderate:  Needs to push off, but tends to fall back; or may have to try more than one time 
using arms of chair, but can get up without help. 
 
4: Severe: Unable to arise without help.   
3.10 GAIT  
 
Instructions to examiner:  Testing gait is best performed by having the patient walking away 
from and towards the examiner so that both right and left sides of the body can be easily 
observed simultaneously. The patient should walk at least 10 meters (30 feet), then turn 
around and return to the examiner. This item measures multiple behaviours: stride amplitude, 
stride speed, height of foot lift, heel strike during walking, turning, and arm swing, but not 
freezing. Assess also for ‘freezing of gait’ (next item 3.11) while the patient is walking. 
Observe posture for item 3.13  
 
0: Normal: No problems. 
 
1: Slight: Independent walking with minor gait impairment. 
 
2: Mild: Independent walking but with substantial gait impairment. 
 
3: Moderate: Requires an assistance device for safe walking (walking stick, walker) but not a 
person. 
 
4: Severe: Cannot walk at all or only with another person’s assistance. 
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3.11 FREEZING OF GAIT 
 
SCORE 
 
Instructions to examiner: While assessing gait, also assess for the presence of any gait freezing 
episodes. Observe for start hesitation and stuttering movement especially when turning and reaching 
the end of the task. To the extent that safety permits, patient may NOT use sensory tricks during the 
assessment. 
0: Normal: No freezing. 
 
1: Slight: Freezes on starting, turning or walking through doorway with a single halt during any of 
these events, but then continues smoothly without freezing during straight walking. 
2: Mild: Freezes on starting, turning or walking through doorway with more than one halt during any 
of these activities, but continues smoothly without freezing during straight walking. 
3:Moderate: Freezes once during straight walking. 
4: Severe: Freezes multiple times during straight walking. 
 
 
 
3.12 POSTURAL STABILITY 
 
 
 
Instructions to examiner:  The test examines the response to sudden body displacement produced by 
a quick, forceful pull on the shoulders while the patient is standing erect with eyes open and feet 
comfortably apart and parallel to each other. Test retropulsion. Stand behind the patient and instruct 
the patient on what is about to happen. Explain that s/he is allowed to take a step backwards to avoid 
falling. There should be a solid wall behind the examiner, at least 1-2 meters away to allow for the 
observation of the number of retropulsive steps. The first pull is an instructional demonstration and is 
purposely milder and not rated. The second time the shoulders are pulled briskly and forcefully 
towards the examiner with enough force to displace the centre of gravity so that the patient MUST 
take a step backwards. The examiner needs to be ready to catch the patient, but must stand 
sufficiently back so as to allow enough room for the patient to take several steps to recover 
independently. Do not allow the patient to flex the body abnormally forward in anticipation of the 
pull. Observe the number of steps backwards or falling. Up to and including two steps for recovery is 
considered normal, so abnormal ratings begin with three steps. If the patient fails to understand the 
test, the examiner can repeat the test so that the rating is based on an assessment that the examiner 
feels reflects the patient’s limitation rather than misunderstanding or lack of preparedness. Observe 
standing posture for item 3.13 
 
0: Normal: No problems: Recovers with one or two steps. 
 
1: Slight: 3-5 steps, but subject recovers unaided. 
 
2: Mild: More than 5 steps, but subject recovers unaided. 
 
3: Moderate: Stands safely, but with absence of postural response; falls if not caught by examiner. 
 
4: Severe: Very unstable, tends to lose balance spontaneously or with just a gentle pull on the 
shoulders. 
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3.13 Posture SCORE 
    
Instructions to examiner: Posture is assessed with the patient standing erect after arising from a 
chair, during walking, and while being tested for postural reflexes. If you notice poor posture, tell 
the patient to stand up straight and see if the posture improves (see option 2 below). Rate the worst 
posture seen in these three observation points. Observe for flexion and side-to-side leaning.   
0: Normal: No problems.   
 
1: Slight: Not quite erect, but posture could be normal for an older person.   
2: Mild: Definite flexion, scoliosis or leaning to one side, but patient can correct posture to normal 
posture when asked to do so.  
3:Moderate: Stooped posture, scoliosis or leaning to one side that cannot be corrected volitionally to 
a normal posture by the patient.   
4: Severe: Flexion, scoliosis or leaning with extreme abnormality of posture. 
 
3.14 GLOBAL SPONTANEITY OF MOVEMENT (BODY BRADYKINEASIA)   
 
Instructions to examiner:  This global rating combines all observations on slowness, hesitancy, and 
small amplitude and poverty of movement in general, including a reduction of gesturing and of 
crossing the legs. This assessment is based on the examiner’s global impression after observing for 
spontaneous gestures while sitting, and the nature of arising and walking. 
 
0: Normal: No problems. 
 
1: Slight: Slight global slowness and poverty of spontaneous movements. 
 
2: Mild: Mild global slowness and poverty of spontaneous movements. 
 
3: Moderate: Moderate global slowness and poverty of spontaneous movements. 
 
4: Severe: Severe global slowness and poverty of spontaneous movements. 
  
 
3.15 POSTURAL TREMOR OF HANDS  
Instructions to examiner: All tremor, including re-emergent rest tremor, that is present in this 
posture is to be included in this rating. Rate each hand separately. Rate the highest amplitude seen. 
Instruct the patient to stretch the arms out in front of the body with the palms down. The wrist 
should be straight and the fingers comfortably separated so that they do not touch each other. 
Observe this posture for 10 seconds. 
 
0: Normal: No tremor. 
 
1: Slight: Tremor is present but less than 1 cm in amplitude 
 
2: Mild: Tremor is at least 1 but less than 3 cm in amplitude 
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3: Moderate: Tremor at least 3 but less than 10 cm in amplitude 
 
4: Severe: Tremor is at least 10 cm in amplitude 
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3.16 KINETIC TREMOR OF HANDS 
    
Instructions to examiner: This is tested by the finger-to-nose maneuver. With the arm starting from 
the outstretched position, have the patient perform at least three finger-to-nose maneuvers with each 
hand reaching as far as possible to touch the examiner’s finger. The finger-to-nose maneuver should 
be performed slowly enough not to hide any tremor that could occur with very fast arm movements. 
Repeat with the other hand, rating each hand separately. The tremor can be present throughout the 
movement or as the tremor reaches each target (nose or finger). Rate the highest amplitude seen.   
    
0: Normal: No tremor.   
1: Slight: Tremor is present but less than 1 cm in amplitude  
2: Mild: Tremor is at least 1 but less than 3 cm in amplitude   
3: Moderate: Tremor at least 3 but less than 10 cm in amplitude 
 4: Severe: Tremor is at least 10 cm in amplitude  
3.17 REST TREMOR AMPLITUDE  
Instructions to examiner:  This and the next item have been placed purposefully at the end of the 
examination to allow the rater to gather observations on rest tremor that may appear at any time 
during the exam, including when quietly sitting, during walking and during activities when some 
body parts are moving but others are at rest. Score the maximum amplitude that is seen at any time 
as the final score. Rate only the amplitude and not the persistence or the intermittency of the tremor. 
As part of this rating, the patient should sit quietly in a chair with the hands place on the arms of the 
chair (not in the lap) and the feet comfortably supported on the floor for 10 seconds with no other 
directives. Rest tremor is assessed separately for all four limbs and also for the lip/jaw. Rate only the 
maximum amplitude that is seen at any time as the final rating 
 
Extremity ratings 
0: Normal: No tremor 
 
1: Slight: < 1 cm in maximal amplitude. 
 
2: Mild: > 1 cm but < 3 cm in maximal amplitude. 
 
3: Moderate: 3 – 10 cm in maximal amplitude. 
 
4: Severe: > 10 cm in maximal amplitude 
 
Lip/jaw ratings 
0: Normal: No tremor 
 
1: Slight: < 1 cm in maximal amplitude. 
 
2: Mild: > 1 cm but < 2 cm in maximal amplitude. 
 
3: Moderate: 2 – 3 cm in maximal amplitude. 
 
4: Severe: > 3 cm in maximal amplitude  
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3.18 CONSTANCY OF REST TREMOR SCORE 
    
Instructions to examiner: This item receives one rating for all rest tremor and focuses on the 
constancy of rest tremor during the examination period when different body parts are variously at 
rest. It is rated purposefully at the end of the examination so that several minutes of information can 
be coalesced into the rating.   
    
0: Normal: No tremor.   
1: Slight: Tremor at rest is present < 25% of the entire examination period.  
2: Mild:  Tremor at rest is present 26-50% of the entire examination period.   
3: Moderate:  Tremor at rest is present 51-75% of the entire examination period. 
 4: Severe:  Tremor at rest is present >75% of the entire examination period.  
 
DYSKINESIA IMPART ON PART III RATINGS 
 
A. Where dyskinesias (chorea or dystonia) present during examination?  No    Yes 
 
B. If yes, did these movement interfere with your rating?                          No     Yes 
 
 
HOEHN AND YAHR STAGE  
 
0: Asymptomatic. 
 
1: Unilateral involvement only. 
 
2: Bilateral involvement without impairment of balance. 
 
3: Mild to moderate involvement: some postural instability but physically independent; needs 
assistance to recover from pull test. 
 
4: Severe disability: still able to walk or stand unassisted. 
 
5: Wheelchair bound or bedridden unless aided. 
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Appendix 6: Short Form 36 
General Health Status Questionnaire (SF-36) 
 
This survey asks for your views about your health. This information will help keep track of how you 
feel and how well you are able to do your usual activities. 
 
Please answer these questions by “check-marking” your choice. Please select only one choice for each 
item. 
 
1. In general, would you say your health is: 
  1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
 
2. Compared to ONE YEAR AGO, how would you rate your health in general NOW? 
  1. MUCH BETTER than one year ago. 
  2. Somewhat BETTER now than one year ago. 
  3. About the SAME as one year ago. 
  4. Somewhat WORSE now than one year ago. 
  5. MUCH WORSE now than one year ago. 
 
 
 
 
 
 
 
3. The following items are about activities you might do during a typical day.  Does your health now 
limit you in these activities? If so, how much? 
Activities 1. Yes, 
Limited A 
Lot 
2.  Yes, 
Limited  
A Little 
3.  No,  
Not Limited 
At All 
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports? 
  1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
b) Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf? 
  1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
c) Lifting or carrying groceries?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
 
d) Climbing several flights of stairs? 
 
  1. Yes, 
limited a 
lot 
 
  2. Yes, 
limited a 
little 
 
  3. No, not 
limited at all 
e) Climbing one flight of stairs?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
f) Bending, kneeing or stooping?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
g) Walking more than a mile?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
h) Walking several blocks?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
i) Walking one block?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
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j) Bathing or dressing yourself?   1. Yes, 
limited a 
lot 
  2. Yes, 
limited a 
little 
  3. No, not 
limited at all 
 
4- During the past 4 weeks, have you had any of the following problems with your work or other 
regular activities as a result of your physical health? 
 Yes No 
a) Cut down on the amount of time you spent on work or other 
activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Were limited in the kind of work or other activities?   1. yes   2. No 
d) Had difficulty performing the work or other activities (for 
example it took extra effort)? 
  1. yes   2. No 
 
5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 Yes No 
a) Cut down on the amount of time you spent on work or other 
activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Didn’t do work or other activities as carefully as usual?   1. yes   2. No 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbors, or groups? 
  1. Not at all  
  2. Slightly  
  3. Moderately      
  4. Quite a bit      
  5. Extremely 
 
7. How much bodily pain have you had during the past 4 weeks? 
  1. None       
  2. Very mild      
  3. Mild     
  4. Moderate     
  5. Severe      
  6. Very severe 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
  1. Not at all  
  2. A little bit  
  3. Moderately      
  4. Quite a bit      
  5. Extremely 
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9. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have been 
feeling.  How much of the time during the past 4 weeks 
 1. All of 
the time 
2. Most 
of the 
time 
3. A good 
bit of the 
time 
4. Some 
of the 
time 
5. A little 
of the time 
6. None of 
the time 
a) Did you feel full 
of pep? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
b) Have you been a 
very nervous 
person? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
c) Have you felt so 
down in the dumps 
that nothing could 
cheer you up?  
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
d) Have you felt 
calm and peaceful? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
e) Did you have a 
lot of energy? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
f) Have you felt 
downhearted and 
blue? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
g) Do you feel 
worn out? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
h) Have you been a 
happy person? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
i) Did you feel 
tired? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of the 
time 
  6. None 
of the time 
 
 
 
 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
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11. How TRUE or FALSE is each of the following statements for you? 
 1. 
Definitely 
true 
2. 
Mostly 
true 
3.  
Don’t 
know 
4. Mostly 
false 
5. 
Definitely 
false 
a) I seem to get sick a 
little easier than other 
people? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
b) I am as healthy as 
anybody I know? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
c) I expect my health to 
get worse? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
d) My health is 
excellent? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
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Appendix 7: Physical Activity Scale for the Elderly 
 
I am interested in how much time you have spent doing the following activities over the last 7 days.  
 
Leisure time activity 
1. Walking outside the home 
How much time was spent on the activity over the last 7 days  
(tick as appropriate) 
Never 
(0 days) 
Seldom 
(1 to 2 days) 
Sometimes 
(3 to 4 days) 
Often 
(5 to 7 days) 
 How many hours per day did you spend on this activity? 
Less than 1hour 1 to 2 hours 2 to 4 hours More than 4 hours 
 
2. Light sport/recreation 
Name the activity/activities__________ 
How much time was spent on the activity over the last 7 days  
(tick as appropriate) 
Never 
(0 days) 
Seldom 
(1 to 2 days) 
Sometimes 
(3 to 4 days) 
Often 
(5 to 7 days) 
 How many hours per day did you spend on this activity? 
Less than 1hour 1 to 2 hours 2 to 4 hours More than 4 hours 
 
3. Moderate sport/recreation 
Name the activity__________ 
How much time was spent on the activity over the last 7 days (tick as appropriate) 
Never 
(0 days) 
Seldom 
(1 to 2 days) 
Sometimes 
(3 to 4 days) 
Often 
(5 to 7 days) 
 How many hours per day did you spend on this activity? 
Less than 1hour 1 to 2 hours 2 to 4 hours More than 4 hours 
 
4. Strenuous sport/recreation 
Name the activity__________ 
How much time was spent on the activity over the last 7 days  
(tick as appropriate) 
Never 
(0 days) 
Seldom 
(1 to 2 days) 
Sometimes 
(3 to 4 days) 
Often 
(5 to 7 days) 
 How many hours per day did you spend on this activity? 
Less than 1hour 1 to 2 hours 2 to 4 hours More than 4 hours 
 
 
5. Muscle strength/endurance exercises 
Name the activity__________ 
How much time was spent on the activity over the last 7 days  
(tick as appropriate) 
Never 
(0 days) 
Seldom 
(1 to 2 days) 
Sometimes 
(3 to 4 days) 
Often 
(5 to 7 days) 
 How many hours per day did you spend on this activity? 
Less than 1hour 1 to 2 hours 2 to 4 hours More than 4 hours 
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Household Physical Activities 
Have you performed the following activities over the last 7 days  
(tick appropriate box) 
 
1. Light housework 
No Yes 
 
2. Heavy housework and chores 
No Yes 
 
3. Home repairs 
No Yes 
 
4. Lawn work  
No Yes 
 
5. Outdoor gardening 
No Yes 
 
6. Caring for another person  
No Yes 
 
Work related physical activity 
In the last 7 days how many hours paid work have you done.__________ 
 
Would you describe your work as mainly:   (Please tick appropriate box) 
1. Sitting with slight arm movements 
 
 
2. Sitting or standing with some walking 
 
 
3. Walking with some handling of materials generally weighing less than 50 pounds 
 
 
4. Walking and heavy manual work often requiring handling of materials weighing over 
50 pounds. 
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Appendix 8: Fitness case report form 
Fitness test   CRF   
                                                                                                
Weight 
(kg)  
Saddle 
height 
Mask 
size  
     
 
Resting  
Heart 
Rate 
BP sys/dia Lactate RPE 
breath 
RPE 
legs 
          /    
 
Exercise assessment  
Increment 
(min) 
Power 
(watts) 
Weight (kg) Heart 
Rate 
RPE 
breath 
RPE 
legs 
Cadence* 
0 (0-3) 0 (Unloaded)     
1 (3-5) 50 1     
2 (5-7) 75 1.5     
3 (7-9) 100 2     
4 (9-11) 125 2.5     
5 (11-13) 150 3     
6 (13-15) 175 3.5     
7 (15-17) 200 4     
8 (17-19) 225 4.5     
9 (19-21) 250 5     
10 (21-23) 275 5.5     
11 (23-25) 300 6     
12 (25-27) 325 6.5     
13 (27-29) 350 7     
14 (29-31) 375 7.5     
*If not 50 
 
End test 
 
Heart 
Rate 
BP sys/dia Lactate RPE 
breath 
RPE 
legs 
         /    
Temp (oC) Pressure 
(mb) 
Humidity 
(%) 
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Physical Activity Readiness-Questionnaire (PAR-Q) 
Please read the following carefully and answer as accurately as possible by ticking the 
appropriate box for each question. 
        Yes  No 
Has a doctor ever said you have heart trouble?      
Do you ever suffer frequently from chest pains?      
Do you often feel faint or have spells of dizziness?     
Has a doctor ever said you have epilepsy?      
Has a doctor ever said you have high blood pressure?     
Has a doctor ever said you have diabetes?      
Has a doctor ever said you have asthma?      
Do you have a bone, joint or muscular problem which 
may be aggravated by exercise?        
Do you have any form of injury?       
Are you currently taking any prescription medications?      
Have you suffered from a viral illness in the last two  
weeks?            
 Yes No 
Have you eaten anything within the last hour?   
Have you consumed alcohol within the last 24 hours?   
Have you performed exhaustive exercise within the last 48 hours?   
If you have answered YES to any of the above questions, or know of any possible reason (physical 
or psychological) that might affect the safety or accuracy of the tests - please inform a member of 
staff. 
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Appendix 9: Borg CR-10 Scale 
 
 
0   Nothing at all 
0.5   Extremely weak 
1  Very Weak 
2  Weak 
3  Moderate 
4   
5  Hard 
6 
7  Very Hard 
8 
9 
10  Extremely Hard 
 
   
 
 
1
4
9
 
 
 
Appendix 10: CONSORT guidelines 
Section/Topic Item 
No 
Checklist item Reported on 
page No 
Title and abstract 
 1a Identification as a randomised trial in the title  
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)  
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale  
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio  
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons  
Participants 4a Eligibility criteria for participants  
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually 
administered 
 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed  
6b Any changes to trial outcomes after the trial commenced, with reasons  
Sample size 7a How sample size was determined  
7b When applicable, explanation of any interim analyses and stopping guidelines  
Randomisation:    
  
   
 
 
1
5
0
 
  
Section/Topic Item 
No 
Checklist item Reported on 
page No 
 Sequence 
generation 
8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as blocking and block size)  
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any 
steps taken to conceal the sequence until interventions were assigned 
 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions  
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing 
outcomes) and how 
 
11b If relevant, description of the similarity of interventions  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes  
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses  
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed 
for the primary outcome 
 
13b For each group, losses and exclusions after randomisation, together with reasons  
Recruitment 14a Dates defining the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group  
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original 
assigned groups 
 
   
 
 
1
5
1
 
 
 
  
Section/Topic Item 
No 
Checklist item Reported on 
page No 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 
95% confidence interval) 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings  
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence  
Other information  
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders  
   
 
 
1
5
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Appendix 11: TiDier (Template for Intervention Description and Replication) Checklist 
Item 
number 
Item Where located 
  Primary paper 
(page or appendix 
number) 
Other † (details) 
 
BRIEF NAME 
  
1. Provide the name or a phrase that describes the intervention.   
 WHY   
2. Describe any rationale, theory, or goal of the elements essential to the intervention.   
 WHAT   
3. Materials: Describe any physical or informational materials used in the intervention, including those provided 
to participants or used in intervention delivery or in training of intervention providers. Provide information on 
where the materials can be accessed (e.g. online appendix, URL). 
  
4. Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any 
enabling or support activities. 
  
 WHO PROVIDED   
5. For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, 
background and any specific training given. 
  
 HOW   
6. Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of 
the intervention and whether it was provided individually or in a group. 
  
   
 
 
1
5
3
 
Item 
number 
 
Item 
 
Where located 
  Primary paper 
(page or appendix 
number) 
Other † (details) 
    
7. Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or 
relevant features. 
  
 
WHEN and HOW MUCH 
  
8. Describe the number of times the intervention was delivered and over what period of time including the 
number of sessions, their schedule, and their duration, intensity or dose. 
  
 TAILORING   
9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.   
 MODIFICATIONS   
10.ǂ If the intervention was modified during the course of the study, describe the changes (what, why, when, and 
how). 
  
    
11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies 
were used to maintain or improve fidelity, describe them. 
  
12.ǂ 
 
Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was 
delivered as planned. 
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Appendix 12: Exercise Diary 
 
 
 
 
 
 
WEEK No 1 
Session 1      Session 2 
 
OXFORD BROOKES UNIVERSITY 
Exercise and Physical Activity Diary 
24 Week programme 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate 
(HR) 
 
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distan
ce 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
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Date__
______
______
______
 
 
 
Date__
______
______
______ 
 
  
4. X Trainer 4. X Trainer 
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Reps 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting 
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 2 
 Session 1     Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distan
ce 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Reps 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
157 
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WEEK No 3 
Session 1      Session 2 
Date____________________    Date____________________ 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
159 
 
  
   
160 
 
WEEK No 4  
Session 1     Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
161 
 
  
   
162 
 
WEEK No 5 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distan
ce 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Reps 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 6 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distan
ce 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Reps 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 7 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distan
ce 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Reps 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 8  
Session 1     Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
166 
 
  
   
167 
 
WEEK No 9 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 10 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 11 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
170 
 
WEEK No 12 
 Session 1     Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
171 
 
  
   
172 
 
WEEK No 13 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 14 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 15 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
    
   
175 
 
WEEK No 16  
Session 1     Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 17 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 18 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 19 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 20  
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 21 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 22 
Session 1      Session 2 
Date____________________   Date____________________ 
 
 
 
 
  
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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WEEK No 24  
Session 1     Session 2 
Date____________________   Date____________________ 
 
 
 
 
 
 
Blood 
Pressure 
     Blood 
Pressure 
    
Heart rate  
 
    Heart rate  
 
   
30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 30mins 
Aerobic 
training 
 
Mins 
 
HR 
 
RPE 
 
Distance 
 
1.Treadmill 
      
1.Treadmill 
    
 
2. Rower 
      
2. Rower 
    
 
3. Bike 
      
3. Bike 
    
 
4. X Trainer 
      
4. X Trainer 
    
 
Stretching 
      
Stretching 
    
 
 
 
Weight 
 
Sets 
 
Rep
s 
 
 
  
 
 
Weight 
 
Sets 
 
Reps 
 
 
 
Leg press 
         
 
1. 
2. 
10 
10 
   
Leg press 
 
           
1. 
2. 
10 
10 
 
Leg 
extension 
         
 
1. 
2. 
10 
10 
  Leg 
extension 
 1. 
2. 
10 
10 
 
 
Sit to stand 
 1. 
2. 
10 
10 
   
Sit to stand 
 1. 
2. 
10 
10 
 
2 arm  
Pull-down 
 1. 
2. 
10 
10 
  2 arm  
Pull-down 
 1. 
2. 
10 
10 
 
Rotation 
Wood chop 
 1. 
2. 
10 
10 
  Rotation 
Wood chop 
 1. 
2. 
10 
10 
 
Arm raises 
(alternate) 
 1. 
2. 
20 
20 
  Arm raises 
(alternate) 
 1. 
2. 
10 
10 
 
Final resting 
BP 
     Final 
resting BP 
    
Final  resting  
Heart Rate 
     Final 
resting   
Heart Rate 
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